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Onvergeeflijk is het, dat de mensen dromen hebben 
en ze niet waarmaken! 
En toch, hoop vervliegt elke dag en overal 
In elke kamer. Ieder bed. 
Op mijn reizen heb ik dit duidelijk gezien: 
Iedere ontmoeting, elk gesprek brengt mensen verder af 
van wat zij willen. 
Zij vertrouwen niet op wat zij zijn, 
maar op hoe zij worden gezien. 
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Aims and outline of the thesis  
 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) is the main inherited predisposition 
to colorectal cancer. Major features of HNPCC are colorectal and endometrial cancers. 
Tumours of the ovaries, stomach, small bowel, biliary tract, urinary tract, skin and brain 
occur at lower frequencies. Mutations in at least 4 different mismatch repair (MMR) genes 
are responsible for HNPCC, namely MSH2 and MLH1 in the majority of cases and, more 
rarely, MSH6 and PMS2. In previous studies, MSH2 and MLH1 mutations were found in 45-
64% of the families with HNPCC73.  
In Chapter 2, we questioned whether unresolved HNPCC families were due to a lack of 
sensitivity of MSH2 and MLH1 mutation detection techniques, or to mutations of MSH6 or 
other genes. To this aim, we thoroughly investigated a cohort of 59 US HNPCC families, 
clinically selected by Prof. Henry Lynch, for the presence of point mutations and genomic 
rearrangements in the MSH2, MLH1 and MSH6 genes. We identified a North American 
founder mutation, a deletion of MSH2 exons 1-6, common to 12% of the cohort. The 
birthplace of the eldest ancestor carrying this founder mutation could be traced back to 
18th century Germany. Additionally we detected a10-Mb paracentric inversion inactivating 
the MSH2 gene. 
The clinical cancer phenotype associated with mutations of MSH6 is less well defined 
when compared to MLH1 and MSH2. In Chapter 3.1 and 3.2, we analysed a large Dutch 
pedigree and a cohort of 20 MSH6 mutation positive families to calculate the cumulative 
age-specific risks of colorectal cancer and endometrial cancer, and compared the 
outcomes with the cancer risks in MSH2 and MLH1 mutation carriers. Based on the 
findings, we formulated MSH6-tailored screenings and preventative options.  
The detection of a germline mutation in MSH2, MLH1 or MSH6 in an individual enables 
predictive genetic testing of at-risk relatives. In Chapter 3.3, we analysed the demand for 
genetic testing of members of 18 Dutch families with a known mutation in MSH2, MLH1 or 
MSH6. Regular colonoscopy reduces the overall mortality by 65% in members of families 
with HNPCC 117. It is therefore of utmost importance that mutation carriers adhere to 
surveillance protocols. We evaluated (Chapter 3.4) the impact of genetic testing on the 
adherence to cancer surveillance protocols. Simultaneously, we investigated the 
satisfaction with cancer screening and genetic testing procedures in 70 proven mutation 
carriers at the long term. 
The studies described in this thesis contribute to the understanding of the molecular 
genetic aetiology of HNPCC, and add to evidence-based clinical care for HNPCC families.
















1.1. Hereditary Non Polyposis Colorectal Cancer syndrome (HNPCC) 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC) or Lynch syndrome 
(MIM114500) is the most common genetic susceptibility for colorectal cancer. It accounts 
for 3-5% of all colorectal cancers in the Western world73. The HNPCC phenotype also 
includes other cancers, predominantly of the endometrium, but also ovarian, gastric, 
small bowel, biliary tract, urinary tract, skin and brain cancer may occur5, 54, 158, 302, 303. 
HNPCC is caused by germline mutations in the mismatch repair (MMR) genes MSH2, MLH1, 
MSH6, and PMS2 (Table 1)10, 26, 58, 152, 206, 218, 225. The inheritance pattern is autosomal 
dominant, as shown by the 50% risk of children of an MMR gene mutation carrier of 
inheriting this predisposition to cancer. The Amsterdam criteria (Table 2) have been 
established by the International Collaborative Group on HNPCC (ICG-HNPCC) to allow 
clinical selection of HNPCC families. However, not all families fulfilling these criteria are 
bona fide HNPCC families. Viceversa, MMR gene mutations are also found in Amsterdam 
criteria negative families. Since loss of mismatch repair function causes microsatellite 
instability (MSI), a type of genetic instability in repetitive DNA sequences in the majority 
of HNPCC related cancers, this and aberrant immunohistochemical staining of MMR 
proteins are additional tools to identify HNPCC families on tumour material. As in the 
majority of cancer predisposition syndromes, (presymptomatic) diagnosis of HNPCC is of 
major importance for appropriate counselling, clinical surveillance and cancer prevention. 
 
1.2. History 
The first HNPCC family was reported in 1913 by A.S. Warthin (Figure 1)324. He 
described the family of his seamstress, known as Family G. Lynch et al. (Figure 1) 





Figure 1.  





Table 1.  











MSH2 MutS 2p21 2,8 16 yes 
MLH1 MutL 3p21-23 2,3 19 yes 
MSH6 MutS 2p21 4,2 10 yes 
PMS2 MutL 7p22 2,6 15 yes 
PMS1 MutL 2q31-33 2.8 12 possibly 
MLH3 MutL 14q24.3 4,7 12 probably not 
MSH3 MutS 5q11-12 3,4 24 probably not 
Exo1  1q42-43 3 14 probably not 







Table 2.  
The Amsterdam criteria for the clinical diagnosis of HNPCC families299,301. 
 
1: At least three relatives with colorectal cancer  
2: One should be first-degree relative of the other two 
3: At least two successive generations should be affected 
4: At least one should be diagnosed before age 50 
5: Familial Adenomatous Polyposis should be excluded 
Amsterdam 
criteria: 
6: Tumours should be verified by pathological examination 
1: At least three relatives with an HNPCC-associated cancer  
    (colorectal, endometrial, small bowel, ureter or renal pelvis cancer) 
2: One should be first-degree relative of the other two 
3: At least two successive generations should be affected 
4: At least one should be diagnosed before age 50 




6: Tumours should be verified by pathological examination 
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Lynch recognised the autosomal dominant pattern of inheritance, and delineated HNPCC 
or Lynch syndrome. In 1986, autosomal dominant inheritance of colorectal cancer was also 
proven using segregation analysis in a cohort of 11 families16.  
International clinical criteria for HNPCC, the Amsterdam criteria, were formulated by the 
ICG-HNPCC in 1991 and subsequently updated in 1999 (Table 2)299, 301.  
In 1993 germline mutations in the MMR gene MSH2 were found to be responsible for 
HNPCC (Table 1), followed by mutations in MLH1, MSH6, and PMS210, 26, 58, 152, 206, 218, 225. 
The Bethesda guidelines to select HNPCC and HNPCC-like families for mutation analysis 
using MSI as a pre-screening tool were formulated in 1997 and updated in 2004 (Table 
3)248, 296. International criteria for the diagnosis of MSI in colorectal cancer were 
formulated in 1998 (Table 4)24. More recently, immunohistochemical (IHC) analysis of the 
MSH2, MLH1, MSH6 and PMS2 protein in tumour sections has been added as an additional 
tool to direct mutation analysis42, 43, 100, 160, 284. Guidelines for screening of HNPCC risk 
carriers were proposed, and were proven to decrease overall mortality considerably27, 117, 
118, 238. Since 1992, the Dutch Foundation for the Detection of Hereditary Tumours 
(Stichting Opsporing Erfelijke Tumoren/STOET) has been registering Dutch HNPCC family 
members and has played an important national and international role in evaluating the 
efficacy of cancer screening in HNPCC risk carriers. In 2001, the American 
Gastroenterological Association formulated recommendations on hereditary colorectal 
cancer and genetic testing73. Also, the Working Group on Oncogenetics of the Dutch 
Association of Clinical Genetics (Vereniging Klinische Genetica Nederland/VKGN) 
formulated guidelines for genetic testing, counselling and surveillance of HNPCC and 
HNPCC-like families201. 
 
1.3. The HNPCC genes and their protein products 
As mentioned above, four MMR genes are known to date to cause HNPCC: MSH2 
and MLH1 are responsible for the majority of the classical cases, whereas mutations in 
MSH6 and PMS2 account for more atypical kindreds (Table 1)(Figure 3).  
MSH2. The MSH2 gene was the first human HNPCC gene to be cloned58, 152. It resides on 
chromosome 2p21 and is the human homologue of the bacterial mismatch repair gene 
MutS. The MSH2 gene contains 16 exons, with a total cDNA length of 2.8kb. In 2000, the 
crystal structure of the MutS protein was elucidated149, 220, providing novel insights in the 
MMR function of the MutS and MSH2 protein. MutS proteins form a dimer with the general 






The Bethesda guidelines to select for MSI testing of colorectal tumours248,296. 
 
1: Individuals with cancer in families that meet the Amsterdam criteria 
2: Individuals with two HNPCC-related cancers, including synchronous and  
    metachronous colorectal cancers or associated extracolonic cancers* 
3: Individuals with colorectal cancer and a first-degree relative with colorectal 
    cancer and/or HNPCC-related extracolonic cancer and/or a colorectal adenoma; 
    one of the cancers diagnosed at age <45y, and the adenoma diagnosed at age      
    <40y 
4: Individuals with colorectal cancer or endometrial cancer diagnosed at age <45y 
5: Individuals with right-sided colorectal cancer with an undifferentiated pattern 
   (solid/scribiform**) on histopathology diagnosed at age <45y 
6: Individuals with signet-ring-cell-type colorectal cancer diagnosed at age <45y*** 
7: Individuals with adenomas diagnosed at age <40y 
Bethesda  
guidelines: 
*   Endometrial, ovarian, gastric, hepatobiliary, or small bowel cancer, or 
    transitional cell cancer of the renal pelvis or ureter. 
**  Solid/scribiform defined as poorly differentated or undifferentiated carcinoma 
    composed of irregular, solid sheets of large eosinophilic cells and containing 
    small gland like spaces. 
*** Composed of >50% signet ring cells 
1: Colorectal cancer diagnosed in a patient who is less than 50y of age 
2: Presence of synchronous, metachronous colorectal or other HNPCC associated 
    tumours* regardless of age 
3: Colorectal cancer with the MSI-H histology** diagnosed in a patient who is less 
    than 60y of age  
4: Colorectal cancer diagnosed in one or more first degree relatives with an HNPCC 
    related tumour, with one of the cancers being diagnosed under age 50y 
5: Colorectal cancer diagnosed in two or more first- or second degree relatives with 




*   Endometrial, stomach, ovarian, pancreas, ureter, renal pelvis, biliairy tract, 
    brain (usually glioblastoma), smal bowel tumour and sebacous gland adenomas 
    and keratoacanthomas 
**  Presence of tumour infiltrating lymphocytes, Crohn’s-like lymphocytic reaction, 





Selected markers for MSI analysis in colorectal cancer and criteria for the interpretation of 
MSI24.  
 
Reference panel Alternative microsatellite markers 
BAT25 BAT40  D18S58 D13S175 D17S787 
BAT26 BAT34C4 D18S61 D17S588 D7S519 
D5S346 TGFßR2 D18S64 D5S107 D20S100 
D2S123 ACTC(635/636) D3S1029 D8S87  
D17S250 D18S55 D10S197 D13S153  





>1 ≥30% MSI-High    (MSI-H) 
1 <30% MSI-Low     (MSI-L) 
Number of markers  
displaying instability 
0 0 MSI-Stable  (MSS) 
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Each MutS subunit contains 5 functional domains: domain I and IV are involved in DNA 
binding, domain V contains ATP-ase activity and links both MutS subunits, domain II and III 
connect the DNA binding and ATP binding domains of the MutS protein.  
Analogue to MutS, MSH2 encompasse
activity, and a domain for protein-p
proteins, MSH6 and MSH3. According
of MutS-related proteins, MSH2-MSH
distinct but overlapping spectra of m
Apart from its role in the repair of s
encompass additional functions. Mar
frequency of chromosomal aberratio
carriers, suggesting a role for misma
interactions of MSH2 with repair pat
Accordingly, Villemure et al.308 repo
deficient tumour cell lines. Also, in 
recombination between non-isogenic
MLH1. The MLH1 gene was recognise
Papadopoulos et al. in 1994225. It is t
and resides on chromosome 3p21-23
length of 2.3 kb88. The aminoacid se
an ATP-ase activity domain and dom











The crystal structure of the MutS dimer:  
Two MutS proteins are represented by ribbon diagrams in 
blue (domains I), green (domains II), yellow (domains III), 
orange (domains IV) and red (domains V). Domain I and IV 
are involved in DNA binding, domain V contains ATP-ase 
activity and links both MutS subunits, domain II and III 
connect the DNA binding and ATP binding domains of the 
MutS protein. In mismatch repair the DNA helix is positioned 
through the gap between domains I and IV. 
 
s DNA binding domains, a domain containing ATP-ase 
rotein interaction with two other MutS-related 
ly, the MSH2 protein forms heterodimeric complexes 
6 (hMutS-α) and MSH2-MSH3 (hMutS-β), to bind DNA at 
ismatches7, 110 
omatic mutations, the MSH2 gene is likely to 
tin et al.195 described a significantly increased 
ns in sperm cells derived from MSH2 mutation 
tch repair in meiosis. Possibly, this is due to 
hways involved in chromosomal recombination. 
rted compromised homologous repair in MSH2 
Msh2-mutant mouse embryonic stem cells homologous 
 DNA strands is highly enhanced281. 
d to cause HNPCC by Bronner et al.26 and 
he human homologue of the bacterial MMR gene MutL 
. This gene contains 19 exons, with a total cDNA 
quence of MLH1 encompasses a DNA binding domain, 
ains for protein-protein interaction. During mismatch 
th other MutL-related proteins, PMS2, MLH3, and 
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PMS1156, 161, 223. The binding of a hMutS heterodimer to a mismatch triggers ATP-dependent 
steps that allow interactions with the hMutL heterodimers and completion of the repair 
process.  
As for MSH2, the MLH1 gene is likely to play additional roles in meiosis. In yeast, a 
complex of Mlh1 and Mlh3 is involved in meiotic recombination, possibly by stabilising the 
Holliday junctions17. 
MSH6. In 1995 Palombo et al.222 and Drummond et al.53 described a complex that binds 
GT-mismatches. This complex appeared to consist of the MSH2 protein and an unknown 
160 kDa protein, they called GTBP (GT binding protein). One year later, both the group of 
Miyaki206 and Akiyama10 described germline mutations in the GTBP gene, now known as the 
MSH6 gene, in HNPCC-like families. The MSH6 gene maps close to MSH2 on chromosome 
2p21, and it encodes for a MutS-related protein homologous to MSH2. It is likely that MSH2 
and MSH6 are the result of an ancient duplication event of the MutS gene of higher 
eukaryotes. The MSH6 gene encompasses 10 exons, with a total cDNA length of 4.2 kb. As 
for MSH2, it includes 2 DNA-binding domains, ATP/GTP-binding sites, and a PWWP-domain 
for protein-protein interaction. The MSH6 protein forms heterodimers with MSH2 that 
specifically recognise GT mismatches.  
PMS2. PMS2 is located on chromosome 7p22 and contains 15 exons for a total cDNA length 
of 2.6 kb. Its protein product is a MutL homologue and forms a heterodimer with MLH1 
during the mismatch repair process. Apart from its protein-protein interaction motifs, 
PMS2 harbours sites for DNA-binding and an ATP-ase activity domain. To date, only few 
PMS2 mutations have been reported in HNPCC patients. Nicolaides et al.217, 218 described 
two distinct germline mutations of the PMS2 gene in two unrelated HNPCC families. PMS2 
mutations were subsequently also found in HNPCC kindreds with central nervous system 
tumours, a condition also known as Turcot syndrome45, 86, 205. Two compound missense 
mutations of PMS2 were detected in a Turcot patient without a family history of cancer, 
whereas a homozygous PMS2 mutation was found in a family with brain tumours and café 
au lait spots, thus suggesting a recessive mode of inheritance45, 46. Several studies of in 
total more than 200 HNPCC and HNPCC-like families did not reveal any PMS2 mutation165, 
169, 306, 319. These data suggest that PMS2 mutations are responsible for a small subset of 
HNPCC or HNPCC-like families, and are possibly preferentially associated with the Turcot 
variant of HNPCC. However, mutation analysis of PMS2 has also been hampered by the 
presence of pseudogenes in the genome, so the current figures of the contribution of this 
gene to HNPCC may be an underestimate46. 
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1.4. Candidate genes 
A number of additional genes have been indicated as putative HNPCC genes. 
These include other members of the mismatch repair machinery like PMS1, MSH3, and 
MLH3, but also genes known to play important roles in cellular functions other than MMR 
like TGFβRII, the SMAD genes and EXOI (Table 1). 
Nicolaides et al.217, 218 described  a germline nonsense mutation of the PMS1 gene resulting 
in exon-skipping in a HNPCC family. No other PMS1 mutations have been reported since. 
The PMS1 gene maps to chromosome  2q31-33 and it encodes for a MutL-like protein that 
forms a heterodimer with MLH1 during mismatch repair. PMS1 contains 12 exons for a 
total cDNA length of 2,8 kb. 
The MSH3 gene maps to chromosome 5q11-12 and encodes for a MutS –like protein. MSH3 
encompasses 24 exons and has a total cDNA length of 3.4 kb. MSH3 forms a heterodimer 
with MSH2 that recognises specific subsets of mismatches in DNA325. To date, MSH3 
mutations have only been found in somatic cells107, 345. 
The MLH3 gene on chromosome 14q24.3 was identified and characterised by Lipkin et al. 
(2000).161. The gene contains 12 exons, and has a total cDNA length of 4.7 kb. As for PMS2 
and PMS1, MLH3 complexes with MLH1 to form the third hMutL heterodimer involved in 
mismatch repair. Wu et al.341 described nine missense mutations and one frameshift 
mutation in a cohort composed of 288 HNPCC-like families. Three of the index patients 
carrying the putative MLH3 missense mutation were shown to carry an additional MSH6 
mutation and no MLH3 mutations were detected in 39 Amsterdam criteria positive HNPCC 
families. Likewise, no pathogenic MLH3 germline mutations were detected in three 
subsequent studies on 142 patients from families with familial colorectal cancer that 
tested negative for mutations in MSH2 or MLH1104, 163, 176. Liu et al.166 described a family 
with both an MLH3 and MSH2 missense mutations, both segregating with colorectal cancer 
in the corresponding kindred. Altogether, these findings suggest that germline mutations 
of MLH3 are not likely to contribute to the development of HNPCC, or may at best 
represent cancer risks modifiers among carriers of mutations of the major MMR genes.  
Functional redundancy among hMutS (MSH2/MSH3 and MSH2/MSH6) and hMutL 
(MLH1/PMS2, MLH1/MLH3, and MLH1/PMS1) heterodimers may explain the differential role 
of MSH2 and MLH1 as main disease-causing genes in HNPCC when compared with other 
MMR genes.  
The Exonuclease 1 (EXO1) gene encodes for an MSH2-interacting protein presumably 
involved in both mismatch repair and DNA recombination258, 290. Wu et al.342 detected a 
splice site mutation in one out of 33 HNPCC families in addition to 13 missense 




families. About half of the tumours available displayed an MSI-High phenotype. Sun et 
al.275 showed that two missense mutations of EXO1, E109K and L410R, interfere with the 
exonuclease activity, and three others, P640S, G759E and P770L, affect MSH2-binding. 
Jaghmohan-Changur et al.116 tested a large series of European CRC patients and 
population controls to clarify whether EXO1 variants may indeed predispose to familial 
CRC. Several variants observed in patients were also observed in controls with similar 
frequencies, including the truncating variant described by Wu et al.342. Thus, no 
conclusive evidence was found for a role of EXO1 as a colorectal cancer susceptibility 
gene. 
Molecular studies in sporadic colorectal cancer have indicated that two distinct signal 
transduction pathways, TGF-β and Wnt signalling pathways, play rate-limiting roles during 
tumour initiation and progression. Therefore, specific members of these signalling 
cascades may be regarded as potential candidate genes for hereditary CRC syndromes. In 
1998 Lu et al.177 described a putative germline mutation in the TGFβRII gene encoding for 
the TGF-β type 2 receptor in a kindred with familial late-onset colorectal cancer. 
Mizuguchi et al.208 showed evidence that this mutation is likely to be a rare polymorphism. 
Also, no germline mutations in this gene were detected in a cohort of 67 patients with 
colorectal cancer below age 55 years, and in a series of HNPCC families305. Hence, TGFβRII 
germline mutations seem not to be associated with HNPCC. Also, no germline mutations of 
three other TGFβ pathway genes, SMAD2, SMAD3 and SMAD4, have been found in HNPCC 
families so far249. 
 
1.5. The HNPCC gene mutation spectra 
A broad spectrum of germline mutations is characteristic of all HNPCC genes 
(mutation database on website: http://www.nfdht.nl). The majority of mutations in MLH1 
and MSH6 are single nucleotide substitutions or small insertions and deletions227, 315. The 
pathogenicity of these mutations is not always straightforward. Nonsense mutations in 
MLH1 as well as in other genes were shown to cause exon skipping, leading to several 
aberrant transcripts273. Also, missense mutations and polymorfisms, as well as intronic 
sequence variations, can be pathogenic by affecting splicing167, 216. Missense mutations can 
also influence the structure and/or function of the encoded protein. Several missense 
mutations were shown to affect protein-protein interaction of MSH2 with MSH3/MSH6, or 
the heterodimer function83, 95. Lipkin et al. described a MLH1 missense mutation (D132H) 
causing susceptibility to MS-Stable colorectal cancer164. The establishment of the 
pathogenicity of a sequence variant still represents a main challenge as it often implies 
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analysis of large cohorts of affected and healthy individuals, cosegregation analysis of the 
alleged mutation with the disease phenotype within extensive, multi-generation 
pedigrees, and in vitro if not in vivo functional studies55, 64, 216, 294. 
As reported in chapter 2.1, we found that large genomic rearrangements significantly 
contribute to the HNPCC mutation spectrum35, 232, 334. Among the 4 MMR genes, MSH2 has 
been shown particularly prone to genomic deletions and other genomic rearrangements297, 
334. The MSH2 locus on chr 2p21 contains a relatively high concentration of repetitive short 
interspersed elements (SINEs) like Alu repeats, which explain the high frequency of 
genomic rearrangements within this gene due to homologous but unequal recombination 
events297, 334. We detected a founder deletion in MSH2, responsible for a substantial part 
of the HNPCC in Mid-western American families192, 315. Several other founder-mutations in 
MLH1 and MSH2 have been described33, 64, 65, 109, 210. One of these (the Newfoundland exon 
5 splice donor site mutation in MSH2) appeared to be a recurrent mutation also49. 
Green et al.81 described a MLH1 promotor mutation in a Newfoundland kindred. Germline 
mutations were also detected in the promotor region of MSH235, 262. Notably, aberrant 
methylation of the MLH1 promotor was found in normal tissue of patients with MSI-High 
tumours, indicative of a hereditary predisposition to aberrant promotor methylation72, 80, 
276. De novo mutations of MLH1, MSH2 and MSH6 seem rare. Only one de novo mutation of 
MSH2 has been described143. 
Biallelic germline mutations in the MMR genes have also been reported. Individuals 
homozygous or compound heterozygous for MLH1, MSH2, MSH6 or PMS2 mutations are at 
risk of childhood tumours, mainly haematological tumours, brain tumours and HNPCC 
related tumours45, 46, 71, 200, 243, 320, 331. We also diagnosed a boy being compound 
heterozygous for a frame shift and a missense mutation in MLH1. He developed a Wilms 
tumour and a glioblastoma at the age of 4 years. The majority of the MMR deficient 
patients have “café au lait spots”, a main feature of neurofibromatosis type 1 (NF1). Also, 
other features of NF1 like neurofibromas or Lish noduli were occasionally reported. 
However, none of these cases fulfilled the clinical criteria for NF1. Mutational analysis of 
the NF1 gene was performed in a child homozygous for a MSH6 mutation200, and was 
negative. 
 
1.6. Molecular basis of tumour initiation and progression in HNPCC  
HNPCC is caused by germline mutations in mismatch repair genes. The DNA 
mismatch repair process is best outlined for the bacteria Escherichia coli (E.coli). It 
repairs single base mispairs, small insertions and deletions caused by slippage of DNA-




or other simple repetitive sequences). In E.coli, four proteins are essential for mismatch 
repair: MutS, MutL, MutH and MutU209. A MutS homodimer recognises and binds to the 
mismatch. It then forms a complex with a MutL homodimer, that (in the presence of ATP) 
juxtaposes the MutS and the MutH protein. MutH has endonuclease activity and recognises 
the newly replicated DNA because GATC sequences in this strand are transiently 
unmethylated. It binds the hemimethylated DNA at a GATC site and cleaves the 
unmethylated DNA strand thus introducing a single strand nick. Subsequently, UvrD 
helicase (MutU) unwinds the DNA thus allowing single strand exonucleases to make a gap 
of approximately 2 kb, from the nick past the mismatch. While the single strand binding 
protein stabilises the remaining DNA strand, DNA polymerase III fills in the gap. DNA ligase 
is required to link the repaired DNA to the pre-existing sequence241. Eukaryotic mismatch 
repair contains several mismatch repair pathways in which several MutS and MutL 
homologues are involved (Figure 3): MSH2, MSH3, and MSH6 are human homologues of 
MutS. MLH1, PMS1, PMS2, and MLH3 are homologues of MutL. No human MutH homologues 










.. ... TGTGTG TGTG TG . ... ..
.. ... ACACACACACAC .. .. ..
T
.. ... TTTTTTT TTTTTT . ....
.. ... AAAAAAA AAAAA A. ....
.. G... GTGT TGT G GT ..T ....
.. ... CACACACACACA.. ....
1HLMPMS2 or1/MLH31HLM2SMP 3HL
.. ... AAAAAAA AAAAA A. ....
.. ... TTTTTTT TTTTTT . ....
.. ... ACACACACACACAC .. ....
.. ... TGTGTG TGTG TGTG .. ... .






.. G... GTGT TGT G GT ..T ....





.....AA AAAAAAAA AAA .....
TTTTTT..... TTTTTT .....T
SM 6H
SM 2HFigure 3. 
Schematic representation of 
the eukaryotic mismatch 
repair (MMR) pathways: 
Single mispairs and small base 
insertion/ deletions are 
preferentially recognised by 
MSH2/MSH6 heterodimers, 
whereas MSH2/MSH3 
heterodimers recognise larger 
insertions/deletions. 
After binding of the mismatch 
by MSH2/MSH6 or MSH2/MSH3, 
heterodimers of MLH1/PMS2,  
MLH1/PMS1 or MLH1/MLH3 are 
recruited. 
Repair of the mismatch is now 
initiated. 
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A heterodimer of MSH2 and MSH6 (hMutS-α) recognises single base substitutions and small 
insertions/deletions-loops (IDL’s; one to four nucleotides). After binding to mispaired 
DNA, this complex recruits a heterodimer of MLH1 and PMS2 (hMutL-α) and triggers 
mismatch repair. In addition to the mismatches recognised by hMutS-α, a heterodimer of 
MSH2 and MSH3 (hMutS-β) recognises larger IDL’s (up to 12 base pairs). hMutS-β recruits 
hMutL-α or possibly a heterodimer of MLH1 and PMS1 or MLH3, again initiating mismatch 
repair19, 121, 126, 138, 139, 193. 
Apart from the repair of DNA-replication errors, the mismatch repair system is also 
involved in the repair of physical DNA damage, and in recombination and meiosis17, 127, 129, 
162, 255, either directly or through cross-talk with other repair systems. Yi Wang et al.322 
described a large (>2MDaltons) protein complex named BASC (BRCA1-associated genome 
complex), encompassing MSH2, MSH6, MLH1, PMS2, together with many other proteins 
involved in genomic recombination and repair (BRCA1, ATM, BLM, RAD50-MRE11-NBS1). 
 
How does MMR deficiency contribute to tumor initiation and progression?  
Cancer is a genetic disease involving mutations in multiple genes. The current concept of 
carcinogenesis is based on the assumption that a single cell may acquire a mutation that 
provides a selective growth advantage. From within the resulting clonal population a cell 
may acquire a second mutation, providing additional growth advantage, thus allowing 
further expansion. Repeated cycles of mutation followed by clonal expansion lead to a 
fully developed malignant tumour. Mutations of two classes of genes, proto-oncogenes, 
tumour-suppressor genes drive carcinogenesis312. 
Proto-oncogenes are involved in regulating proliferation and differentiation of normal 
cells. Mutations of proto-oncogenes result in a ‘gain of function’, and are dominant at the 
cellular level. Altered forms of these genes may evade cellular control and deregulate cell 
growth. Contrary to oncogenes, the function of tumour suppressor genes is to constrain 
cell growth. From this point of view, DNA repair genes involved in the maintenance of 
genome integrity, can be classified as tumour suppressor genes. Mutations of tumour-
suppressor genes result in a ‘loss of function’, and are recessive at the cellular level as 
represented in the Knudson model (Figure 4)134, 135. This model was formulated based on 
observations on the incidence and distribution of sporadic and inherited retinoblastoma. 
Biallelic mutations of RB1 cause retinoblastoma, an eye tumour. In the inherited form of 
retinoblastoma, the first ‘hit’ (mutation) is already present in the germline. For tumour 
formation, a second somatic mutation is needed. In view of the number of retina cells and 




cell is highly likely to occur. In sporadic retinoblastoma, two independent somatic 
mutations must occur in the same cell.  
The Knudson model illustrates how inherited and somatic mutations contribute to 
carcinogenesis and provides a rationale for the main clinical features of individuals with a 
genetic predisposition to cancer when compared with sporadic patients, e.g. age of onset, 
tumour multiplicity and multi-organ distribution.  
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Schematic representation 
of the Knudson model: 
The bars represent the 
alleles of a tumour 
suppressor gene, whereas 
the crosses symbolise 
mutations.  
In sporadic tumours, all 
mutations are somatic, 
while in inherited tumours
the first mutation is 
already present in the 
germline. 2 other regulatory genes 
malignancy174. Moreover, 
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genes are tumour-suppressor genes. In 2004, 291 genes involved in carcinogenesis have 
been reported. Ninety percent of these show somatic mutations whereas 20% are known to 
be mutated in the germline of hereditary cancer patients70. 
The MMR genes responsible for HNPCC when mutated in the germline, are classified as 
tumour suppressor genes. Loss of the wild type allele (loss of heterozygosity, LOH) has 
been observed in 44% of colorectal tumours from patients with a MLH1 germline 
mutation98. Also, somatic mutations of MLH1 occur102. LOH and somatic mutations of the 
wild type allele have been found less frequently in MSH2- than in MLH1-associated 
tumours4, 98, 102. 
Colorectal tumours progress through a series of clinical and histopathologic stages, ranging 
from normal epithelium to single crypt lesions (aberrant crypt foci) to small benign 
tumours (adenomatous polyps) and malignant cancer (carcinomas), the so-called 
adenoma-carcinoma sequence (“the Vogelgram”, Figure 5). This stepwise progression 
results from a series of genetic changes that involve the activation of oncogenes and the 
inactivation of tumour suppressor genes133, 310. Current insights reveal that the single 
mutations among the adenoma-carcinoma sequence are indicative of the activation or 
inactivation of specific cellular regulatory pathways312. Signal transduction pathways 
involved in the development of colorectal cancer are Wnt/β-catenin, KRAS, TGF-β, and 
p53 pathways. A colorectal cell has to deregulate these signalling pathways to trigger 
adenoma formation and malignant transformation40, 68, 78, 89, 151, 312. The temporal order at 
which these mutations occur is also important: APC (triggering constitutive Wnt/β-catenin 
signalling) and KRAS mutations are generally involved in adenoma formation and growth, 
while mutations in the p53 gene and in members of the TGF-β pathway are usually 
associated with malignant transformation.  
Notably, although the general scheme of the adenoma-carcinoma sequence is common to 
hereditary and sporadic colorectal cancers, the somatic mutation profile of HNPCC-related 
tumours differs from other inherited and sporadic colorectal cancers at several points. In 
general, the vast majority of all colorectal cancers are characterised by aneuploidy and 
allelic losses (loss of heterozygosity, LOH), also referred to as chromosomal instability 
(CIN). Loss of mismatch repair function causes accumulation of DNA mismatches at an 
increased rate in coding and non-coding sequences, the so-called microsatellite instability 
(MIN/MSI). MIN tumours, both inherited and sporadic, are near-diploid. MSI is found in 12-
18% of colorectal cancers4, 114, 285 whereas HNPCC-related colorectal cancers show MSI in 
more than 90% of the cases4, 67 As mentioned before, mutations of the MMR genes are 
present in the germline of HNPCC patients. In these cases, and in agreement with the 




In contrast, more than 80% of sporadic MSI-High tumours are characterised by somatic 
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noitatum RIIβFGT /XABFigure 5. 
The adenoma-carcinoma sequence: 
The stepwise progression from normal epithelium to carcinoma results from a series of genetic 
changes that involve the activation of oncogenes and the inactivation of tumour suppressor genes. 
The different genes predominantly affected in CIN (upper part of the scheme) and MIN (lowers part 
of the scheme) tumours are depicted. Members of the Wnt signal transduction pathway are mutated in both CIN and MIN 
tumours. The main tumour suppressing function of this signalling pathway is the regulation 
of β-catenin, a protein involved both in cell adhesion, when located at the cell 
membrane, and transcriptional regulation, when translocated to the nucleus (Figure 6). 
Several different extracellular Wnt ligands can bind and activate Frizzled and LRP6 
receptors.  
This ligand-receptor interaction prevents the formation of an intracellular multiprotein 
complex, the so-called ‘destruction complex’, composed of APC, β-catenin, GSK-3β, AXIN1 
and AXIN2 (the latter also known as conductin). This complex earmarks β-catenin by 
Ser/Thr phosphorylation, thus triggering its ubiquitin-mediated proteolytic degradation61. 
In the absence of a functional APC protein, β-catenin accumulates in the cytoplasm and 
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eventually translocates to the nucleus where it acts as a transcriptional co-activator by 
associating with members of the T-cell factor/lymphoid enhancer (TCF/LEF) family. 
Downstream targets of the Wnt-signalling pathway are, among others, genes like c-MYC 
and cyclinD1, known to play a role in cell cycle regulation61, 94, 283. 
In the lower third of the colonic crypt, where intestinal stem and transient cells divide 
before migrating upwards and differentiate, Wnt/β-catenin signalling is responsible for 
stimulation of cell proliferation and inhibition of cell differentiation132. 
 Loss of APC function constitutively activates signalling of β-catenin to the nucleus thus 
disturbing the equilibrium between proliferation and differentiation in the colonic crypt, 
and allowing clonal expansion, the first step in tumour formation. Specific activating β-
catenin point mutations that render it resistant to proteolytic degradation are functionally 
equivalent to biallelic APC mutations213.  
Figure 6. 
A schematic representation of 
the Wnt-signalling pathway: 
The interaction of the WNT 
ligand with its receptor Frizzled 
prevents the formation of an 
intracellular multiprotein 
complex composed of APC, β-
catenin, GSK-3β, AXIN1 and 
AXIN2 (the latter also known as 
conductin). This complex 
earmarks β-catenin by Ser/Thr 
phosphorylation, thus triggering 
its degradation. In the presence 
of a Wnt-signal β-catenin is not 
degradated and translocates to 
the nucleus, activating 
downstream targets. 
In the absence of a functional 
APC protein or in the presence of
a stabilising β-catenin mutation, 
β-catenin accumulates in the 
cytoplasm and eventually 
translocates to the nucleus 
where it acts as a transcriptional 
co-activator by associating with 
members of the T-cell 
factor/lymphoid enhancer  

















































Other members of the Wnt pathway such as AXIN1 have been found to be mutated in 
colorectal cancers with no APC mutations170, 211, 270.Among CIN tumours, APC mutations are 
found in the vast majority of the cases, whereas gain-of-function β-catenin alterations are 
usually found in the minority of tumours with wild type APC 213,215, 267. In MIN tumours, APC 
mutations are less common, though still detected at a considerably high incidence142. 
Somatic APC mutations were detected in 11 out of 19 (58%) MSI-High tumours from HNPCC 
patients, and were predominantly frameshifts within intragenic repeat sequences105, 106. In 
sporadic and HNPCC-related MSI-High colorectal tumours, mutations in β-catenin and in 
other components or downstream targets of Wnt-signalling occur more frequently11, 170, 204, 
260, 287. 
Germline mutations of members of the Wnt signalling pathway underlie hereditary 
colorectal cancer syndromes. Germline APC mutations are responsible for Familial 
Adenomatosis Polyposis (FAP), a hereditary predisposition to the development of hundreds 
to thousands colorectal polyps (see section “Differential diagnosis”). AXIN2 germline 
mutations were found in individuals with tooth agenesis and a predisposition to colorectal 
cancer150. 
In about 40% of both CIN and MIN colorectal cancers the KRAS pathway is activated by 
oncogenic KRAS mutations. KRAS belongs to the family of RAS proteins (KRAS, HRAS and 
MRAS) that are localised at the internal side of the cytoplasmatic membrane (Figure 7)8, 
151. The activation in normal cells is triggered by the activation of growth factor receptors 













csnart noitpir KPAMFigure 7. 
A schematic 
representation of the 
KRAS-signalling pathway: 
Activation of growth 
factor receptors in the 
cell membrane activates 
RAS. Through other 
members of the pathway 
like RAF, MEK, and MAPK, 
RAS signalling results in 
the transcription of 
target genes. Introduction 
GTP is normally dephosforylated to GDP by GAPs (GTP-ase activating proteins). Through 
other members of the pathway like RAF, MEK, and MAPK, RAS signalling influences cell 
shape, motility and growth. Also, RAS activation up-regulates vascular endothelial growth 
factor (VEGF), important in vascularisation of tumours89. KRAS mutations in colorectal 
adenoma and carcinoma lock KRAS in the GTP-bound form by interfering with its 
interaction with GAP. Mutations in the RAF gene BRAF are frequently found in sporadic but 
not in HNPCC related MSI-High tumours48, 197. 
The TGFβ-receptor pathway (Figure 8) is deregulated in both CIN and MIN tumours by 
mutations in different genes, respectively SMAD2/4 and TGFβIIR22, 151, 252. A polyA tract in 
TGFβIIR represents a mutational hotspot in MSI-High tumours. Normally TGFβ binds TGFβ 
type 2 receptor (directly or via TGFβ type 3 receptor), which complexes with TGFβ type 1 
receptor thus triggering its phosphorylation. TGFβ type 1 receptor phosphorylates SMAD2 
or SMAD3, which bind to SMAD4. The heterodimer moves to the nucleus and induces 
transcription of specific target genes. TGFβ signalling induces cell cycle arrest in G1, 
differentiation, and apoptosis in normal cells.  
Also, members of the TGFβ-receptor-pathway have been found to be mutated in the 
germline in men. In 1998 Lu et al. 177 described a germline mutation in the TGFβ type2 
receptor in a family with familial late onset colorectal cancer. Intriguingly, Mizugucho et 
al.208 showed TGFβIIR germline mutations to cause Marfan syndrome, a connective tissue 
disease. They also make likely that the mutation described by Lu et al. is a rare 







representation of the 
TGFβ-signalling pathway: 
TGFβ binds TGFβ type 2 
receptor (directly or via 
TGFβ type 3 receptor), 
which complexes with 
TGFβ type 1 receptor 
thus triggering its 
phosphorylation. 
TGFß type 1 receptor 
phosphorylates SMAD2 or 
SMAD3, which bind to 
SMAD4. The heterodimer 
moves to the nucleus and 
induces transcription of 














The p53-pathway controls cellular responses to genotoxic damage, in particular apoptosis 
or cell cycle arrest to allow DNA repair (Figure 9).TP53 mutations occur in 75% of CIN 
tumours, but not in MIN tumours. However, about 42% of MIN tumours carry mutations in 
the BAX gene266, another member of the p53 pathway. P53 is normally activated by DNA 
damage (for example by hypoxia or ionizing radiation), aberrant growth signals (for 
example resulting from expression of the oncogenic RAS or MYC), chemotherapeutic 
drugs, UV-light, and/or protein-kinase inhibitors311. The p53 proteins form a tetramer able 
to bind DNA. The 5’ side of the protein (the acid domain) can act as a transcription factor 
that can increase transcription of growth inhibiting genes like BAX, thus triggering 
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A schematic representation of 
the p53-pathway: 
P53 is normally activated by 
DNA damage, aberrant growth 
signals, chemotherapeutic 
drugs, UV-light, and/or 
protein-kinase inhibitors.  
The p53 proteins form a 
tetramer able to bind DNA. 
The 5’ side of the protein (the 
acid domain) can act as a 
transcription factor that can 
increase transcription of 
growth inhibiting genes like 
BAX, thus triggering apoptosis, 
or p21, causing G1 cell cycle 
arrest by inhibition of cyclin 
dependent kinases (CDK). 
Also, p53 upregulates 
thrombospondin-1, an 
angiogenesis inhibitor, and is 
involved in the initiation of 
DNA repair. (CDK)89, 151. Also, p53 upregulates thrombospondin-1, an angiogenesis inhibitor, and is 
involved in the initiation of DNA repair89. 
TP53 germline mutations cause the Li Fraumeni syndrome, a cancer syndrome with 
childhood cancer (sarcomas and brain tumours), early onset breast cancer in addition to 
other tumours, among which, more occasionally, also colorectal cancer207, 271.  
 
By overcoming or modulating the different regulatory pathways as described above, 
tumour cells acquire the necessary qualities for local invasion and metastasis: autocrine 
growth signals (e.g. Wnt signalling and RAS pathway), insensitivity to growth inhibition 
(e.g. TGFβ pathway), resistance to apoptosis (e.g. MMR, p53 pathway), limitless 
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replicative potential (p53 pathway), sustained angiogenesis (e.g. p53 and RAS pathway), 
and tissue invasion and metastasis (e.g.Wnt signalling). In HNPCC, deregulation of the 
described pathways occurs predominantly through mutation of pathway members like 
TGFβR2 and TCF4, that have been shown to encompass intragenic repeat sequences prone 
to replication errors normally repaired by MMR228. This accumulation of mutations at 
increased rate is often referred to as the mutator phenotype. Although the role of the 
mutator phenotype in tumour progression is generally accepted, different models have 
been advocated for the mechanisms underlying tumor initiation due to loss of MMR 
function. In a normal cell, excessive mutation load triggers apoptosis. MMR deficient cells 
have been shown to be resistant to apoptosis and the latter is more likely to represent the 
true selective advantage that enables the initial clonal expansion of MMR deficient cells. 
Accordingly, MMR genes have been shown to play a central role in ‘sensing’ the presence 
of DNA mismatches and the activation of either repair or apoptotic machinery59, 127, 228.  
 
The vulnerability of specific genes involved in carcinogenesis for MMR deficiency due to 
the repetitive nature of their coding sequences may at least partly explain the difference 
in tumor phenotypes in MSH2, MLH1 and MSH6 mutation carriers, the so-called genotype-
phenotype correlation (see section “Cancer risks”). MSH6 is mainly involved in the 
recognition of single nucleotide mismatches, wheraes MLH1 and MSH2 are also important 
in the repair of larger mispairs or loops. Loss of the different MMR proteins is therefore 
likely to result in the accumulation of mispairs in respectively mononucleotide repeats and 
both mono- and multiple-nucleotide repeats. Regulatory genes in different tissues may be 
more or less prone to deficiency of a particular MMR pathway, depending on the nature of 
their repetitive sequences228. The observation of different MSI patterns in HNPCC related 
colorectal and endometrial cancer supports this theory145.  
  
1.7. Cancer risks  
 Many studies have been performed on cancer risks in HNPCC, though only a few 
have addressed proven MLH1, MSH2 and MSH6 mutations carriers. A summary of the 
results of these studies is presented in Table 55, 54, 101, 158, 302, 303, 314.  
Colorectal cancer risk at age 70 years in MLH1 and MSH2 mutation carriers ranges between 
65-100% in male and 30-83% in female carriers5, 54, 158, 302, 303. In the Netherlands, the 
Working Group on Oncogenetics of the Dutch Association of Clinical Genetics (Vereniging 
Klinische Genetica Nederland/VKGN) advises a lifetime risk of colorectal cancer of 60-90% 
for counselling purposes in high risk families. The mean age at diagnosis of colorectal 




158, 302, 303. The risk at age 70 years of male and female MSH6 mutation carriers is 69% and 
30% respectively, being significantly lower in female MSH6 compared to male MSH6 
mutation carriers, and in MLH1 and MSH2 mutation carriers of both sexes. The age at 
diagnosis in both male and female MSH6 mutation carriers is an average 5-10 years 
delayed when compared with MSH2 and MLH1 mutation carriers of both sexes (Table 5 and 
6)101, 314. Only one third of sporadic colorectal cancer develops proximal to the splenic 
flexure, whereas approximately two thirds of HNPCC-associated colorectal cancers do. 
Multiple colorectal cancers occur frequently in HNPCC. Synchronous colorectal cancers 
have been reported at a frequency of 7.4% and 6.7% in MLH1- and MSH2- associated 
colorectal cancer, vs. 2.4% in sporadic colorectal cancer. The annual rate of a second 
colorectal cancer is 2.1% and 1.7% in MLH1 and MSH2 mutation carriers respectively, vs. 
0.33% in sporadic patients159, 180, 198, 199, 302.  
Endometrial cancer risk at age 70 years ranges between 25-61% in female MLH1 and MSH2 
mutation carriers. The risk in MSH2 carriers has been suggested to be somewhat higher 
than in MLH1 carriers5, 54, 158, 302, 303. The VKGN advices a lifetime risk of 30-40% for 
counselling purposes in high risk families. Female MSH6 mutation carriers are at higher 
risk of endometrial cancer when compared to MSH2 and MLH1 mutation carriers (71% at 
age 70), though age at diagnosis is delayed by an average 5-10 years (Table 5 and 6)101, 233, 
314.  
Other extracolonic tumours. Tumours of the stomach, ovary, urinary tract, small bowel 
(including Papilla Vateri), biliary tract, skin and brain are part of the tumour spectrum of 
HNPCC. Associations with other tumours are also incidentally reported, like pancreatic 
cancer184, 199, laryngeal cancer183, fibrous histiocytoma264, prostate cancer 269, and breast 
cancer245. Of note, no consensus exists whether breast cancer is part of the HNPCC tumour 
spectrum44, 214, 245, 304.  
The cumulative risk at age 70 years of all extracolonic tumours (except endometrial 
cancer) usually does not exceed 10% among MSH2 and MLH1 mutation carriers (Table 5)5, 
54, 302, 303. Vasen et al.303 and Lin et al.158 described a higher risk of extracolonic cancers in 
MSH2 compared to MLH1 mutation carriers.The risk of MSH6- associated other 
extracolonic tumours are at present largely unknown. The frequency of the extracolonic 
tumours in HNPCC must be evaluated in relation to their incidence rates in the general 
population186, 226, 259. Also, environmental factors and other genetic factors may influence 
the incidence of extracolonic tumours in HNPCC. Preliminary data suggest earlier ages at 
diagnosis of extracolonic tumours in HNPCC when compared to sporadic cases, in 
particular among MLH1 and MSH2 mutation carriers (Table 6). This phenomenon adds to 
clinical recognition of MLH1 and MSH2 mutation families. 
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Table 5. 
Cumulative lifetime risks of colorectal (CRC), endometrial (EC), stomach (ST), ovarian 
(OV), urothelial cell (UR), small bowel (SMB), biliary tract (BIL) cancer and brain tumours 
(BT) in MLH1, MSH2 and MSH6 mutation carriers compared to the population 
risks5,54,101,158,302,303,314. 
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     3.35 
Dunlop et al. ‘97 
n=67       (at 70 yrs) 
MLH1 
MSH2 
74 30 42       
MLH1 94 63 Lin et al. ‘98 
n=105*    (at 60 yrs) MSH2 96 39 
       
Aarnio et al. ‘99 
n=360     (at 70 yrs) 
MLH1 
MSH2 
100 54 60 13 12 <4 <4 <4 <4 
MLH1 65 55 25 2.1 3.4 1.3 7.2  0 Vasen et al. ‘01 
n=676**  (at 70 yrs) MSH2 75 55 37 4.3 10.4 5.4 4.5  1.2 
Wagner et al. ‘01 
n=34      (at 80 yrs) 
MSH6 32        
Hendriks et al. ‘03 
n=146    (at 70 yrs) 
MSH6 69 30 71       
Population  5 1.5 1 1.5 <1 <0.1 <1 0.5 





Mean age of onset (in years) of colorectal (CRC), endometrial (EC), stomach (ST), ovarian 
(OV), urothelial cell (UR), small bowel (SMB), biliary tract (BIL) cancer and brain tumours 
(BT) in MLH1, MSH2 and MSH6 mutation carriers compared to the age of onset of these 
tumours in the population5,54,101,158,247,302,303,314. 
Mean age of onset (YRS) Publication Gene 
CRC EC ST OV UR SMB BIL BT 
Vasen et al. ‘96 MLH1/
MSH2 
41-44 48-49       
Dunlop et al. ‘97 MLH1/
MSH2 
47-50 54 59      
Aarnio et al. ‘97 MLH1/
MSH2 
  57      
Lin et al. ‘98 MLH1/
MSH2 
45-52        
Rodrigues et al. ‘98 MLH1/
MSH2 
     49   
Aarnio et al. ‘99 MLH1/
MSH2 
   45    53 
Vasen et al. ‘01 MLH1/
MSH2 
43-44  68 43 50 54  56 
Parc et al. ‘03 MLH1/
MSH2 
43-48 46 49 40 49-53 45 43 63 
Vasen et al. ‘01 MSH6 50        
Wagner et al. ‘01 MSH6 55 55       
Hendriks et al. ‘03 MSH6 56 55       




1.8 HNPCC tumours: histopathologic features  
The main precursors of colorectal cancer are adenomatous polyps and flat 
adenomas326. In agreement with the underlying MMR genetic defect, polyps from HNPCC 
patients seem to progress to invasive cancer more rapidly than in sporadic or even FAP 
patients119. Specific pathologic characteristics of HNPCC colorectal tumours have been 
identified, but none of them are pathognomic: poor differentiation, presence of mucinous 
and signet cells, medullary features, peritumoural lymphocytic infiltration, Crohn’s like 
reaction, and tumour infiltrating lymphocytes (TIL) mixed with tumour cells181, 198, 346.  
Most HNPCC-associated endometrial cancers are of the endometroid subtype43.  
Among other extracolonic HNPCC-associated neoplasms, gastric cancers are generally of 
the intestinal type6, whereas ovarian cancers are adenocarcinomas, most commonly of the 
serous or mucinous type5, 180. With respect to tumours of the urinary tract, transitional 
cell carcinomas are associated with HNPCC, localised in the ureter and renal pelvis, 
though not in the bladder265, 328. Small bowel cancers are adenocarcinomas180, 182, 247.  
The skin tumours characteristic of the Muir-Torre allelic variant of HNPCC are 
predominantly sebaceous adenomas and adenocarcinomas. In 1995, Hamilton86 recognised 
that HNPCC-related brain tumours are predominantly glioblastomas. The latter 
observation was subsequently confirmed by Vasen et al.300 and Aarnio et al.5. 
 
1.9 Microsatellite Instability (MSI) 
Microsatellite instability (MSI) is defined as the type of genomic instability 
associated with defective DNA mismatch repair in tumours. MSI provides an indication of 
the presence of genetic instability in a given tumour by comparing the size of a subset of 
simple repeated sequences occurring throughout the genome (mono-, di-, tri-, and, less 
frequently, tetranucleotide repeats) between normal and tumour DNA from the same 
individual. Slippage of DNA polymerases during replication of such simple sequence 
repeats often causes expansions and contractions of their alleles which are efficiently 
repaired by the MMR machinery. In MMR-deficient cells these errors are not properly 
corrected and accumulate at each cell division. Notably, MSI is rarely caused by processes 
other than defective mismatch repair, e.g. reduced replication fidelity by polymerase 
alterations, or imbalance in deoxynucleoside triphosphate pools128.  
MSI was initially described in a subset of colorectal cancers in 19934, 114, 285. Initially, some 
authors used the term replication errors (RER), though in 1998 the National Cancer 
Institute Workshop on HNPCC recommended the use of the term MSI and established “MSI 
golden standards” that are currently employed in research and diagnostic laboratories 
worldwide24 (see also chapter 1.14). 
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More than 90% of the HNPCC-associated colorectal cancers displays MSI4, 67, compared to 
12-18% of the sporadic tumours114, 285. MSI is also found in ~80% of adenomas of variable 
size from HNPCC patients112. With respect to MSI analysis of colorectal cancers, the NCI 
workshop recommended five most informative markers, and has formulated guidelines for 
MSI interpretation (Table 4 and chapter 1.14)24. 
No international criteria have been formulated for MSI analysis of endometrial cancer. 
However, based on studies with different microsatellite markers including those commonly 
used for colorectal cancer, at least 75% of the endometrial cancers from MSH2 and MLH1 
mutation carriers displays MSI43, 111, 246, compared to only 15-30% of the sporadic tumours97, 
246, 339. Notably, MSH6-related endometrial cancers predominantly show instability at 
mononucleotide markers43.  
Insufficient data are yet available on MSI analysis of other HNPCC-related extracolonic 
tumours. However, in agreement with its molecular-genetic basis and based on studies 
with different microsatellite markers and on incidentally tested tumours in HNPCC 
families, MSI seems to represent the common denominator of virtually all HNPCC-related 
cancers: 75% of the HNPCC related gastric cancer displayed MSI vs 15-39% of sporadic 
gastric cancers6, 51, 263, 278; 5/5 HNPCC-related ovarian tumours were MSI-High vs. an overall 
frequency of 17% of MSI in ovarian tumours38, 66, 111; 21-31% of upper tract urothelial 
carcinomas exhibit MSI (Low and High) whereas incidentally tested HNPCC-related 
carcinomas of the same histological type were positive for MSI21, 90, 314; 3/3 HNPCC-related 
pancreatic ductal adenocarcinomas (Papilla Vateri) showed MSI vs. 26/100 sporadic 
tumours343. Entius et al.56 detected MSI in 6 out of 10 sebacous gland tumours of possible 
Muir-Torre patients. Moreover, MSI is detected in a subset of early onset gliomas124, 155.  
Other tumour types thought not to belong to the HNPCC spectrum, like breast and other 
relatively common cancers, often display MSI in proven MMR mutation carriers, suggesting 
a role of MMR-deficiency in the development of these particular tumours44, 245, 264, 269. 
 
1.10 Prognosis 
The prognosis of colorectal cancer patients from HNPCC families appears to be 
more favourable than that of sporadic CRC patients, with overall 5 years and 10 years 
survival rates of 65% vs. 44%, and 68% vs. 37%, respectively181, 254, 327. It has been 
hypothesized that this is caused by a higher sensitivity to chemotherapy of mismatch 
repair deficient tumours99, 115. However, a recent study did not show benefit of 
fluorouracil-based adjuvant chemotherapy in patients with MSI-High tumours242. Also, 
MMR-deficient cells are tolerant to alkylating chemotherapeutics. Another possible 




enhanced immune-response to the highly genetically unstable MSI tumours250, 251. Chang et 
al.34 assumed that the abundant presence of immune cells in MMR-mutant tumours 
increases oxidative stress. Vulnerability of MMR-deficient cells to oxidative stress may 
cause cell cycle arrest and lead to a more favourable prognosis.  
No difference in survival of endometrial cancer was found between HNPCC-related and 
sporadic patients23.  
 
1.11 Screening  
An overview of the current screening advices in HNPCC and in other families 
reminiscent of HNPCC is presented in Table 7. In the Netherlands, members from these 
families are registered by the Dutch Foundation for the Detection of Hereditary Tumours 
(Stichting Opsporing Erfelijke Tumoren/STOET). This foundation sends timely notification 
to their gastrointestinal specialists to perform the colonoscopic screening and, reversely, 
receives information on the screening results. Hence, the foundation plays a central role 
in the optimisation of screening protocols for hereditary colorectal cancer families. 
Colonoscopy is the technique of first choice for colorectal screening. It is a powerful tool 
in the detection and treatment of premalignant adenomas or early colorectal carcinomas 
in at-risk individuals. Regular colonoscopy was reported to reduce the colorectal cancer 
rate by 62%, and to decrease the overall mortality by about 65%117, 118, 238. These figure can 
be expected to improve with the development of high-resolution and -magnification 
techniques like magnifying endoscopy141. Currently, healthy MMR gene mutation carriers 
are advised to undergo a colonoscopy every 1-2 years from the age of 20-25 years 
onward27, 87. In female MSH6 mutation carriers, the age to start colonoscopic screening 
may be postponed to 30 years101. In Amsterdam criteria positive families without a MMR 
gene mutation, colorectal screening advices are the same as for mutation positive 
families, and apply to all 1st-degree relatives of individuals diagnosed with an HNPCC 
related tumour and to all 2nd-degree relatives whose parent died at young age. Screening 
advices to affected relatives are weighted carefully, taking into account the prognosis due 
to the former tumour. Clear disadvantages of colonoscopy are the burden of this 
procedure for the patient, the risk of perforation of the colorectum (0.1%), the risk of 
bleeding, and the costs. Among 42 healthy Dutch MMR gene mutation carriers, 88% had 
colonoscopic screening every 1-2 years. In chapter 3.4, we discuss the appreciation of 
colonoscopy in these mutation carriers. In individuals with a contra-indication for 
colonoscopy, barium enema and/or faecal occult blood testing are, though less sensitive, 
alternatives29, 337. Testing for genetic markers TP53, BAT26, APC and KRAS in stool may 
represent a future non-invasive screening protocol to preselect patients for colonoscopy9, 
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50, 157, 268, 292, 293. Virtual colonoscopy is also considered a potential non-invasive screening 
tool79. Using computer tomography (CT), 80-90% of the polyps larger than 6 mm can be 
detected. Because of the radiation load in CT scanning, magnetic resonance imaging (MRI) 
is a more patient-friendly alternative. However, since detection rates of smaller and flat 
polyps are rather poor in both CT and MRI, virtual colonoscopy is not likely to replace 
conventional colonoscopy in the near future. Moreover, when a polyp is detected by 
virtual colonoscopy, conventional colonoscopy has to be performed anyhow to allow 
polypectomy. No consensus exists on prophylactic colectomy in mutation carriers as a 
standard procedure, primarily because the combined colonoscopy and polypectomy are a 
highly reliable and effective surveillance and preventive strategy137. However, at time of 
diagnosis of colorectal cancer or polyps, subtotal colectomy may be considered in MMR 
gene mutation carriers87, 187.  
Yearly gynaecological examination is advised to female MMR gene carriers starting from 
the age of 30-35 years. This examination includes endometrial aspirate or vaginal 
ultrasound of the uterus and ovaries, and CA125 measurements in blood (CA 125 is a 
tumour marker of ovarian cancer)27, 87, 298. However, the value of this screening is disputed 
and adequate management of early symptoms remains very important52, 244. Prophylactic 
hysterectomy is not routinely offered, but in female carriers already scheduled for a 
colectomy and in female MSH6 carriers, this procedure may be considered. In case of a 
family history of ovarian cancer, prophylactic oophorectomy may also be considered in 
view of the limited value of screening and the poor prognosis of this tumour type87. 
Advises for regular screening for other HNPCC related cancers are tailored based on the 
individual family history27, 87, 298. In families with two or more gastric cancers, gastroscopic 
screening is recommended from the age of 30-35 years every 1-2 years27, 87. Of note, 
gastroscopic screening had no beneficial effect in Finnish MLH1 mutation carriers at a 
follow-up of 3-4 years239. However, limitations of this study are the size of the patient 
cohort, the genetic homology (the majority of the patients carried a Finnish founder 
mutation in MLH1) and the short follow-up period. Helicobacter Pylori may also represent 
a confounding factor. In HNPCC families with familial or early onset gastric cancer 
relatives should be analysed for H. Pylori infection. Urinary tract screening is also advised 
from the age of 30-35 years by cytological urine sediment analysis every 1-2 years. The 
sensitivity of this technique can be improved by molecular methods like microsatellite 







Table 7.  
Screening advises in HNPCC(-like) families27,29,30,73,201. These advices apply to healthy first 
degree relatives of individuals with an HNPCC related tumour. Of note, if a parent died 










colon colonoscopy 20-25* 
or  
5 yrs before 
earliest crc in 
family 
1-2 Consider colectomy 
with ileorectal 
anastomosis at diagnosis 
of cancer or in case of 
multiple recurrent 
polyps. 
In female MSH6 carriers 
the age of onset of 
screening may be 







30-35 1 Consider prophylactic 
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colon colonoscopy 20-25 1-2 or starting 5 years 
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30-35 1 depending on family** 
1 first-degree 
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colon colonoscopy 45-50  
or  
5 years before 
youngest crc 


















on request  
Fecal Occult Blood 
Testing (FOBT) is less 
invasive but also less 
sensitive than other 
screening tools. 
Colonoscopy is the 
most sensitive tool. 
 
** If 2 or more relatives are affected with stomach, small bowel or urinary tract cancer (If only 1 
relative is affected at an early age, screening the first degree relatives can be considered in view of 
additional riskfactors in this branch of the family). 





It is generally believed that diet has a profound impact on colorectal cancer risk. 
However, experimental evidence has been hard to obtain and it is unlikely that the 
colorectal cancer risks of MMR gene mutation carriers can be significantly modulated by 
dietary factors131, 236. No difference in meat consumption was seen in sporadic colorectal 
adenoma cases and HNPCC cases in the Netherlands313. A study on the prevention of 
polyps in HNPCC carriers by resistant starch supplements is in progress28. Nevertheless, a 
balanced diet with adequate fruit, vegetable and cereals intake, restricted alcohol 
consumption, no smoking, weight control, and regular physical exercise are reasonable 
advises.  
Chemoprevention studies in HNPCC carriers are limited309. Studies on calcium carbonate 
were not conclusive91. A international study (CAPP2) on the effect of aspirin (alone and in 
combination with resistant starch) in HNPCC carriers is ongoing28. NSAIDs (non-steroidal 
anti-inflammatory drugs), including aspirin, have been consistently associated with a 
reduced risk of colorectal cancer28, 236. Aspirin inhibits the conversion of arachidonic acid 
to prostaglandins by cyclo-oxygenase 1 and 2 (COX1 and COX2). Because the adverse 
effects of long-term aspirin use are mainly caused by COX1 inhibition, novel NSAIDs, e.g. 
Celecoxib, were developed that selectively inhibit COX2. However, also selective COX2-
inhibitors may increase the risk of cardiovascular events213, making them unsuitable for 
chemoprevention purposes. Also, the spectrum of antineoplastic actions of NSAIDs is broad 
and includes inhibition of angiogenesis, induction of apoptosis, and cancer growth 
inhibition by interference with several signal transduction pathways108, 288. Both Celecoxib 
and Sulindac were reported to cause adenoma regression in patients with familial 
adenomatous polyposis (FAP)41, 74, 91, 108, 288. Also, a significant reduction in duodenal 
polyposis was seen in FAP carriers after treatment with Celecoxib231. However, no effect 
was observed in FAP carriers ranging from 8 to 25 years of age using standard doses of 
sulindac75. A study (CAPP1) on the effects of aspirin in FAP mutation carriers is about to 
report its results28. More insights in the molecular genetic mechanisms underlying tumour 
initiation and progression in HNPCC are expected to lead to the identification of new safe 
targets for tailor-made chemoprevention. For an overview of the status quo of 
chemoprevention in colorectal cancer see Hawk et.al.92. 
The mutator phenotype characteristic of HNPCC tumours causes frameshift mutations in a 
broad spectrum of genes leading to novel peptides that can be recognised by T cells and 
trigger an immune response. The characterisation of peptides specific for MSI-positive 
colorectal cancer cells fuels hope for the development of a prophylactic vaccine for 
HNPCC carriers250. 
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1.13 Differential diagnosis 
The Muir-Torre Syndrome. In 1966 Muir212 described a syndrome with multiple 
primary tumours of the colon, duodenum, larynx, and skin. In 1968 Torre291 presented an 
additional patient with multiple sebaceous adenomata and colon cancer. In the 1980’s 
Lynch et al.69, 188, 190 recognised the Muir-Torre syndrome as a clinical variation of HNPCC. 
Since then, germline mutations of MSH2 and in a lesser extend of MLH1 have been 
found in Muir-Torre families140, 144.  
The Turcot Syndrome. Another clinically defined syndrome that appeared to be an allelic 
variant of HNPCC is Turcot syndrome. In 1959 Turcot295 described two cases (a brother and 
sister) with central nervous system tumours and polyposis coli. In 1995 Hamilton86 
recognised that this association could derive from two distinct types of germline defects: 
mutations in the APC gene that cause Familial Adenomatous Polyposis (FAP) and mismatch 
repair gene mutations (MLH1 and PMS2). The brain tumours in FAP are predominantly 
medulloblastoma, while the HNPCC-associated brain tumours are glioblastoma5, 300. Wang 
et al.321 demonstrated NF1 somatic mutations in MMR-mutant cell lines, possibly providing 
a molecular basis for the development of brain tumours in a subset of MMR gene mutation 
carriers. 
Familial Adenomatosis Polyposis (FAP) and Attenuated FAP (AFAP). In the majority of the 
cases, the clinical diagnosis of Familial Adenomatosis Polyposis is facilitated by the 
presence of hundreds to thousands colorectal adenomas. More than 95% of FAP patients 
carries a disease-causing APC mutation147. MMR gene defects play no apparent role in APC 
mutation negative FAP families96.  
An atypical variant of FAP, attenuated FAP (AFAP), characterised by reduced polyp 
multiplicity (between 5-10 and 100) and a delayed age of onset, is more reminiscent of 
the HNPCC phenotype32. AFAP is caused by specific APC mutations, usually located at the 
extreme 5’ or in the 3’ half of the gene63, or by biallelic MYH mutations15, 122. The latter 
form is now referred to as MAP, MYH-associated polyposis. Wang et al.318 described two 
patients with early onset colorectal cancer and respectively zero and three polyps, both 
homozygous for MYH mutations. In these cases family history and MSI/IHC tests are helpful 
to differentiate diagnoses. In case of a MSI stable phenotype, MMR-gene defects become 
unlikely and analysis of APC and MYH should be considered15, 122.  
Familial colorectal cancer. Colorectal cancer is a common type of cancer and random 
familial clustering of CRC cases is seen in about 15% of the families of patients with 
colorectal cancer. For example allelic variants of high risk colorectal cancer susceptibility 
genes can contribute to less penetrant forms of CRC predisposition164. The guidelines 




families and those kindreds with a clustering of colorectal cancers due to other hereditary 
or non-hereditary factors. Detailed phenotypic characterisation will continue to be of 
great importance for the subclassification of the remaining unresolved colorectal cancer 
families. Until the moment additional molecular genetic markers will be available for 
most of the familial colorectal cancer syndromes, screening advises will mainly be based 
on accurate family history data (Table 7)29, 30. 
Crohn’s disease and colitis ulcerosa. Inflammatory bowel disease is a known risk factor for 
colorectal cancer. NOD2 has been identified as a low risk susceptibility gene for Crohn’s 
disease221. The pathological features of HNPCC related colorectal tumours can include a 
Crohn’s like reaction with tumour infiltrating lymphocytes (TIL) mixed with tumour 
cells181, 198. However, Crohn’s disease and colitis ulcerosa are distinct clinical entities, 
which can easily be differentiated from HNPCC by symptoms and a detailed family history.  
Hyperplastic polyposis, mixed polyposis and serrated adenomatosis. Hyperplastic polyposis 
is a loosely defined syndrome characterised by the occurrence of multiple hyperplastic 
polyps in the colorectum. Hyperplastic polyps are generally considered less prone to 
malignant transformation when compared with adenomatous polyps. However, dysplasia 
has been described in hyperplastic polyps and, especially in cases with high polyp 
multiplicity’s, patients are at increased risk of colorectal cancer93, 136, 153, 237.  
A few families have been described with a combination of different types of colorectal 
polyps, atypical juvenile polyps, adenomas and hyperplastic polyps256, 330. These families 
and are classified as affected by Hereditary Mixed Polyposis Syndrome (HMPS). The 
disorder was mapped to chromosome 6q in 1996, though its genetic basis is yet to be 
elucidated286.  
Occasionally, polyps may display both hyperplastic and adenomatous features. These 
polyps are usually referred to as serrated adenomas. It has been claimed that these 
adenomas arise through a distinct MSI-Low pathway120, 257.  
As the above entities have overlapping clinical features with attenuated or atypical HNPCC 
and FAP cases, their diagnosis should always be excluded in families with hyperplastic, 
mixed or serated polyposis.  
The hamartomatous polyposis syndromes. In juvenile polyposis, the Peutz-Jeghers 
syndrome, and the Cowden syndrome, colorectal hamartomatous polyps and cancer occur 
at increased frequency76, 338. Hamartomatous polyps can be pathologically distinguished 
from HNPCC-related adenomas. Hamartomatous polyposis are often considered as non-
neoplastic. However, they may sometimes harbour dysplasia and their true neoplastic 
potential is yet unknown. Nevertheless, an increased cancer risk both within and outside 
the gastrointestinal tract exists in these syndromes. Other clinical features of 
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hamartomatous polyposis syndromes, like early age at diagnosis of juvenile polyposis, the 
mucocutanous pigmentations in Peutz-Jeghers syndrome and the tricholemmoma in 
Cowden syndrome, may help to differentiate them from HNPCC. Finally, mutation analysis 
of the respective causative genes (SMAD4 and BMPR1A for juvenile polyposis, LKB1/STK11 
for Peutz-Jeghers syndrome, and PTEN for Cowden syndrome) may indisputably resolve 
these syndromes from HNPCC. 
Hereditary breast-ovarian cancer. Germline BRCA1 and BRCA2 mutations cause an 
increased risk for breast and ovarian cancer202, 340. In familial ovarian cancer families both 
BRCA1/BRCA2 susceptibility and HNPCC should be considered. Apart from mutation 
analysis of BRCA1/BRCA2 and the MMR genes, MSI and IHC analysis may help to distinguish 
the two entities. However, data on MSI and IHC testing in ovarian cancer are limited. 
Familial gastric cancer. Familial gastric cancer has been linked to two genetic 
predispositions, E-cadherin mutations and HNPCC31. Pathologically, E-cadherin mutations 
give rise to diffuse gastric cancer, while HNPCC-associated gastric cancer tends to be of 
the intestinal type. Once again, detailed family history, clinical data, and MSI/IHC tumour 
analysis can help to direct further molecular analysis and formulate a more accurate 
diagnosis84, 230. 
Neurofibromatosis type 1 (NF1). Though individuals with NF1 have an increased risk of 
colorectal cancer, the phenotype is generally easy to distinguish by the occurrence of café 
au lait spots, freckling and neurofibromas. However, children with biallelic MMR gene 
mutations develop features of neurofibromatosis type 1 in addition to other 
malignancies45, 46, 71, 200, 243, 320, 331. Hence, in children with features of NF1 and a family 
history of HNPCC-related tumours or a more recessive inheritance pattern, one should 
consider MMR gene mutation analysis. 
 
1.14. Molecular diagnostics of HNPCC 
 The molecular diagnosis of HNPCC in a given kindred implies several steps and 
analytical procedures. Rather than directly applying mutation detection techniques to 
identify HNPCC-causing lesions in MMR genes, most diagnostic centres initiate their search 
by investigating tumour material (when available) to assess genetic instability and loss of 
specific MMR protein expression by MSI (microsatellite instability) and IHC 
(immunohistochemistry) analysis respectively. They allow confirmation of the MMR defect 
in the tumour (MSI and IHC) and the identification of a specific gene whose protein 
expression has been lost in the tumour (IHC). The latter gene will then represent the first 




(usually blood) patient material. Here, each technical approach will be described 
separately.   
Microsatellite instability (MSI) is defined as the type of genomic instability associated with 
defective DNA mismatch repair in tumours. Analysis of MSI is performed by PCR 
amplification of specific mono- and dinucleotide microsatellite repeats and by comparing 
the size of their alleles between normal and tumour DNA. Tumour-specific changes in 
allele sizes are indicative of genetic instability due to loss of MMR function. MSI analysis is 
usually performed on paraffin embedded tumour samples with or without microdissection 
of the parenchymal cells. The National Cancer Institute recommended five most 
informative markers with respect to colorectal cancers, and has formulated guidelines for 
MSI interpretation (Table 4)24. According to the degree of MSI detected, tumours are 
subdivided in high-frequency MSI (MSI-H), if two or more of the five markers show 
instability, and low-frequency MSI (MSI-L), if only one of the five markers shows instability. 
Tumours with no instability in any of the markers are considered to be microsatellite 
stable (MSS). The implications for MSI-L are not yet clear. It is suggested that if enough 
markers are tested, all colorectal tumours display some degree of instability146. The 
resolution between microsatellite high (MSI-H) and low frequency MSI (MSI-L) can only be 
accomplished if a greater set of markers (especially including mononucleotide markers like 
BAT40) is utilised (Table 4)24, 296. The use of additional mononucleotide repeats is also 
useful when dealing with HNPCC due to MSH6 germline mutations, known to be associated 
with preferential microsatellite instability at mononucleotide repeats43, 101. The same NCI 
markers are also employed for the prediction of a MMR gene defect in endometrial 
cancers43, though little data are yet available on their reliability for other HNPCC-related 
tumours. 
Immunohistochemical analysis (IHC) is a rapid and inexpensive method for identifying 
MMR-gene alterations160. As for MSI, IHC is also performed on histological sections from 
paraffin embedded tumours with antibodies specifically raised against the main MMR 
proteins: MSH2, MLH1, MSH6 and PMS242, 43. Absence of staining for a specific protein is 
likely to result from the 2nd somatic hit at the MMR gene where the germline mutation is 
present. Therefore, IHC represents a useful tool to direct mutation analysis and enhance 
cost-effectiveness of the mutation detection procedure. Normal staining of a given MMR 
protein, however, does not exclude the presence of a mutation of the corresponding 
gene160, 317.   
Tissue Microarrays (TMAs) represent a powerful novel technology for high-throughput 
analysis of protein expression in a large number of tissue (tumour) samples. Hundreds of 
tissue cores are arranged on a single slide, and then analysed by a single IHC reaction123. 
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TMA’s can significantly enhance the processivity of IHC, although their systematic use in a 
diagnostic setting has not been evaluated yet.  
In order to detect mutations in genomic DNA, a large number of protocols are available280. 
However, since the comprehensive description of these diverse technologies is outside the 
scope of this thesis, I will here only briefly describe the HNPCC mutation detection 
protocols most commonly employed in our laboratory. 
Denaturing gradient gel electrophoresis (DGGE) allows the rapid screening for single base 
changes in PCR-amplified genomic DNA62. The technique is based on the migration of 
double-stranded DNA molecules through polyacrylamide gels containing linearly increasing 
concentrations of a denaturing agent. The mobility of the DNA molecule is strongly 
retarded at the concentration at which the DNA strands with the lowest melting domain 
dissociate. This branched structure becomes entangled in the gel matrix and no further 
movement occurs. Complete strand separation is prevented by the presence of a high 
melting domain, which is usually artificially created at one end of the molecule by 
incorporation of a GC clamp. The latter is usually accomplished during PCR amplification 
using a primer with a 5' tail consisting of a random sequence of approx. 40 GC. Single base 
substitutions, deletions and insertions are detected with high sensitivity by DGGE 
analysis62.  For HNPCC mutation analysis, individual MSH2, MLH1 and MSH6 exons are 
amplified by PCR, with one of the two primers implemented with a 5’ GC-clamp. The PCR 
product is then loaded on the denaturing gradient gel. Exons with altered patterns of 
migration on DGGE are subsequently sequenced to determine the nucleotide alteration335, 
336.  
Mutation detection techniques such as DGGE detect “point mutations”, i.e. single base 
substitutions and small (1-10 nt) deletions and insertions. However, larger genomic 
rearrangements such as deletions, duplications, insertions, and inversions also represent a 
frequent cause of hereditary conditions. To detect this type of genetic defect the 
implementation of other mutation analysis strategies is required. 
Southern blot analysis is a rather old and cumbersome method but, to date, it still 
represents the most reliable and accurate approach to detect large rearrangements in 
total genomic DNA. High molecular weight DNA is usually extracted from peripheral blood 
lymphocytes though many other types of tissues can be employed. DNA is then digested by 
restriction endonucleases, fractionated according to the molecular weight of the resulting 
fragments by electrophoresis through agarose gels, and then transferred onto a nylon 
membrane. The latter are hybridized with (radioactively) labelled DNA probes that 





Conform to our previously established protocol334, Southern analysis of the MSH2 gene is 
performed with XbaI, EcoRI, HindIII, NsiI, genomic DNA digests, followed by hybridization 
with three MSH2-specific probes (encompassing exons 1-7, 7-12, and 10-16 respectively). 
MLH1 and MSH6 Southern analysis is performed with XbaI, ApaI, HindIII and NsiI genomic 
DNA digests followed by hybridization with two MLH1- (exons 1-12 and 11-19) and two 
MSH6-specific probes (exons 1-4 and 5-10)334. As reported in chapter 2, the 
implementation of the Southern blotting procedure in the analysis of the MMR genes in 
HNPCC has resulted in the identification of a significant number of genomic deletions and 
other less common types of rearrangements297, 315, 334. Although Southern analysis is still 
the method of choice in a “discovery phase”, i.e. to define the spectrum of genomic 
rearrangements at any given disease locus, its protocol is too cumbersome and time-
consuming to be efficiently implemented in diagnostic laboratories. PCR-based methods 
for the detection of genomic deletions and duplications are nowadays available.  
Multiplex Ligation-dependent Probe Amplification (MLPA) is based on quantitative 
multiplex PCR in order to determine the relative copy number of each exon within a gene 
of interest77. Two specific probes are hybridised with the denatured target DNA. If 
hybridised, the probes are ligated and PCR amplified. The amount of probe amplification 
product reflects the copy number of the target sequence. MLPA has been successfully 
applied for the detection of MMR genomic rearrangements in HNPCC patients35, 36, 77, 189, 220, 
232, 307, 315, 321. However, there are some limitations. For example, rearrangements not 
encompassing the coding region will not be detected by MLPA unless specific PCR 
strategies are designed to cover extensive portions of the flanking regions where 
regulatory elements are likely to be located. Also, Southern analysis, when performed 
with at least two different restriction enzymes, allows accurate mapping of the extent of 
the rearrangement and the consequent design of PCR primers to specifically amplify the 
breakpoints and the rapid detection of the disease-causing deletion/insertion in other 
affected family members. MLPA does provide indication of the presence of a genomic 
deletion/duplication but not on the exact location of the breakpoint, especially when 
dealing with disease genes with very large introns. Moreover, inversions are not detected 
by MLPA as no quantitative change at the genomic DNA level is observed113.  
Other analytical approaches are available to aid molecular genetic investigations on 
specific cases, e.g. missense mutations of questionable pathogenicity, or MMR mutation-
negative individuals belonging to Amsterdam positive families with MSI-H tumours and/or 
informative IHC assays.  
Mono-Allelic Mutation Analysis (MAMA or conversion technology) represents a useful tool 
for the analysis of “masked” mutations (hard to detect by conventional techniques), 
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missense mutations, splicing errors and genomic alterations216, 224, 344. To allow RNA and 
protein expression analysis of putative disease-causing MMR alleles in a heterologous 
genetic background, somatic cell hybrids are obtained by fusing patient-derived cells 
(typically blood lymphocytes) with Msh2-deficient mouse cells (GMP Conversion 
Technologies Inc., Waltham, MA)224, 344. Somatic cell hybrids carrying the chromosome of 
interest can be identified by genotyping with dinucleotide repeat markers and are then 
selected for mono-allelic expression analysis, e.g. by northern or western blot analyses or, 
if MSH2 is the gene of interest, by more functional assays taking advantage of the absence 
of endogenous Msh2 expression in the recipient murine cells.  
Additional functional assays can be performed in yeast based on interference of 
recombinant human MLH1 with the yeast MMR machinery261. Alternatively, yeast strains 
expressing mismatch repair genes mutations at codons homologous to ’suspected’ 
substitutions found in HNPCC patients can be analysed by MMR assay that measures 
stability of mono- or dinucleotide repetitive tracts in vivo55, 234. Other functional assays 
make use of the ability of MLH1 and PMS2 or MSH2 and MSH6 to dimerize by co-
immunoprecipitation analysis after transfection of mutant or wildtype MLH1, PMS2, MSH2 
or MSH6 in MLH1- or MSH2-deficient colorectal cancer cells or in insect cells(Sf9)25, 125, 219, 
294.   
In the Netherlands, diagnostic mutation analysis of the MLH1, MSH2 and MSH6 genes is 
provided by university-affiliated DNA laboratories. Each gene analysis usually takes 3 to 6 
months. At present, PMS2 testing is not offered in diagnostic settings. The costs per gene 
per 2004 amount to approximately ∈650. MSI and IHC analysis of HNPCC related tumours 
are offered by several pathology departments at variable costs. Costs for MSI, IHC, and 
mutation analyses are fully covered by health insurance companies. Diagnostic MMR gene 
testing is also offered by several laboratories in Europe on a non-profit basis 
(www.EDDNAL.com). Commercial tests are available in the United States (Myriad 
Genetics) and Europe (Gendia).   
 
1.15 Selection for mutation analysis 
The Amsterdam criteria, established by the International Collaborative Group on 
HNPCC (Table 2)299, 301, are valuable guidelines for the clinical recognition of HNPCC. 
Families fulfilling these criteria have a high a priori risk (45%- 64%) to carry germline 
mutations in one of the two major MMR genes73, 333. Also families not fulfilling the 
Amsterdam criteria may harbour a MMR gene mutation, though chances are significantly 




We showed that failure to detect a MMR gene mutation in Amsterdam criteria positive 
families could be explained by either (1) marginal fulfilment of the criteria in true-
mutation negative families, or (2) incorrect patient selection (phenocopy) in mutation 
positive families, or (3) failure of mutation detection techniques in mutation positive 
families. Due to the relatively high incidence of colorectal cancer in the general 
population, families may fulfil the Amsterdam criteria by chance. Katballe et al.130 
calculated that the Amsterdam criteria I would be met by chance only in 1 out of 77 
families with a young colorectal cancer patient (age of diagnosis <50 years). We detected 
a MMR mutation (mainly in MLH1 and MSH2) in all families tested with 2 additional HNPCC-
associated tumours apart from the Amsterdam criteria315 and in all families fulfilling the 
Amsterdam criteria by the presence of a relative with a non-colorectal HNPCC-associated 
cancer, as formulated in the revised Amsterdam criteria. HNPCC-associated cancers 
become more common at older age. To minimise the risk of testing a phenocopy, the 
patient tested for MMR mutations should therefore preferentially be the youngest affected 
individual within the family. Using a comprehensive set of mutation detection techniques, 
we detected a MSH2 or MLH1 mutation in more than 90% of Amsterdam criteria positive 
families315.  
Families with a MMR gene mutation may fail to meet the Amsterdam criteria for several 
reasons, namely reduced penetrance of specific MMR mutant alleles (e.g. MSH6 and 
PMS2), early death of relatives due to cancer unrelated causes, non-paternity, lack of 
family history data, and small family size. However, most of these families will eventually 
qualify as Amsterdam positive, after efforts have been made to expand the pedigree 
structure and to obtain additional medical information. Anamnestic data on family history 
should be verified whenever possible203.  
In addition to family history, MSI and IHC analysis have been proven useful tools for the 
selection for mutation analysis18, 47, 148, 175, 282. More than 90% of HNPCC-associated 
colorectal cancers display microsatellite instability3, 67, in contrast to 12-18% of the 
sporadic colorectal cancers114. Reversely, Liu et al.168 detected a MMR gene germline 
mutation in 73% of families with familial colorectal cancer and a MSI-High tumour in one 
of the patients. MSI as the only pre-screening tool for MMR gene mutation analysis in 
unselected colorectal cancer will result in a mutation detection rate of only 5-10%. Since 
MSI is an expensive and laborious technique, and in view of the many sporadic MSI-High 
tumours that would be detected, screening of all colorectal cancer by MSI analysis is 
unattractive as a pre-screen tool.  
The Bethesda guidelines for selection of tumours for MSI analysis were formulated in 1997 
and revised in 2004 (Table 3)248, 296. When compared to the Amsterdam criteria as a 
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clinical prescreen tool, the Bethesda guidelines improve the MMR gene mutation analysis 
sensitivity, but lowers its specificity as a considerable number of families with more 
atypical phenotypes are included 277. However, these atypical families may harbour MSH6 
or PMS2 mutations42. This pleads for a liberal selection of cases for MSI analysis as 
appreciated in the revised Bethesda criteria. 
MSI analysis is preferentially performed on colorectal cancer of the youngest patient in 
the family. If no colorectal cancer is available, endometrial cancer, or other HNPCC-
associated cancers, or adenomas, are often tested. However, the interpretation of normal 
MSI results (MSS) in these latter settings is more difficult and has to be scored as non-
conclusive. 
Immunohistochemical (IHC) analysis of MMR proteins has earned a place as a pre-screening 
tool for MMR gene mutation analysis42, 43, 100, 160. Of note, positive IHC staining does not 
exclude the presence of a MMR gene mutation, as certain mutation types do not interfere 
with the translation of a protein detectable by IHC317. Also, many sporadic colorectal 
cancers show a decreased MLH1 expression due to promotor hypermethylation. MSI and 
IHC patterns generally show a high degree of concordance38, 39, 47, 160, 240, 317. Berends et al. 
indicate that IHC analysis might be the best prescreen tool in colorectal cancers diagnosed 
under the age of 50 years20. 
Few studies have been carried out to evaluate the concordance between the presence of a 
MLH1, MSH2 or MSH6 germline mutation, and the MSI and/or IHC status of the 
corresponding tumours20, 39, 47, 100, 317, 323. The results of these studies are summarised in 
Table 8. In total, 98 out of 106 tumours from mutation carriers (92%) tested as MSI-High, 
89 (84%) revealed aberrant MLH1, MSH2 or MSH6 staining patterns, whereas 87 (82%) had 
both. Eleven mutation carriers (10%) only displayed MSI with no IHC staining aberrations. 
Two patients (2%) only displayed aberrant IHC and no MSI. Therefore, a total of 13 
mutation carriers (12% of all tumours) displayed either only MSI, or aberrant IHC staining 
in their tumours. Three of the mutations in these 13 carriers were of unknown 
significance. By combining MSI and IHC analysis, 100 out of 106 (94%) mutation carriers 
were detected; the 6 mutations unnoticed by MSI or IHC analysis were of unknown 
significance. Sixteen mutation negative index patients (33%) displayed both MSI and IHC 
aberrations, suggesting failure of mutation detection techniques. In 82 tumours from MMR 
gene mutation carriers in which at least MLH1 and MSH2 IHC-staining results were 
available, a strong correlation was found between aberrant staining and the presence of a 
germline mutation: 29 tumours from 30 MLH1 mutation carriers were MLH1-negative (no 
nuclear staining) but positive for MSH2; 39 out of 42 tumours of MSH2 mutation carriers 




from MSH6 mutation carriers displayed no MSH6 staining but were positive for MLH1 and 
MSH2. Among those cases tested for all three MMR proteins, MSH6 staining was often 
negative in tumours from MSH2 mutation carriers and occasionally in MLH- related 
tumours. 
To date, a combined approach of family history, MSI and IHC analysis is generally 
recognised as the most evidence-based and cost-effective way to select patients for MMR 
gene mutation analysis42, 47, 175, 240, 296. A practical flowchart of the steps involved in the 
selection of individuals with multiple or early onset HNPCC-associated tumours for MMR 
gene mutation analysis, and of families with some clustering of HNPCC-associated 
tumours, is shown in Figure 10.  
Wijnen et al.336 proposed a statistical approach for the selection of families for MMR gene 
mutation detection. They devised a logistic model for estimating the likelihood of a MLH1 
or MSH2 mutation based on clinical data (Table 9). They recommended mutation analysis 
for any individual with a likelihood over 20% of carrying an MMR gene mutation. Loukola et 
al.175 proposed to perform MSI analysis on tumours of individuals with a likelihood of more 
than 5% according to the algoritm developed by Wijnen et al.  
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A practical flowchart for the management of individuals with multiple or early onset HNPCC-associated 
tumours, and/of families with clustering of HNPCC-associated tumours. * The more “classic” the family,
the less additional value has MSI and/or IHC, however IHC can be used to direct mutation analysis.  50 Introduction 
Table 8.  
Comparison of MSI and IHC analysis in 154 tumours of 119 families analysed for MLH1, and 
MSH2 mutations20,39,47,100,317,323. In all studies except in that of Debniak et al. the 
international markers for MSI analysis24 (sometimes enhanced with BAT40) were used. 
Debniak et al. used 10 markers including 3 international markers and BAT40. Hendriks et 
al. and Berends et al. also performed IHC for MSh6 and mutation analysis of MSH6. 
 Mutation Normal IHC (%) Aberrant IHC (%) Total (%) 
MLH1 8 (25) 24 (75) 32  
MSH2 1  (4) 26 (96) 27 
MSH6 2  (5) 37 (95) 39 
positive 
Subtotal 11 (11) 87 (89) 98 (92) 
Negative 8 (33) 16 (67) 24 
MSI-H/L (%) 
Subtotal 19 103 122 (79) 
MLH1 3 (75) 1 (25) 4 
MSH2   3 (100) 0 3 
MSH6 0 1 (100) 1 
positive 
Subtotal 6 (75) 2  (25) 8 (8) 
Negative 23 (96) 1    (4)  24 
MSS (%) 
Subtotal 29 3 32 (21) 
Total  48 106 154 
MLH1 11 (31) 25 (69) 36 
MSH2 4 (13) 26 (87) 30 
MSH6 2 (5) 38 (95) 40 
positive 
Subtotal 17 (16) 89 (84) 106 (69) 
All (%) 
Negative 31 (65) 17 (35)  48 (31) 
Total  48 (31) 106 (69) 154 
 
Table 9.  
Logistic regression model for selection of families for MSH2 and MLH1 mutation analysis336. 
Including Amsterdam criteria I 
Log Odds = L  
L = 1,4 + (-0.1)V1 + 1,7V2 + 2,4V3
V1 = mean age at diagnosis of all crc patients 
in the family 
 V2 = equal 1 if at least 1 relative has ec; 
otherwise it equals 0 
 V3 = equals1 if family meets ACI;  
otherwise it equals 0  
Including Amsterdam criteria II 
Log Odds = L 
L = 2,34 + (-0,1)V1 + 0,25V2 + 1,6V3 + 0,96V4
V1 = mean age at diagnosis of all crc 
patients in the family 
 V2 = number of patients with crc 
 V3 = number of patients with both crc/ec 
 V4 = equals1 if family meets ACII;  
otherwise it equals 0 
Excluding Amsterdam criteria I and II 
Log Odds = L  
L = 2,79 + (-0,1)V1 + 0,33V2 +1,45V3
V1 = mean age at diagnosis of all crc patients 
in the family 
 V2 = number of patients with crc 
 V3 = number of patients with both crc and ec 
Mutation analysis of MSH2 and MLH1 is performed if  eL/(1-e)L ≥ 0.2  
(probability of finding MLH1 or MSH2 mutation ≥20%) 




1.16. Genetic counselling 
Appropriate counselling is a prerequisite before genetic testing for HNPCC takes 
place, in view of the medical, psychological and social consequences for mutation carriers 
and their relatives. With respect to genetic diseases, the World Health Organization 
defines counselling as the ‘provision of accurate, full and unbiased information in a 
caring, professional relationship that offers guidance, but allows individuals and families 
to come to their own decisions’332. General guidelines for cancer susceptibility testing 
were formulated by the American Society of Clinical Oncology in 1996 and updated in 
20031, 2.  
The counselee who initially seeks genetic advice generally fulfils a central role in the 
counselling of the family. He/she is asked to contact affected relatives for their 
participation in MSI/IHC and/or MMR gene analysis. Screening advises for relatives are 
initially communicated through the initial counselee. It is the task of the genetic 
counsellor to assist and advice the counselee in this process. Also, the implications of not 
finding a MMR gene mutation in a family must be understood by the counselee prior to 
testing.  
In families with a known mutation in MLH1, MSH2 or MSH6, genetic testing is offered to all 
affected and healthy adult risk carriers. Since the cancer risks in HNPCC start rising from 
about 20-25 years of age, genetic testing is not offered before adulthood. The use of 
genetic testing in families with a known MMR gene mutation has been studied by us and 
others12, 154, 316. Though the studies were performed in different settings, the test rate in 
individuals with a priori risk of 50% of carrying a mutation varied from 57 to 75%. If the 
counselee is affected by an HNPCC-related tumour, the risk of carrying the mutation is 
high though not 100%, and is therefore worth confirming by DNA analysis.  
The recommended protocol for genetic testing includes three counselling sessions, a pre-
test session, a session during which blood sampling is performed, and the test disclosure 
session 13, 154, 179. Generally, this counselling procedure is judged as sufficient (see chapter 
3.4)13. Of note, Dutch mutation carriers indicated that they would appreciate a regular 
update on new developments or scientific progress in the field of HNPCC, in addition to 
this protocol (see chapter 3.4). 
Clearly, the absence or presence of a mutation is of considerable medical significance. 
Healthy individuals not carrying the mutation can be dismissed from medical surveillance, 
sparing them from invasive screening and reducing health-care costs272. Importantly, 
mutation carriers can benefit from medical surveillance programs. In 42 healthy Dutch 
HNPCC carriers, the compliance for colon screening increased from 31% before testing to 
88% after testing (see chapter 3.4). 
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Genetic testing may also have a considerable psychological impact. Knowledge of having a 
cancer predisposition increases cancer worry. Several studies showed that most tested 
individuals are able to cope with a positive test result on the short-term, particularly in 
HNPCC12, 13, 171. After a short period of increased distress after the test result disclosure, 
the distress generally declines to levels comparable with those of non-carriers at one year 
follow-up14. Like in non-carriers, the ability to cope with a positive test result, is closely 
related to the ability to cope with problems overall, and to pre-test distress171. Also, on 
the long term the majority of Dutch mutation carrier was able to cope with being a gene 
carrier (chapter 3.4). In our study, about 10% of the mutation carriers experienced cancer 
worry on the long term. This was significantly associated with a high perceived risk of 
colorectal cancer. Regret of being tested occurred in 6 of 70 mutation carriers (9%) tested 
at our department (chapter 3.4). Notably, in 4 of these 6 mutation carriers, serious cancer 
events had happened in the family since their personal test disclosure. Events in the 
family are also known to influence perceived cancer risk196.  
Since the majority of the unaffected at risk relatives will receive a negative test result329, 
most test applicants are relieved from fear. However, also non-carriers might experience 
adverse effects of testing. Especially if non-carriers show high pre-test distress and less 
effective coping strategies, they are at increased risk of post-test psychological distress 
and complex emotions summarised as “survivors guilt”14, 171, 178, 289. Non-carriers might feel 
guilty because they do not have the predisposition while close relatives have. This can 
have a large impact on family relationships; people even may become alienated from their 
family178. The relief of personal risk may also activate unresolved grief, and a few non-
carriers will continue to have cancer fear172.  
Genetic testing may have considerable social consequences. First of all at the family-
level, where several conflicts may arise. To search for the familial germline MMR 
mutation, co-operation of an affected relative often needs to be sought. Relatives may be 
unwilling to co-operate, depending on prior relationships and also on personal views. 
Sometimes unaffected relatives put too much pressure on their affected relatives to 
obtain their co-operation. Different coping strategies of relatives may disturb 
relationships. Informing children and family members about a genetic cancer risk is 
generally experienced as a burden, especially if more distant family members are 
concerned. There is no legal duty to inform relatives about a MMR gene mutation in the 
family, but most family members and professionals feel a moral duty to do so57. Peterson 
et al.229 interviewed 39 members of 5 mutation positive HNPCC families. All participants 
had suspected a hereditary predisposition for cancer in their family prior to the 




the same as the pattern used to communicate other non-urgent family news. The 
information was experienced as private but not secret and discussed first with the nuclear 
family members. Individuals who are encouraged by their relatives to seek genetic 
counselling seem to opt for genetic testing more frequently85, 229.  
Another important issue is the (fear of) employment and insurance discrimination. There 
is large international variation in legislation concerning individuals with a genetic 
predisposition to cancer. In the Netherlands, employers or insurers are forbidden by law 
to exclude individuals with a genetic predisposition for cancer from jobs or health 
insurance. For life or disability insurances, no questions about genetic predispositions may 
be asked by insurance employees for insurances below a certain limit (∈160.00 for life 
insurance and ∈32.000 in the first year of a disability insurance and ∈22.000 the following 
years). To our experience, possible future employment and insurance discrimination is an 
increasingly important reason to postpone or refrain from testing. Of 10 Dutch healthy 
HNPCC carriers opting for life or disability insurance or mortgage, 4 mentioned some 
trouble (see chapter 3.4). This is confirmed by Hadley et al.85 who found potential effect 
on health insurance as the most important reason to refrain from testing in 50% risk 
carriers in 15 American families. 
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Molecular Analysis of Hereditary Nonpolyposis Colorectal Cancer
in the United States: High Mutation Detection Rate among Clinically
Selected Families and Characterization of an American Founder Genomic
Deletion of the MSH2 Gene
Anja Wagner,1,3,* Alicia Barrows,4,* Juul Th. Wijnen,1 Heleen van der Klift,1
Patrick F. Franken,1 Paul Verkuijlen,1 Hidewaki Nakagawa,5 Marjan Geugien,1
Shantie Jaghmohan-Changur,1 Cor Breukel,1 Hanne Meijers-Heijboer,3 Hans Morreau,2
Marjo van Puijenbroek,2 John Burn,6 Stephany Coronel,4 Yulia Kinarski,4 Ross Okimoto,4
Patrice Watson,4 Jane F. Lynch,4 Albert de la Chapelle,5 Henry T. Lynch,4 and Riccardo Fodde1
1Center for Human and Clinical Genetics and 2Department of Pathology, Leiden University Medical Center, Leiden, The Netherlands;
3Department of Clinical Genetics, Erasmus University Medical Center, Rotterdam, The Netherlands; 4Department of Preventive Medicine and
Public Health, Creighton University, Omaha, NE; 5Human Cancer Genetics Program, Comprehensive Cancer Center, The Ohio State
University, Columbus, OH; and 6Department of Clinical Genetics, University of Newcastle, Newcastle upon Tyne, United Kingdom
The identification of germline mutations in families with HNPCC is hampered by genetic heterogeneity and clinical
variability. In previous studies, MSH2 and MLH1 mutations were found in approximately two-thirds of the Am-
sterdam-criteria–positive families and inmuch lower percentages of the Amsterdam-criteria–negative families.There-
fore, a considerable proportion of HNPCC seems not to be accounted for by the major mismatch repair (MMR)
genes. Does the latter result from a lack of sensitivity of mutation detection techniques, or do additional genes
underlie the remaining cases? In this study we address these questions by thoroughly investigating a cohort of
clinically selected North American families with HNPCC. We analyzed 59 clinically well-defined U.S. families with
HNPCC for MSH2, MLH1, and MSH6 mutations. To maximize mutation detection, different techniques were
employed, including denaturing gradient gel electrophoresis, Southern analysis, microsatellite instability, immuno-
histochemistry, and monoallelic expression analysis. In 45 (92%) of the 49 Amsterdam-criteria–positive families
and in 7 (70%) of the 10 Amsterdam-criteria–negative families, a mutation was detected in one of the three analyzed
MMR genes. Forty-nine mutations were in MSH2 or MLH1, and only three were in MSH6. A considerable
proportion (27%) of the mutations were genomic rearrangements (12 in MSH2 and 2 in MLH1). Notably, a deletion
encompassing exons 1–6 of MSH2 was detected in seven apparently unrelated families (12% of the total cohort)
and was subsequently proven to be a founder. Screening of a second U.S. cohort with HNPCC from Ohio allowed
the identification of two additional kindreds with the identical founder deletion. In the present study, we show that
optimal mutation detection in HNPCC is achieved by combining accurate and expert clinical selection with an
extensive mutation detection strategy. Notably, we identified a common North American deletion in MSH2, ac-
counting for ∼10% of our cohort. Genealogical, molecular, and haplotype studies showed that this deletion rep-
resents a North American founder mutation that could be traced back to the 19th century.
Introduction
Hereditary nonpolyposis colorectal cancer (HNPCC
[MIM 114500]) is the most frequent autosomal domi-
nant predisposition to the development of colorectal
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cancer. It is caused by germline mutations in human
homologues of the bacterial mismatch repair (MMR)
genes MutL and MutS: MSH2 on chromosome 2p16,
MLH1 on 3p21, MSH6 on 2p15, and PMS1 and PMS2
on 7p22 (Fishel et al. 1993; Bronner et al. 1994; Ni-
colaides et al. 1994; Akiyama et al. 1997; Miyaki et al.
1997). The identification of germline mutations in fam-
ilies with HNPCC and HNPCC-like disease is hampered
not only by this locus heterogeneity but also by the clin-
ical variability among families with HNPCC.Apart from
a lifetime risk of colorectal cancer of ∼80% (Vasen et
al. 1996; Aarnio et al. 1999), individuals with an MMR
gene mutation are characterized by an increased risk of
tumors of the endometrium, stomach, small intestine,
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pancreas, hepatobiliary system, urinary tract, ovary,
brain, and skin (Lynch 1999). The vast majority of
HNPCC-causing mutations have been reported inMSH2
and MLH1 (Peltomaki and Vasen 1997). Accordingly,
mutations in these genes give rise to the “classical”
HNPCC phenotype (Wijnen et al. 1997; Giardiello et
al. 2001), whereasMSH6mutations have been described
in families with more atypical HNPCC (Kolodner et al.
1999; Wijnen et al. 1999; Wu et al. 1999; Wagner et al.
2001). Only a few PMS2 germline mutations have been
described so far (Hamilton et al. 1995; Liu et al. 2001).
Identification of HNPCC-causing MMR gene muta-
tions enables at-risk relatives to be informed about their
cancer risks and to benefit from intensive surveillance
programs that have been proven to reduce their over-
all mortality by 65% (Jarvinen et al. 2000). To opti-
mize mutation analysis in families with HNPCC and
HNPCC-like disease, several clinical criteria have been
formulated. Of these, the Amsterdam criteria, estab-
lished by the International Collaborative Group on
HNPCC (Vasen et al. 1991, 1999), are now recognized
as the gold standard in HNPCC clinical selection. Pre-
viously, MLH1 or MSH2 mutations have been found
in only 45%–64% and 0%–47% of the Amsterdam
criteria–positive and –negative families, respectively
(Giardiello et al. 2001). Since 190% of HNPCC colo-
rectal cancers display microsatellite instability (MSI)
(Aaltonen et al. 1994; Fujiwara et al. 1998), in contrast
to 12%–18% of the sporadic colorectal cancers (Ionov
et al. 1993; Thibodeau et al. 1993), the “Bethesda
guidelines” include MSI as an additional selection tool
for MMR gene mutation analysis (Rodriguez-Bigas et
al. 1997). However, although the application of the Be-
thesda guidelines does improve the mutation analysis
sensitivity, it also results in a remarkable reduction of
its specificity compared with the Amsterdam criteria,
since a considerable number of families with more atyp-
ical phenotypes are included (Syngal et al. 2000). The
value of immunohistochemical (IHC) analysis of MMR
proteins as a valuable additional selective tool has been
shown in several studies (de Leeuw et al. 2000; Lindor
et al. 2002; Hendriks et al. 2003), although positive
IHC staining is observed in the presence of certain mu-
tation types (Wahlenberg et al. 2002).
The fact that germline MSH2 and MLH1 mutations
cannot be identified in a still-considerable proportion
of the families with “classical” HNPCC may be ex-
plained by the involvement of additional HNPCC genes.
MSH6, PMS2, and the more recently described MLH3
and EXO1 genes may represent candidate disease-caus-
ing genes for MSH2- and MLH1-negative families (Wu
et al. 2001a, 2001b). However, preliminary data indi-
cate that germline mutations in these genes are more
likely to either result in atypical HNPCC phenotypes
and are rare in families with “classical”HNPCC (MSH6
and PMS2) or represent only mild genetic modifiers
(EXO1 and MLH3) (Hamilton et al. 1995; Kolodner
et al. 1999; Wijnen et al. 1999; Wu et al. 1999, 2001a,
2001b; Wagner et al. 2001; Jagmohan-Changur et al.
2003). By means of more-sensitive mutation detection
protocols (conversion technology or monoallelic mu-
tation analysis [MAMA]), Yan et al. (2000) showed
involvement of MSH2 or MLH1 in all the families with
“classical” HNPCC analyzed. This suggested that clin-
ically well-defined HNPCC is caused by MSH2 and
MLH1 alone and that our efforts should be focused on
developing new and/or more-thorough mutation detec-
tion approaches. To this end, we analyzed a cohort of
families with clinically very well defined HNPCC and
HNPCC-like disease from the United States for the pres-
ence of MSH2, MLH1, and MSH6 germline mutations,
by using different techniques to optimize mutation de-
tection. The results presented here not only provide a
comprehensive spectrum of the molecular basis of
HNPCC in the United States but also underscore the
need for clinical selection for a cost-effective screening
of MMR genes.
Patients and Methods
The Henry Lynch HNPCC Cohort
The study included a total of 59 extended families
selected for having conditions reminiscent of HNPCC
by H. Lynch at the Department of Preventive Medicine
and Public Health, Creighton University. The process of
genetic counseling employed in the management of these
families has been described elsewhere (Lynch et al.
1999). Forty-nine families fulfilled the Amsterdam cri-
teria. Of the 10 Amsterdam criteria–negative families, 9
were characterized by two first-degree relatives with an
HNPCC-related tumor (colorectal, endometrial, urinary
tract, or small bowel cancer), with one relative diagnosed
before the age of 50 years. Only one family did not meet
the criteria because of the later (50 years) age at onset
of the HNPCC-related tumors. However, one patient
from this family presented with multiple HNPCC-re-
lated tumors. The majority of the families (80%) en-
compasses five or more generations, whereas, in the re-
maining cases, four generations were recorded. More
family characteristics are listed in table 1. For each fam-
ily, the youngest affected relative available was selected
for mutation analysis, with only three exceptions: in two
families, only a single relative with colorectal carcinoma
in situ was available for mutation analysis; in a third
one, only a nonpenetrant individual was available. Of
the selected probands, 24 had colorectal cancer diag-
nosed before the age of 50 years (and 17 at the age of
45 years or younger). Eight probands had endometrial
cancer (six diagnosed before the age of 50 years), and
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Mean no. per family 7.4 1.9 2.1
Mean age at onset, in years (range) 45.2 (19–85) 46.4 (31–77) 52.8 (27–76)
a Ovary cancer, stomach cancer, urinary tract cancer, and small-bowel cancer.
one had small bowel cancer at age 29 years. Twenty-
three probands had multiple HNPCC-related tumors
(including sebaceous adenomas).
Eleven families with HNPCC selected for this study
and screened only for the founder mutation were di-
agnosed at the Ohio State University’s James Cancer
Hospital, Columbus, Ohio. Among these, five were Am-
sterdam-positive and, in the remaining six families, there
were features highly suggestive of HNPCC, including
early onset and/or multiple primary cancers in the pro-
band, one or two first-degree relatives with endometrial
cancer, or multiple second-degree relatives with colorec-
tal or endometrial cancer. An additional cohort of 128
patients with colorectal ( ) or endometrial (n p 85 n p
) cancer from Ohio was studied. These patients rep-43
resented all MSI-positive cases (98 MSI-high and 30
MSI-low) from a cohort of 716 unselected, consecutive,
newly diagnosed patients with colorectal ( ) orn p 482
endometrial ( ) cancer in the Columbus area,n p 234
collected in 1998–2000.
Denaturing Gradient Gel Electrophoresis (DGGE)
DNA from at least one affected relative of every kin-
dred was analyzed. Genomic DNA was obtained from
peripheral blood lymphocytes. Initial DNA analysis was
performed by DGGE and direct sequencing, as described
elsewhere (Wijnen et al. 1998b, 1999). In short, MSH2-
and MLH1-specific exons were amplified by PCR and
were analyzed by GC-clamped DGGE. Exons with al-
tered patterns of migration on DGGE were sequenced,
to determine the nucleotide alteration. MSH6 was an-
alyzed by DGGE in families negative for pathogenic mu-
tations in MSH2 or MLH1.
Southern Blot Analysis
Southern analysis of MSH2, MLH1, and MSH6 was
performed in the families negative for a pathogenic point
mutation after DGGE analysis, according to our pre-
viously established protocol (Wijnen et al. 1998a). Anal-
ysis of MSH2 was performed with XbaI, HindIII, NsiI,
and EcoRI genomic DNA digests, followed by hybrid-
ization with three overlapping cDNA probes (encom-
passing exons 1–7, exons 7–12, and exons 10–16). Anal-
ysis of MLH1 was performed with XbaI, ApaI, HindIII,
and NsiI digests hybridized with two specific cDNA
probes encompassing exons 1–12 and exons 11–19;
MSH6 Southern analysis was performed with XbaI and
ApaI digests, followed by hybridization with two cDNA
probes encompassing exons 1–4 and exons 5–10.
Characterization of the Founder Deletion in MSH2
Molecular Analysis.—An apparently identical dele-
tion encompassing exons 1–6 of the MSH2 gene was
identified by Southern analysis in seven apparently un-
related families. Primers were designed around the ap-
proximate location of breakpoints inferred from the
restriction map of the deleted chromosome. The 3�
primer (F3) was located in intron 6 of the MSH2 gene
(5�-AAGCATCACAGTTACTGTTG-3�), whereas the 5�
primer (R3) was derived on the basis of genomic se-
quences ∼2 kb upstream of exon 1 (5�-GCTGAATTAG-
GTTTTGGAAC-3�). Through use of these primers, a
deletion-specific PCR product of ∼1,700 bp was ob-
tained by long range PCR (Roche Molecular Biochem-
icals). This product was partly sequenced using a third
primer (R2) located ∼1 kb upstream of exon 1 (5�-
TTTCAATCTGTCGCCCACGC-3�). These primers
were also employed to screen two Ohio cohorts.
Genealogical Studies.—Genealogical data were ob-
tained from the records of the Mormon Church (Fam-
ilySearch Internet Web site) and the Offices of Vital Sta-
tistics, as well as from cemeteries’ records and patient
recollection.
Haplotype Analysis.—To determine the genetic history
of the deletion chromosome, chromosome 2 haplotypes
were derived from several affected and unaffected indi-
viduals by PCR amplification of CA repeat markers prox-
imal and distal to the MSH2 gene. The employed chro-
mosome 2markers were as follows: tel-D2S119-D2S288-
D2S391-MSH2IVS10�12gra-CA1-D2S123-D2S378-cen.
Primers and PCR conditions were as described elsewhere
(Gyapay et al. 1994; Wijnen et al. 1994; Hutter et al.
2000). Also, amonochromosomal somatic cell hybrid (see
below), containing the founder exon 1–6 deletion, was
derived from Ohio family 726NM, to facilitate the study
of the haplotype of the mutation-carrying chromosome.
MSI, IHC, and MAMA
MSI and IHC analysis was performed on tumor sam-
ples from one index patient negative for MSH2, MLH1,
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( )N p 59
AC-Positive
Families
( )N p 49
AC-Negative
Families
( )N p 10
MLH1:
Frameshift 8 0 8
Nonsense 2 1 3
Splice site 6 2 8
Missense 3 1 4
Subtotal 19 4 23
MSH2:
Frameshift 4 0 4
Nonsense 3 1 4
Splice site 1 0 1
Missense 1 1b 2
Subtotal 9 2 11
MSH6:
Frameshift 1 0 1
In-frame deletion 0 1 1
Missense 1 0 1
Subtotal 2 1 3
Total 30 7 37
NOTE.—In case of double mutations, only the assumed disease-
causing mutation is reported.
a AC p Amsterdam criteria.
b A636P in MSH2, a pathogenic Ashkenazi Jewish founder
mutation (Yuan et al. 1999; Foulkes et al. 2002).
or MSH6 mutation (family 101), as well as from one
index patient (family 125) with a missense mutation in
MSH2. MSI analysis was performed with the National
Cancer Institute–recommended markers (Boland et al.
1998), complemented by markers BAT40, MSH3, and
MSH6 (Hendriks et al. 2003). IHC was performed with
antibodies against MSH2, MLH1, and MSH6, as de-
scribed elsewhere (de Leeuw et al. 2000). MSI status in
the Ohio cohorts was determined with the NCI-rec-
ommended markers. Both MSI-high and -low cases were
included.
We have applied MAMA of the alleged mutated allele
isolated in a murine background (Papadopoulos et al.
1995; Yan et al. 2000). However, because of the limited
availability of appropriate patient material from the 59
families with HNPCC, only few selected cases were an-
alyzed by MAMA, mainly to provide proof of feasibility
for this technical approach: the paracentric chromosome
2p inversion (family 140) (Wagner et al. 2002), a de-
letion of exons 1–13 of MLH1 (family 103), and one
family negative for mutations in MSH2, MLH1, or
MSH6 (family 143). In brief, somatic cell hybrids con-
taining only one chromosome 2p or 3p allele from the
index patient were generated by fusing peripheral blood
lymphocytes or lymphoblastoid cell lines within an
Msh2-deficient murine epithelial cell line (GMP Con-
version Technologies) (Papadopoulos et al. 1995; Yan
et al. 2000). Somatic cell hybrids were genotyped by CA
repeat markers around the MSH2 and MLH1 genes on
chromosomes 2p and 3p, respectively, and were selected
for MAMA. Total RNA and protein samples were iso-
lated from the different hybrid cell lines. RT-PCR using
random hexamers (Fermentas) was performed, followed
by a standard PCR using human-specific primers for
MSH2 (forward primer 5�-ATATCATGGAACCAGCA-
3� and reverse primer 5�-TACCTTCATTCCATTACT-
GG-3�), MLH1 (forward primer 5-GCCATTGTCACA-
GAGGATAA-3� and reverse primer 5�-CGAAGGAGTG-
GTTAAGCAAC-3�) and MSH6 (forward primer 5�-T-
CGGTAGCGCCTGCTGCCCC-3� and reverse primer
5�-TAAGTTGTGCCTACCTCCA-3�). In addition, west-
ern blot analysis was performed on protein lysates ob-
tained from the somatic cell hybrid lines through use of
a rabbit polyclonal antibody raised against amino acids
402–737 of human MSH2 (Smits et al. 2000).
Results
Point-Mutation Analysis
A total of 37 germline mutations was detected in
MSH2, MLH1, andMSH6 by DGGE analysis, including
seven mutations of uncertain pathologic significance (six
missense mutations and one in-frame 3-nt deletion) (ta-
ble 2). In another three families, both a missense and a
pathogenic mutation were detected (table 3). Most point
mutations (23 of 37) were detected in MLH1. In three
independent families, an identical nonsense mutation in
MLH1 exon 12 leading to exon skipping was found
(Stella et al. 2001).
Detection of Genomic Rearrangements
Southern blot analysis was performed in 29 of the 59
families with HNPCC, where no pathogenic point mu-
tation was found. In total, 14 genomic rearrangements
were detected, 12 in MSH2 and 2 in MLH1 (table 4).
One of the deletions is a �13-kb deletion 6 kb upstream
ofMSH2 (family 177). All families with a rearrangement
of MSH2 or MLH1 fulfilled the Amsterdam criteria. In
seven families, an identical deletion of exons 1–6 of the
MSH2 gene was identified. The further characterization
of this deletion is described below. Other deletions and
types of rearrangement were also observed in theMSH2
gene: a second but different deletion of at least 20 kb
encompassing exons 1–6 (family 108), an ∼2-kb exon
3 deletion (family 150), and a deletion of exons 3–8 of
∼50 kb (family 136). The chromosome 2 paracentric
inversion encompassingMSH2 exons 8–16 found in one
kindred (family 140) has been reported elsewhere (Wag-
ner et al. 2002). In MLH1, two genomic deletions, en-
Table 3







103 � D exons 1–13 and E578G
104 � G67R
107 � IVS5�3art












120 � D exon 6
121 � IVS6�2arg
122 � D exons 1–6b
123 � D exons 1–6b
124 � D exons 1–6b
125 � T552P
126 � 129delTC and S473L
127 � R226L (splice site)
128 � 52insA
129 � V185L

















148 � D exons 1–6b
149 � 806insA
150 � D exon 3
151 �
152 � D exons 1–6b
153 � 1087insC
154 � 1013delCTT
155 � D exons 1–6b
157 � R680X
158 � IVS3�3trg






a AC p Amsterdam criteria.
b Founder genomic deletion encompassing exons 1–6 of the MSH2 gene.
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103 Deletion of exons 1–13
108 Deletion of exons 1–6
120 Deletion of exon 6
122 Deletion of exons 1–6a
123 Deletion of exons 1–6a
124 Deletion of exons 1–6a
130 Deletion of exons 1–6a
136 Deletion of exons 3–8
140 Inversion of exons 8–16
148 Deletion of exons 1–6a
150 Deletion of exon 3
152 Deletion of exons 1–6a
155 Deletion of exons 1–6a
177 Upstream deletionb
Total 12 2
a The founder genomic deletion encompassing exons 1–6 of
the MSH2 gene.
b An ∼13-kb deletion, the 3� breakpoint end of which maps
6 kb 5� of MSH2. The pathogenicity of this deletion could not
be investigated.
Table 5
Overview of the Results of the Complete Mutation Analysis of the
MSH2, MLH1, and MSH6 Genes in the 59 Families with HNPCC
GENE AND MUTATION TYPE
NO. OF MUTATIONS IN
TOTAL
( )N p 59
AC-Positive
Families
( )N p 49
AC-Negative
Families
( )N p 10
MLH1:
Point mutation 19 4 23
Genomic deletion 2 0 2
Subtotal 21 4 25 (42%)
MSH2:
Point mutation 10a 2 12
Genomic deletion/inversion 12 0 12
Subtotal 22 2 24 (41%)
MSH6:
Point mutation 2 0 2
In-frame deletion 0 1 1
Subtotal 2 1 3 (5%)
Total 45 (92%) 7 (70%) 52 (88%)
NOTE.—In the case of double mutations, only the assumed disease-
causing mutation is reported.
a Including the splice-site mutation detected by MAMA analysis by
Yan et al. (2000).
compassing exon 6 (∼2.3 kb; family 120) and exons
1–13 (at least 42 kb; family 103), were identified. No
MSH6 genomic rearrangements were found among the
29 families (tables 4 and 5).
Characterization of the MSH2 Exon 1–6 Founder
Deletion
Molecular Analysis.—In seven patients, aberrant frag-
ments of ∼14 kb were apparent by Southern analysis
after digestion with EcoRI and hybridization with the
MSH2 exon 7 probe (fig. 1a). Also, on the basis of de-
creased intensity of the wild-type fragment and addi-
tional hybridizations with exon 1–6 probes (data not
shown), the presence of the aberrant EcoRI fragment
was indicative of a genomic deletion of exons 1–6 of
the MSH2 gene. Digestion by BclI revealed an ∼13-kb
aberrant fragment and confirmed the presence of an
identical rearrangement in these seven families. To fur-
ther characterize this recurring North American deletion
previously not found among HNPCC samples of Eu-
ropean origin (Wijnen et al. 1998a), PCR primers were
designed around the approximate location of break-
points inferred from the restriction map of the deleted
chromosome. The 5� primer (R3) was based on genomic
sequences ∼2 kb upstream of exon 1, whereas the 3�
primer (F3) was located in intron 6 of the MSH2 gene.
Long range PCR with these primers resulted in a dele-
tion-specific PCR product of ∼1,700 bp, exclusively ob-
served in carriers of the common deletion and not in
deletion-negative controls (data not shown). Sequencing
of the breakpoint revealed exactly the same nucleotide
sequence in all seven families diagnosed with the exon
1–6 deletion by Southern analysis. The breakpoints are
positioned within two Alu repeats (fig. 1B and 1C).
Thus, the deletion is likely to have arisen through an
Alu-mediated recombination. The presence of identical
breakpoint sequences in all seven cases is suggestive of
a founder mutation, since a frequently recurring recom-
bination event would be likely to result in at least a few
single-nucleotide differences.
Screening for the Founder Deletion.—An additional
cohort of 11 clinically selected families with HNPCC
from Ohio was investigated for the presence of the com-
mon deletion, through use of the PCR primers (R3 and
F3) described above. Two additional deletions were de-
tected (families 726NM and CG336). Notably, the same
mutation was not found in a consecutive series (n p
) of newly diagnosed MSI-positive patients with128
colorectal and endometrial cancer derived from a total
of 716 Ohio patients studied for MSI.
Haplotype Analysis.—To confirm the common genetic
origin of the deletion of exons 1–6, haplotype analysis
was performed (fig. 2). With the exception of families
124 and CG336, the haplotype of the deleted allele was
reconstructed in the seven remaining families, six from
the Lynch cohort and one of the two Ohio kindreds
(726NM) found to carry the identical MSH2 deletion.
A common haplotype is evident in all families, with the
one exception of kindred 155, which shows, possibly as
the result of mitotic recombination, novel alleles at
markers DS288 and D2S119. Additional variation was
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MSH6 genomic rearrangements were found among the
29 families (tables 4 and 5).
Characterization of the MSH2 Exon 1–6 Founder
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Molecular Analysis.—In seven patients, aberrant frag-
ments of ∼14 kb were apparent by Southern analysis
after digestion with EcoRI and hybridization with the
MSH2 exon 7 probe (fig. 1a). Also, on the basis of de-
creased intensity of the wild-type fragment and addi-
tional hybridizations with exon 1–6 probes (data not
shown), the presence of the aberrant EcoRI fragment
was indicative of a genomic deletion of exons 1–6 of
the MSH2 gene. Digestion by BclI revealed an ∼13-kb
aberrant fragment and confirmed the presence of an
identical rearrangement in these seven families. To fur-
ther characterize this recurring North American deletion
previously not found among HNPCC samples of Eu-
ropean origin (Wijnen et al. 1998a), PCR primers were
designed around the approximate location of break-
points inferred from the restriction map of the deleted
chromosome. The 5� primer (R3) was based on genomic
sequences ∼2 kb upstream of exon 1, whereas the 3�
primer (F3) was located in intron 6 of the MSH2 gene.
Long range PCR with these primers resulted in a dele-
tion-specific PCR product of ∼1,700 bp, exclusively ob-
served in carriers of the common deletion and not in
deletion-negative controls (data not shown). Sequencing
of the breakpoint revealed exactly the same nucleotide
sequence in all seven families diagnosed with the exon
1–6 deletion by Southern analysis. The breakpoints are
positioned within two Alu repeats (fig. 1B and 1C).
Thus, the deletion is likely to have arisen through an
Alu-mediated recombination. The presence of identical
breakpoint sequences in all seven cases is suggestive of
a founder mutation, since a frequently recurring recom-
bination event would be likely to result in at least a few
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Screening for the Founder Deletion.—An additional
cohort of 11 clinically selected families with HNPCC
from Ohio was investigated for the presence of the com-
mon deletion, through use of the PCR primers (R3 and
F3) described above. Two additional deletions were de-
tected (families 726NM and CG336). Notably, the same
mutation was not found in a consecutive series (n p
) of newly diagnosed MSI-positive patients with128
colorectal and endometrial cancer derived from a total
of 716 Ohio patients studied for MSI.
Haplotype Analysis.—To confirm the common genetic
origin of the deletion of exons 1–6, haplotype analysis
was performed (fig. 2). With the exception of families
124 and CG336, the haplotype of the deleted allele was
reconstructed in the seven remaining families, six from
the Lynch cohort and one of the two Ohio kindreds
(726NM) found to carry the identical MSH2 deletion.
A common haplotype is evident in all families, with the
one exception of kindred 155, which shows, possibly as
the result of mitotic recombination, novel alleles at
markers DS288 and D2S119. Additional variation was
Figure 1 A, Southern blot analysis of genomic DNA samples from North American individuals with HNPCC, revealing a common rear-
rangement. Total genomic DNA was digested with EcoRI and was hybridized with the MSH2 exon 7–specific probe. An aberrant ∼14-kb band
was observed in lanes 7, 8, 9, 10, 14, 17, and 18, corresponding to individuals from families 122, 123, 124, 130, 148, 152, and 155, respectively.
Aberrant fragments of different sizes are also observed in lanes 4 (family 108, carrying a similar but distinct MSH2 exon 1–6 deletion) and 20 (a
previously identified carrier of an MSH2 exon 6 deletion, employed here as positive control). Also note that the presence of additional bands is
accompanied by a decreased intensity of the ∼9-kb wild-type fragments encompassing exon 7. The latter was confirmed by hybridizations with
exon 1–6 probes and by BclI digestion (data not shown). B, Genomic map of the normal and deleted MSH2 gene. For the sake of clarity, only the
EcoRI restriction sites, the Alu repeats involved in the recombination (shaded boxes), and the relevant MSH2 exons (blackened boxes) are depicted.
The normal (∼9-kb) and aberrant (∼14-kb) EcoRI restriction fragments also shown in panel A are indicated, as well as the primers (R3, R2, and
F3) employed to selectively amplify the deletion breakpoint by PCR. C, Nucleotide sequence of the founder deletion breakpoint. Three distinct
sequences are reported from top to bottom: the normal sequence flanking MSH2 at the 5� side, the deletion breakpoint, and the normal sequence
of MSH2 intron 6. The shaded boxes indicate the nucleotide homology between the two Alu repeats present in the 5� flanking sequence and within
intron 6 of MSH2. Because of the extensive homology, it is difficult to pinpoint the exact deletion breakpoint. The arrow indicates its most likely
position on the basis of nucleotide homology.
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Figure 2 Haplotype analysis of the founder MSH2 deletion chromosome. A total of seven polymorphic markers flanking MSH2 on both
the telomeric and centromeric side were employed. The haplotype encompassing the founder MSH2 deletion could be reconstructed in most
families, with the exception of family 124 from the Lynch cohort and kindred CG336 from the Ohio cohort, because of a lack of samples from
informative relatives. The haplotype of family 726NM was derived from a somatic cell hybrid containing the isolated deletion chromosome in
a rodent background. Shaded boxes indicate the alleged founder haplotype. Both alleles are indicated in those cases where the exact phase
could not be derived.
observed exclusively at more-distant centromeric mark-
ers—that is, D2S123 and D2S378 (fig. 2).
Genealogical Studies.—By means of genealogical
studies, a common ancestry could be traced for five of
the nine families found to carry the MSH2 exon 1–6
founder deletion. The alleged ancestor was born around
1814 in Alabama and was presumably of German origin.
He married and became a Mormon. From Alabama, he
and his family undertook a long journey to Utah, fol-
lowing the Mississippi River through Kentucky andMis-
souri. Some family members moved to southeastern
Iowa, bordering Illinois, and then followed the Missouri
River to Nebraska and Wyoming, eventually settling in
Utah. However, the ancestor was excommunicated from
the Mormon Church and moved, with an unspecified
number of children, to California. Two of the families
studied here (122 and 152) still carry the same ancestral
name and live in California. The other families reside
along the trail of their ancestors (A.B., A.W., P.F.F., S.C.,
Y.K., P.W., R.O., J.F.L., R.F., A.D., and H.T.L., unpub-
lished data).
Alternative Approaches to Unresolved Cases
Even when applying the most thorough mutation de-
tection strategy, unresolved cases—that is, mutation-
negative samples or missense mutations of unknown
pathogenic relevance—require additional analyses for
their elucidation. In our study, we were confronted with
a number of such cases. Unfortunately, the limited avail-
ability of blood or tumor samples hampered the appli-
cation of additional approaches to some cases. However,
a number of cases provided proof of feasibility for the
general strategy (table 6).
In one of the families negative for MSH2, MLH1, or
MSH6 mutations (family 101), analysis of the corre-
sponding colorectal cancer revealed an MSI-high phe-
notype and no expression of MSH2 by immunohisto-
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101 � High Decreased expression MSH2 NP
104 � G67R MLH1 NP NP NP
112 � A29S MLH1 NP NP NP
114 � NP NP NP
125 � T552P MSH2 High Normal expression MSH2, MLH1, MSH6 NP
129 � V185L MLH1 NP NP NP
143 � NP NP Normal expression MSH2, MLH1, MSH6
146 � NP NP NP
147 � NP NP NP
151 � NP NP NP
154 � 1013delCTT MSH6 NP NP NP
177 � D 5� MSH2 NP NP NP
178 � G244D MLH1 NP NP NP
207 � NP NP NP
208 � M492V MSH6 NP NP NP
a AC p Amsterdam criteria.
b NP p not performed.
chemistry. This kindred was characterized by a classical
clinical HNPCC phenotype that is likely the result of a
genetic defect in the MSH2 gene that was missed by the
DGGE and Southern approaches. In one other individual
found to carry anMSH2missense mutation of unknown
pathogenic relevance (family 125), analysis of tumor
DNA again revealed an MSI-high phenotype. IHC anal-
ysis of the corresponding tumor sections showed normal
expression of MSH2, MLH1, and MSH6. Although it
is possible that the mutant MSH2 proteins are func-
tionally hampered by the missense mutations, at present
we cannot determine the pathogenicity of this mutation
(Wahlenberg et al. 2002).
MAMA, or conversion technology, represents a useful
and promising approach for the analysis of missense
mutations in MSH2 (Papadopoulos et al. 1995; Yan et
al. 2000). It has also proven to be a useful tool in the
analysis of both splicing errors and genomic alterations
(Nakagawa et al. 2002). Somatic cell hybrids containing
the alleged mutated chromosome in a murine back-
ground can be analyzed by RT-PCR, northern, or west-
ern analysis, to ensure expression and stability of the
human MSH2 gene. We demonstrated proof of feasi-
bility for this approach in the analysis of the pathoge-
nicity of the chromosome 2p paracentric inversion (Wag-
ner et al. 2002). Moreover, the chromosome 3 allele
harboring the MLH1 deletion of exons 1–13 (family
103) did not show any expression of this gene by RT-
PCR after conversion (not shown). Conversion analysis
of the chromosome 2 and 3 alleles of the index patient
negative for mutations in MSH2, MLH1, and MSH6
(family 143) displayed expression of the same genes by
RT-PCR and western blot analysis of the somatic cell
hybrids.
Discussion
The overall mutation detection rate in our study is re-
markably high, compared with most previous studies
(Giardiello et al. 2001). In 39 (80%) of 49 families ful-
filling the Amsterdam criteria, and in 5 (50%) of the 10
Amsterdam criteria–negative families, a pathogenic mu-
tation was found in one of the three MMR genes ana-
lyzed. When the mutations of uncertain significance (ta-
ble 6) are included, the detection percentages rise to 92%
(45 of 49) and 70% (7 of 10) for Amsterdam-positive
and -negative families, respectively (table 5). These re-
sults are supportive of the extremely high MSH2 and
MLH1 mutation detection rate among clinically well-
selected HNPCC families. It is safe to assume that ex-
tension of the MAMA analysis to all the 59 index pa-
tients, improvement of the DGGE strategy, and further
functional analysis of the nucleotide variants of as-yet-
uncertain pathogenic significance would increase detec-
tion rate to close to 95%.
Apart from the more straightforward nonsense and
deletion mutations that are expected to be disease-caus-
ing by nature, several missense mutations were detected
in this study. One of these, the A636P mutation in
MSH2, is a founder mutation in the Ashkenazi Jewish
population and was proven to be pathogenic (Yuan et
al. 1999; Foulkes et al. 2002). Two other missense mu-
tations (G67R and V185L in MLH; families 104 and
129, respectively) were previously described to affect
mismatch repair (Shimodaira et al. 1998; Ellison et al.
2001). In one index patient found to carry an MSH2
missense mutation (T552P in family 125), tumor anal-
ysis revealed an MSI-high phenotype. As described by
Foulkes et al. (2002), one possible approach to the anal-
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ysis of the pathogenicity of missense mutations is the
analysis of large cohorts of affected and healthy indi-
viduals. Moreover, cosegregation analysis of the alleged
mutation with the disease phenotype within extensive,
multigeneration pedigrees can provide strong support
for the pathogenicity of the missense substitution. How-
ever, definitive proof or disproof of the pathogenicity
of such mutations can be obtained only by implement-
ing functional studies. The latter have been primarily
performed in yeast (Ellison et al. 2001), although novel
protocols based on mammalian expression systems have
also been applied successfully (Nakagawa et al. 2002;
Trojan et al. 2002; see below).
In a kindred with classical HNPCC that was negative
for mutations in MSH2, MLH1, or MSH6 (family 101),
analysis of a colorectal cancer showed an MSI-high phe-
notype and loss of MSH2 protein expression by IHC,
indicating that functional impairment of MSH2—for ex-
ample, by a promotor mutation (Shin et al. 2002) or a
splicing error due to a change within an intron—may
underlie HNPCC in this family. In another kindred with
classical HNPCC (family 158), a mutation was detected,
by MAMA, by Yan et al. (2000). By using this technique,
these authors found a splice-acceptor mutation inMSH2
that was proven hard to detect by conventional mutation
analysis (table 3) (Yan et al. 2000). One other family
negative for mutations inMSH2,MLH1, orMSH6 (fam-
ily 143) was studied byMAMA.This family did not fulfill
the Amsterdam criteria but was highly reminiscent of
HNPCC, because of the presence of multiple related tu-
mors in an affected individual and colorectal cancer in
several individuals. The index patient from this family
presented with colorectal cancer at age 56 years. Con-
version analysis showed expression of the three MMR
genes. Hence, the latter case may represent a bona fide
carrier of a genetic defect at a locus other than the major
MMR genes. Alternatively, the index patient may rep-
resent a phenocopy. This underscores the importance of
testing individuals who are most likely, on the basis of
clinical features, to carry the familial genetic defect—
namely, the presence of HNPCC-related tumors and their
age at onset (Wijnen et al. 1998b).
In total, only two mutations were found in MSH6.
One is a frameshift mutation, and the other is an in-
frame deletion of 3 nt of unknown significance (in fam-
ilies 153 and 154, respectively). Both families are char-
acterized by patients with endometrial cancer and by a
relatively late onset of colorectal cancer, in agreement
with the atypical phenotypic features associated with
MSH6 mutations (Kolodner et al. 1999; Wijnen et al.
1999; Wu et al. 1999; Wagner et al. 2001). The rela-
tively low incidence of MSH6 mutations is interesting
in view of the percentages (8% and 30% of the Am-
sterdam-positive and -negative kindreds, respectively) of
the families with HNPCC in which no mutation could
be detected. It is likely that genes like MSH6 that cause
an overlapping though distinct phenotype are respon-
sible for a small subset of the families with HNPCC
and for a larger proportion of the atypical kindreds.
The high detection rate in our study is partially due
to the screening for and identification of larger genomic
rearrangements. The latter enabled us to identify one
common ∼20-kb deletion, encompassing exons 1–6 of
the MSH2 gene, that was proven to represent a founder
mutation in the North American population. The origin
of this mutation could be traced back to the beginning
of the 19th century. Nucleotide sequence analysis of the
nine deletion breakpoints did not reveal any base pair
difference, as would be expected from a recurring re-
combination event. Also, haplotype analysis of the seven
of the nine families with HNPCC carrying the common
deletion by CA repeat markers flanking the MSH2 gene
was in agreement with the founder hypothesis. In the
majority of the cases, a region of ∼8 cM is conserved.
This is in agreement with a relatively young age of the
founder deletion. Accordingly, although the alleged an-
cestor was of German origin, we were unable to find
the same deletion in an extensive analysis of European
patients with HNPCC (Wijnen et al. 1998a) and in a
cohort of 89 German families with HNPCC (authors’
unpublished data). As confirmed by the PCR screening
of the small but clinically selected Ohio cohort, this
mutation represents �10% of the disease-causing mu-
tations among the Midwestern white families with
HNPCC. Further analyses are needed to determine the
frequency of this founder in other U.S. populations. No-
tably, screening of the MSI-positive Ohio cohort (n p
, 98 of whom were MSI-high and 30 of whom were128
MSI-low) for the presence of the founder MSH2 dele-
tion failed to detect any additional carrier. The latter
finding does not affect the alleged frequency of the foun-
der mutation, since it is known that a large fraction of
the MSI-high cases represent sporadic tumors due to
hypermethylation of the MLH1 promoter. Moreover, a
large fraction of sporadic CRC is known to be MSI-
low (Halford et al. 2002). Therefore, this finding em-
phasizes the importance of clinical selection.
Seven additional genomic rearrangements were de-
tected in our cohort. Five of the genomic rearrange-
ments were in MSH2. Notably, in the case of family
177, the 13-kb deletion maps 6 kb 5� of MSH2. Pre-
sumably, this deletion encompasses upstream regulatory
sequences, although no evidence for its true pathoge-
nicity could be demonstrated in this study. Also, in view
of the high frequency of genomic rearrangements de-
tected in the MSH2 gene in our (data not shown) (Wij-
nen et al. 1998a) and other laboratories (Charbonnier
et al. 2002), this locus may contain sequences prone to
recombination. Indeed, genomic sequences immediately
upstream of MSH2 and some of its larger introns (in-
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trons 6, 7, and 8; 13.3 kb, 15.6 kb, and 17.4 kb, re-
spectively) do contain many repetitive sequences, like
Alu and other repeats (from our own analysis by
RepeatMasker [RepeatMasker Web Server]) (Charbon-
nier et al. 2002). These repeats are known to mediate
recombination events between partially homologous se-
quences resulting in genomic deletions, insertions, in-
versions, or other more-complex rearrangements (Wag-
ner et al. 2002). On the basis of our findings, mutation
analysis must include screening for genomic rearrange-
ments, since these represent a frequent cause of disease
at the major MMR genes (in this study, 24% of the
total HNPCC burden and 50% of the cases due to
MSH2). The characterization of the breakpoints of the
most common genomic rearrangements will allow the
development of PCR-based screening protocols (present
study) to circumvent more cumbersome and time-con-
suming methods such as Southern blotting.
Overall, accurate and expert clinical selection of the
studied families greatly improves mutation detection,
especially when combined with a thorough and exten-
sive methodological approach. Thirty-four (69%) of the
Amsterdam criteria–positive families in our cohort had
two additional relatives with an HNPCC-related tumor,
exceeding the Amsterdam criteria requirements. In all
these families, an MSH2 or MLH1 mutation was de-
tected. Also, a pathogenic mutation was detected in all
families fulfilling the revised Amsterdam criteria, only
one of which was in MSH6. This indicates that the
fulfillment of the Amsterdam criteria by three patients
with colorectal cancer is not necessarily an indication
of the presence of an MSH2 or MLH1 mutation. This
is probably because of the high frequency of colorectal
cancer in the general population, often with relatively
early age at onset, and because of other forms of familial
clustering of colorectal cancer cases. The presence of
additional relatives with HNPCC-related tumors con-
siderably increases the chance of MSH2 or MLH1 mu-
tation detection. Patients with multiple HNPCC-related
tumors or with sebaceous tumors reminiscent of Muir-
Torre syndrome were observed in mutation-positive
families that did not fulfill the Amsterdam criteria. Con-
versely, we were unable to detect the disease-causing
mutation in one family with “classical” HNPCC (family
101). A colorectal tumor sample of the index patient
from this family displayed an MSI-high phenotype and
loss of MSH2 expression.
In conclusion, improved clinical selection forms the
basis of optimal mutation detection in HNPCC. Mu-
tation analysis in “classical” HNPCC should focus on
the two major MMR genes—that is,MSH2 andMLH1.
We underscore that, apart from point mutations,
genomic rearrangements strongly contribute to the
HNPCC mutation spectrum. MSI and IHC analyses will
direct further mutation detection strategies in the mu-
tation-negative families with classical HNPCC and in
the more atypical HNPCC cases. This approach has also
led to the identification of a common North American
deletion in MSH2 accounting for ∼10% of our cohort.
Genealogical, molecular, and haplotype studies showed
that this common deletion represents a North American
founder mutation that could be traced back to the 19th
century.
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A 10-Mb Paracentric Inversion of Chromosome Arm
2p Inactivates MSH2 and Is Responsible for
Hereditary Nonpolyposis Colorectal Cancer in a
North-American Kindred
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Genomic deletions of theMSH2 gene are a frequent cause of hereditary nonpolyposis colorectal cancer (HNPCC), a common
hereditary predisposition to the development of tumors in several organs including the gastrointestinal and urinary tracts and
endometrium. The mutation spectrum at the MSH2 gene is extremely heterogeneous because it includes nonsense and
missense point mutations, small insertions and deletions leading to frameshifts, and larger genomic deletions, the latter
representing approximately 25% of the total mutation burden. Here, we report the identification and molecular character-
ization of the first paracentric inversion of the MSH2 locus known to cause HNPCC. Southern blot analysis and inverse PCR
showed that the centromeric and telomeric breakpoints of the paracentric inversion map within intron 7 and to a contig 10
Mb 3� ofMSH2, respectively. Pathogenicity of the paracentric inversion was demonstrated by conversion analysis. The patient’s
lymphocytes were employed to generate somatic cell hybrids to analyze the expression of the inverted MSH2 allele in an
Msh2-deficient rodent cellular background. The inversion was shown to abolish MSH2 expression by both northern and
western analysis. This study confirms that Southern blot analysis still represents a useful and informative tool to screen for
and identify complex genomic rearrangements in HNPCC. Moreover, monoallelic expression analysis represents an attractive
approach to demonstrate pathogenicity of unusual mutations in autosomal dominant hereditary conditions.
© 2002 Wiley-Liss, Inc.
INTRODUCTION
Hereditary nonpolyposis colorectal cancer
(HNPCC) or Lynch syndrome is a common auto-
somal dominant cancer syndrome caused by germ-
line mutations inMSH2 andMSH6 on chromosome
2, MLH1 on chromosome 3, and PMS2 on chromo-
some 7 (Fishel et al., 1993; Bronner et al., 1994;
Nicolaides et al., 1994; Akiyama et al., 1997; Miyaki
et al., 1997). These genes are responsible for DNA
mismatch repair (MMR) and are homologs of the
Escherichia coli MutS and MutL MMR genes. Carri-
ers of a germline mutation in one of these genes are
at increased risk of developing colorectal, endome-
trial, and ovarian cancer, transitional cell carcinoma
of the ureters and renal pelvis, gastric and small
bowel cancer, brain tumors, and sebaceous skin
cancer (Lynch, 1999). Clinically, HNPCC is de-
fined by the Amsterdam criteria: at least three cases
of pathologically verified colorectal, endometrial,
transitional cell, or small bowel cancer should be
present within two generations, one of which was
diagnosed under the age of 50. Moreover, one pa-
tient must be a first-degree relative of the others
and familial adenomatous polyposis (FAP) has to
be excluded (Vasen et al., 1999).
In the vast majority of HNPCC families, germ-
line mutations are found in MSH2 and MLH1 (Pel-
tomaki and Vasen, 1997). These mutations are pre-
dominantly single nucleotide substitutions or small
insertions or deletions. However, larger genomic
deletions have also been recognized as a frequent
cause of HNPCC (Wijnen et al., 1998a). Here, we
describe the first HNPCC family caused by an
inversion within the short arm of chromosome 2
disrupting the MSH2 gene.
Supported by: Dutch Cancer Society (KWF).
*Correspondence to: Dr. Riccardo Fodde, Leiden University
Medical Center, MGC–Department of Human and Clinical Genet-
ics, Wassenaarseweg 72, 2333 AL Leiden, The Netherlands.
E-mail: r.fodde@lumc.nl
Received 13 November 2001; Accepted 12 February 2002
DOI 10.1002/gcc.10094
GENES, CHROMOSOMES & CANCER 35:49–57 (2002)
© 2002 Wiley-Liss, Inc.
MATERIALS AND METHODS
The Family
The family described herein is Caucasian and is
part of the cohort of North-American HNPCC fam-
ilies collected by Dr. Henry Lynch. The kindred
fully comply with the clinical Amsterdam criteria
for HNPCC (Fig. 1). The index patient is a 77-
year-old male (III:5), who had a malignant rectal
polyp at age 41, a transitional cell carcinoma of the
left kidney at 65, and a small bowel carcinoma at
73. At the age of 71, he was also diagnosed with
several sebaceous adenomas and squamous cell car-
cinomas. One of the index’s three daughters devel-
oped an endometroid carcinoma of the ovary at age
41 (IV:4). His mother was diagnosed with cervical
cancer and died of an abdominal carcinoma at 52
years of age (II:5). Her brother had rectal cancer at
34 and died at 36 (II:4). One of her sisters devel-
oped two colon adenocarcinomas at 52 and 69
years, respectively, and a kidney adenocarcinoma
at 65 (II:2). She died at 72 years of age. Her son
presented with adenocarcinomas of the colon at age
52 and 67, respectively (III:1). Furthermore, he was
diagnosed with transitional cell carcinoma of the
right ureter and bladder at 69 and 73 years. At the
age of 76, he developed an adenocarcinoma of the
cecum and died of cardiac disease at 77. Two of his
daughters (from different marriages) also presented
with HNPCC-related tumors (IV:1 and IV:3). There
was no evidence of miscarriages in this family.
Denaturing Gradient Gel Electrophoresis (DGGE)
Mutation analysis of the MSH2, MLH1, and
MSH6 genes was performed by DGGE as previ-
ously described (Wijnen et al., 1998b, 1999).
Southern Blot Analysis
DNAwas extracted from peripheral blood lympho-
cytes. Conforming to our previously established pro-
tocol (Wijnen et al., 1998a), Southern blot analysis of
Figure 1. Pedigree of the North-American HNPCC family. Symbols: �, carrier of the paracentric
inversion; C, colorectal cancer; Rec, rectal cancer; Ce, cecal cancer; E, endometrial cancer; Ov, ovarian
cancer; U, urinary tract cancer; Ki, kidney cancer; SmB, small bowel cancer; Sk, skin cancer; Cx, cervical
cancer; Abd, abdominal cancer. The index patient, III:5, is indicated with an arrow.
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MSH2 was performed with XbaI, EcoRI,HindIII, and
NsiI genomic DNA digests followed by hybridization
with three MSH2 probes: probe 5, encompassing ex-
ons 1–7; probe 3a, for exons 7–12; and probe 3b, for
exons 10–16 (see also Fig. 2). In addition, digestion
with the restriction endonucleases Bsp 1407I, HincII,
and BclI was performed. The latter filters were hy-
bridized with several exon-specific MSH2 probes, in-
cluding exons 6 to 9. MLH1 and MSH6 Southern
analysis was performed with XbaI, ApaI,HindIII, and
NsiI genomic DNA digests followed by hybridization
with two MLH1 probes (encompassing exons 1–12
and exons 11–19) and twoMSH6 probes (encompass-
ing exons 1–4 and exons 5–10) (Wijnen et al., 1998a).
Cytogenetic and Fluorescence In Situ
Hybridization Analyses
Prometaphase and metaphase chromosomes
were obtained from EBV-transformed lymphoblas-
tic cells according to standard protocols (Dauwerse
et al., 1992). Karyotyping was performed using
GTG-banding (Seabright, 1971) and multicolor flu-
orescence in situ hybridization (MFISH). For
MFISH, the COBRA (for COmbined Binary RA-
tio) labeling technique with p/q arm distinction was
employed as previously described (Tanke et al.,
1999; Wiegant et al., 2000).
Inverse Polymerase Chain Reaction (IPCR)
IPCR was performed as previously described
(Fodde et al., 1990) (Fig. 3). A 5-�g sample of
genomic DNA extracted from lympoblastoid cells
was digested with HincII. The digested DNA was
extracted by phenol-chloroform, ethanol-precipi-
tated, diluted to a concentration of 1 �g/ml in
ligation buffer (Fermentas, St. Leon-Rot, Germa-
ny), and ligated overnight at 16°C with 1 U/�l
ligase (Fermentas).
Figure 2. Southern blot analysis of the index patient and other affected and nonaffected relatives from
the HNPCC family. XbaI (A) and BspI (B) digests hybridized with the 3a probe (encompassing MSH2 exons
7–12). Lane 1: index patient (III:5); lanes 2–5: unaffected 50% risk carriers; lane 6: affected relative (III:1); lane
7: normal control. M indicates the molecular weight markers. The molecular weight of the specific MSH2
bands is indicated. HincII (C) digests from a normal control (lane 1) and from individual III:5 (lane 2) were
hybridized with the 3a probe.
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A forward primer (F1) was designed at the 3� end
of exon 8 (5�-AGAAACAACTTTAGATATGG-
3�), whereas the reverse primer (R1) was developed
3� of the BclI site at position 13,392 within intron 7
(5�-AGACTTTGTAAAGCTACATTC-3�) (Fig.
3). High-fidelity PCR (Roche Molecular Diagnos-
tic Systems, Alameda, CA) was performed with
these primers. The IPCR product was analyzed by
agarose gel electrophoresis. An approximately
2.0-kb band was observed in the index DNA but
Figure 3. Cloning and characteriza-
tion of the 3� (telomeric) inversion
breakpoint by inverse-PCR. A: The in-
verse-PCR procedure. Genomic DNA
from the index patient (III:5) was di-
gested by HincII. The latter result in an
aberrant 4.0-kb fragment encompassing
MSH2 exon 8 and the 3� breakpoint as
indicated. The digested DNA was li-
gated as described under Materials and
Methods. The ligated DNA was em-
ployed in a PCR reaction with primer
sets F1/R1 and F2/R2, indicated by ar-
rows. In both cases, only DNA from
carriers of the paracentric inversion re-
sulted in the expected inverse-PCR
products. The latter encompass the 5�
end of MSH2 intron 8, the original
HincII site, the inversion breakpoint,
and the 3� end of MSH2 intron 7. B:
Both the sense and antisense strands of
the sequences around the 3� (telo-
meric) inversion breakpoint are de-
picted. The alignment shows (from top
to bottom) the wild-type MSH2 intron
7 sequence, the 3� (telomeric) break-
point obtained by inverse PCR, and the
sequence of the contig AC010878, lo-
cated 10 Mb 3� (telomeric) to MSH2.
The shaded boxes indicate the homol-
ogies among the three aligned se-
quences. The orientations of both the
centromere and telomere relative to
the reported sequences are indicated.
The sequence of MSH2 intron 7 is de-
picted in the reverse direction relative
to the other two sequences.
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not in the normal control. This band was excised
and purified using a nucleotrap kit (Machery-Na-
gel, Düren, Germany). The purified product was
cloned by TOPO-cloning (Invitrogen, La Jolla,
CA) and sequenced using the same F1 and R1
primers. Based on the newly obtained sequences,
new primers were designed, that is, a forward
primer (F2) in intron 8 (5�-TCAAGCTATCCTC-
CGGCCTC-3�) and a reverse primer (R2) in intron
7 (5�-GGATGCAGTGAACAGGGAAC-3�) (Fig.
3). The IPCR procedure was then repeated with
F2 and R2, and the patient-specific PCR product
was sequenced.
This sequence also enabled us to develop addi-
tional primers around the 5� (centromeric) break-
point (Fig. 4): a forward primer (F3, 5�-TGCTGA-
CATGGCCCATTCCTAC-3�) within the contig
AC010878, and a reverse primer (R3, 5�-TCCC-
AGTTTAACTCTAGCAG-3�) in intron 7. PCR
amplification with these primers resulted in a frag-
ment of approximately 900 bp in the index patient
(III:5) and in two other affected individuals (III:1
and IV:4) but not in a normal control (see also Fig.
4C). This fragment was again excised and purified
by the nucleotrap procedure and sequenced using
the PCR forward and reverse primers.
Monoallelic Expression Analysis
To allow RNA and protein expression analysis of
theMSH2 allele carrying the inversion, somatic cell
hybrids containing the wild type and rearranged
chromosome 2p from the index patient were gen-
erated in a Msh2-deficient murine background
(GMP Conversion Technologies, Waltham, MA)
(Papadopoulos et al., 1995; Yan et al., 2000). So-
matic cell hybrids were genotyped by CA repeat
markers around the MSH2 gene on chromosome
arm 2p and selected for monoallelic expression
analysis. Total RNA and protein samples were iso-
lated from the different hybrid cell lines, and
northern and western blot analyses were carried out
according to conventional procedures. Probe 3b
(MSH2 exons 10–16) was employed for the north-
ern analysis, whereas a rabbit polyclonal antibody
raised against amino acids 402–737 of human




DGGE analysis of MSH2, MLH1, and MSH6 did
not reveal any mutation in the index patient.
Therefore, Southern blot analysis was performed.
MLH1 and MSH6 hybridizations did not show any
aberrant fragments. After hybridization with the
MSH2 5� probe (encompassing exons 1–7), an ab-
errant band of approximately 30 kb was seen in the
XbaI digest (not shown). Hybridization with the
MSH2 3a probe (exons 7–12) revealed two aberrant
fragments of 29 and 18 kb, respectively (Fig. 2A).
Based on the decreased intensity of the wild-type
26-kb fragment encompassing MSH2 exons 7 and
8, we assumed that the genomic rearrangement
involved this segment of the gene. Hybridization
with exon 7- and exon 8-specific probes indicated
that the 29-kb band contained exon 7, whereas the
18-kb fragment encompassed exon 8 of MSH2.
This was confirmed by digestion with Bsp1407I: in
addition to the wild type 20-kb fragment contain-
ing exons 7 and 8, hybridization with both the
3�a-specific and the exon 7- and exon 8-specific
probes revealed two fragments of 29 and 16 kb,
encompassing exon 7 and exon 8, respectively (Fig.
2B). These results are indicative of a complex re-
arrangement encompassing both exon 7 and exon 8
in the mutated allele. The normal intensity of all
other digestion fragments suggested that no other
MSH2 exon was involved in the rearrangement
(data not shown). This also indicated that the
genomic rearrangement was likely to be a translo-
cation or inversion with a breakpoint in intron 7.
The aberrant restriction site closest to the break-
point appeared to be a HincII site at position
11,738 in intron 7 (Fig. 2C). BclI digestion showed
no aberrant fragment after hybridization with an
exon 8-specific probe, indicating that the break-
point had to map 5� to the BclI site located at
position 13,392 within intron 7. Given that no other
aberrant fragments were found after hybridization
with any of the other MSH2 probes, the other
breakpoint had to map outside the MSH2 gene.
Additional Southern blot analysis of individual
III1, IV4, and several unaffected relatives showed
co-segregation of the rearrangement with the dis-
ease in this family (not shown).
Cytogenetic and FISH Analyses
Karyotype analysis of the index patient by GTG-
banding and PQ-COBRA-FISH did not show ei-
ther any apparent translocation or an inversion con-
cerning chromosome 2. This indicated that the
alleged genomic rearrangement had to be either a
small inter- or intrachromosomal translocation, or a
paracentric inversion (data not shown).
53HNPCC CAUSED BY A CHROMOSOMAL INVERSION
IPCR
To discriminate among the above possibilities,
we set out to characterize the intron 7 breakpoint
by IPCR (Fig. 3A). Based on the Southern blot
analysis,HincII digestion results in a 4-kb fragment
encompassing exon 8 and the breakpoint of the
genomic rearrangement within intron 7 (Fig. 2C).
The IPCR procedure enabled us to obtain an ap-
Figure 4. Cloning and characterization of the 5� (centromeric)
inversion breakpoint. A: Scheme of the wild-type and mutated MSH2
alleles. Only the part of the chromosome 2 region involved in the
paracentric inversion is shown. Shaded and black boxes indicate exons
7, 8, and 9 of the MSH2 gene, respectively. Only the HincII and BclI
restriction sites and the 5� (centromeric) and 3� (telomeric) break-
points are depicted for the sake of clarity. AC010878 is the contig
located 10 Mb 3� of MSH2. The primer sets employed to amplify and
sequence both breakpoints (F1/R1, F2/R2, F3/R3) are indicated by
arrows. B: Both the sense and antisense strands of the sequences
around the 5� (centromeric) inversion breakpoint are depicted. The
alignment shows (from top to bottom) the wild-type MSH2 intron 7
sequence, the 5� breakpoint obtained by PCR with primers F3 and R3,
and the sequence of the contig AC010878, located 10 Mb 3� (telomeric)
to MSH2. The shaded boxes indicate the homologies among the three
aligned sequences. The orientations of both the centromere and telo-
mere relative to the reported sequences are indicated. The sequence of
the AC010878 contig is depicted in the reverse orientation relative to
the other two sequences. C: 5� Breakpoint-specific PCR results ob-
tained with primers F3 and R3 (see A) in affected (IV:4, III:5, III:1) and
nonaffected (IV:5) individuals.
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proximately 2-kb PCR product containing the 5�
end of intron 8, the HincII site used for digestion
and ligation, 60 base pairs of an unknown se-
quence, the breakpoint, and the 3� end of intron 7
(Fig. 3B). The IPCR product was not observed
when genomic DNA from a healthy individual was
subjected to the procedure. By use of the Basic
Local Alignment Search Tool (BLAST) database
of the National Center of Biotechnology Informa-
tion, a perfect match was found between the un-
known sequence and a contig (AC010878) located
10 Mb 3� of MSH2. The latter finding indicated
that the genomic rearrangement in this kindred is
likely to be a 10-Mb inversion of exons 8 to 16 of
the MSH2 gene (Fig. 4A). To test this hypothesis,
PCR primers (F3 and R3) were designed within
AC010878 and in MSH2 intron 7, to allow amplifi-
cation and sequencing of the 5� (centromeric)
breakpoint of the 10-Mb inversion (Fig. 4A). The
approximately 900-bp PCR product obtained using
these primers encompasses sequences derived
from AC010878 (in the reverse direction relative to
the sequence found in the 3� telomeric breakpoint
sequence), the 5� centromeric breakpoint, and 5�
intron 7 sequences (again, in the reverse orienta-
tion relative to the 3� telomeric breakpoint se-
quence) (Fig. 4B). Moreover, the combination of
these primers resulted in the 900-bp product only
when DNA from the index patient or the other two
available affected individuals (III:1 and IV:4 in Fig.
1) from the affected kindred were employed (Fig.
4C). This proved that the rearrangement in this
family was indeed a paracentric inversion of about
10 Mb, including exons 8 to 16 of the MSH2 gene.
Genomic rearrangements were previously de-
scribed in MSH2, as well as in other cancer-suscep-
tibility genes like APC, MLH1, BRCA1, TP53, NF2,
and STK11 (van der Luijt et al., 1995; Petrij-Bosch
et al., 1997; Jenne et al., 1998; Slebos et al., 1998;
Wijnen et al., 1998a; Puget et al., 1999; Legoix et
al., 2000; Chan et al., 2001). These rearrangements
may result from nonhomologous breakage and re-
union events but also from homologous recombi-
nation between repetitive sequences dispersed
throughout the genome, like Alu repeats (Nys-
trom-Lahti et al., 1995; Mauillon et al., 1996; Sle-
bos et al., 1998). Also, genomic inversions have
been described in hemophilia resulting from un-
equal alignments between small-sequence homol-
ogies (Lakich et al., 1993). Computer analysis
(BLAST) of intron 7 of the MSH2 gene revealed
many repetitive sequences, among which were Alu
and simple-sequence repeats (not shown). During
our search for mutations in HNPCC families, we
identified four genomic deletions of MSH2 with a
breakpoint within intron 7 (unpublished observa-
tions). However, because the deletion breakpoints
in these families, including the one studied here,
appear to be located at different sites along intron
7, no actual recombination hotspot can be pin-
pointed. We did not find Alu repeats at or in the
flanking regions of the breakpoints of the inversion
reported here. Hence, a nonhomologous breakage
and reunion recombination event is the most likely
cause of the genomic rearrangement observed in
this family. Notably, during the recombination pro-
cess, nine base pairs were lost from intron 7,
whereas an additional seven base pairs were found
at the 5� (centromeric) breakpoint (Figs. 3B and
4B). The latter does not result from a PCR artifact,
given that sequence analysis of the 5� breakpoint of
the affected individuals III:1 and IV:4 confirmed
the presence of the 9-bp deletion and the 7-bp
insertion (data not shown). To elucidate the recom-
bination mechanism underlying the paracentric in-
version, we searched the entire intron 7 and
AC010878 sequences for the presence of the 7-bp
insertion. Because of the presence of two dinucle-
otide repeats within these short sequences, several
hits were obtained by BLAST in both genomic
sequences. The latter does not allow us to infer the
exact recombination mechanism leading to the
present rearrangement.
Monoallelic Expression Analysis
To confirm the pathogenicity of the newly char-
acterized genomic rearrangement, MSH2 expres-
sion was analyzed by northern and western blots of
somatic cell hybrids containing the wild-type and
inversion chromosomes 2 from the index patient
(GMP Conversion Technologies) (Papadopoulos et
al., 1995; Yan et al., 2000). The murine cell line
employed for this aim was Msh2-deficient and was
therefore particularly suited to analyze expression
of the human MSH2 gene without the interference
of the highly homologous and ubiquitously ex-
pressed mouse homolog. Neither MSH2 mRNA
nor MSH2 protein was detectable in the hybrid
containing the rearranged chromosome arm 2p,
whereas the full-length allele was observed in the
hybrid containing the wild-type allele (Fig. 5).
Hence, the paracentric chromosome arm 2p inver-
sion represents a true null allele because it disrupts
the MSH2 gene and its expression.
In conclusion, we report a novel 10-Mb paracen-
tric inversion of chromosome 2 responsible for
HNPCC in a North American family. In agreement
with previous reports (Wijnen et al., 1998a), this
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study confirms that the MSH2 gene is susceptible
to genomic rearrangements such as deletions and
inversions. In view of the latter, Southern blot
analysis still represents a useful and informative
tool to identify and characterize disease-causing
complex genomic rearrangement in HNPCC fam-
ilies, and to facilitate presymptomatic diagnosis
and patient care. Moreover, the generation of so-
matic cell hybrids containing the alleged mutant
chromosome arm 2p allele in a Msh2-deficient mu-
rine cellular background greatly facilitates the anal-
ysis of its pathogenicity.
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Abstract
Hereditary non-polyposis colorectal can-
cer (HNPCC) is the most common genetic
susceptibility syndrome for colorectal
cancer. HNPCC is most frequently caused
by germline mutations in the DNA mis-
match repair (MMR) genes MSH2 and
MLH1. Recently, mutations in another
MMR gene,MSH6 (also known as GTBP),
have also been shown to result in HNPCC.
Preliminary data indicate that the pheno-
type related to MSH6 mutations may
diVer from the classical HNPCC caused
by defects inMSH2 andMLH1.
Here, we describe an extended Dutch
HNPCC family not fulfilling the Amster-
dam criteria II and resulting from aMSH6
mutation. Overall, the penetrance of
colorectal cancer appears to be signifi-
cantly decreased (p<0.001) among the
MSH6 mutation carriers in this family
when compared with MSH2 and MLH1
carriers (32% by the age of 80 v >80%).
Endometrial cancer is a frequent mani-
festation among female carriers (six out of
13 malignant tumours). Transitional cell
carcinoma of the urinary tract is also
relatively common in both male and
female carriers (10% of the carriers).
Moreover, the mean age of onset of both
colorectal cancer (MSH6 v MSH2/MLH1 =
55 years v 44/41 years) and endometrial
carcinomas (MSH6 v MSH2/MLH1 = 55
years v 49/48 years) is delayed. As previ-
ously reported, we confirm that the pat-
tern of microsatellite instability, in
combination with immunohistochemical
analysis, can predict the presence of a
MSH6 germline defect.
The detailed characterisation of the
clinical phenotype of this kindred contrib-
utes to the establishment of genotype-
phenotype correlations in HNPCC owing
to mutations in specific mismatch repair
genes.
(J Med Genet 2001;38:318–322)
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Hereditary non-polyposis colorectal cancer
(HNPCC) is one of the most common
autosomal dominant conditions predisposing
to cancer. HNPCC carriers are at risk for the
development of a broad spectrum of malig-
nancies including tumours of the colon,
endometrium, stomach, small intestine, hepa-
tobiliary system, ureter, renal pelvis, and
ovary.1 HNPCC is caused by germline muta-
tions in DNA mismatch repair (MMR) genes,
predominantly MSH2 on chromosome 2p162
andMLH1 on chromosome 3p21.3 In a minor-
ity of cases, mutations have been described in
other MMR genes like PMS1 and PMS2.4
Recently, germline mutations in the MSH6
gene on chromosome 2p15 were recognised as
a frequent cause of atypical HNPCC, that is,
not complying with the clinical “Amsterdam
criteria”.5–9
The involvement of MMR genes in HNPCC
is reflected by the occurrence of instability of
simple repetitive DNA sequences (microsatel-
lite instability or MSI) in tumours from
HNPCC patients. Accordingly, more than
90% of the colorectal tumours and at least 75%
of the endometrial tumours from HNPCC
patients display MSI.10–12 In sporadic colorectal
and endometrial cancer,MSI is found in about
15-30% of tumours.13 14
The first reports on MSH6 germline muta-
tions have indicated that the clinical phenotype
of the aVected families may diVer from the
“classical” HNPCC caused by MSH2 and
MLH1 mutations.5–9 The penetrance of colo-
rectal cancer seemed to be reduced. However,
endometrial cancer was likely to represent a
more important clinical manifestation among
female MSH6 carriers. The reported mean age
of onset of colorectal and endometrial cancer
appeared to be delayed in families with MSH6
germline mutations, 50 years and older com-
pared to 44 (MSH2) and 41 (MLH1) years of
age15 and 53 years and older compared to 49
(MSH2) and 48 (MLH1) years, respectively.7
Notably, MSI analysis of tumours from MSH6
mutation carriers suggested a reduced pen-
etrance of the MSI-H phenotype and preferen-
tial instability at mononucleotide repeats.7–9 12
Here, we report the clinical and molecular
characterisation of a large HNPCC kindred






























































Accepted for publication 15
February 2001
www.jmedgenet.com
resulting from a frameshift mutation in the
MSH6 gene.
Patients
The proband, a 50 year old female, was referred
to the Department of Clinical Genetics,
Rotterdam by her gynaecologist in 1993. At
that time, three of her six sisters were
diagnosed with endometrial cancer at 50, 57,
and 60 years of age. A fourth sister had devel-
oped ovarian cancer (endometroid adenocarci-
noma) at the age of 50. The proband’s father
died at the age of 85 without any symptoms of
HNPCC. Her mother underwent a hysterec-
tomy for leiomyomata at 55 and was in good
health at 92 years of age.
The diVerential diagnosis in this family
included HNPCC. Mutation analysis of the
MLH1 and MSH2 genes by PCR and DGGE
in one of the aVected sisters of the proband did
not show any pathogenic mutation. In the
meantime, the proband developed endometrial
cancer at the age of 53, the fourth case of
endometrial cancer in this sibship.
As soon as MSH6 mutation analysis became
available, mutation screening was performed
and a frameshift mutation (del T codon 594) in
exon 4 was identified.7 The proband, her
aVected sisters, and mother were found to
carry the same mutation.
At the request of the proband, family mem-
bers were informed about the findings and
were invited to contact the Department of
Clinical Genetics for additional information
and/or to be tested for the presence of the
mutation.
We were also able to link the family to
another kindred under investigation at the
Department of Clinical Genetics at the Leiden
University Medical Centre.
Mutation analysis
In total, DNA testing for the MSH6 mutation
was performed in 80 out of 132 living relatives
with at least a 25% risk of being carrier of the
MSH6 mutation (fig 1), 27 males (out of 63,
43%) and 53 females (out of 69, 77%). Out of
these 132 relatives, 11 were previously diag-
nosed with an HNPCC related tumour and all
of them were tested. Two tested unaVected
relatives were obligate carriers. Out of 75 carri-
ers at 50% risk and 44 at 25% risk, 46 (61%)
and 21 (48%) were tested, respectively (tables
1 and 2).
Ten of the 11 aVected subjects were carriers
of the familial MSH6 mutation. The patient
(IV.6) negative for the mutation was a 55 year
old male, diagnosed with numerous tubulovil-
lous adenomas at the age of 53. Since his clini-
cal presentation was suggestive of familial
adenomatous polyposis (FAP), though with a
delayed age of onset, mutation analysis of the
APC gene was performed. This did not show
any alteration.
The MSH6 mutation was confirmed in both
unaVected obligate carriers.
Out of the 46 tested healthy subjects with a
50% risk for the mutation, 17 (37%) were
found to carry the MSH6 mutation; none of
those with a 25% risk tested positive (table 2).
All 17 unaVected mutation carriers above the
age of 25 years (five males and 12 females) were
oVered the generally accepted surveillance for
HNPCC, namely colonoscopy every one to two
years, yearly gynaecological examination with

































































































































Figure 1 Pedigree of MSH6 family. C = colorectal cancer. E = endometrial cancer.
U = urinary tract cancer. P = polyp. O = ovarian cancer. B = breast cancer. Bt = brain
tumour. Ca? = cancer of unknown origin. + = MSH6 mutation positive.  = MSH6
mutation negative.
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(for female carriers), and yearly urine sediment
testing and cytology. During the first screening
the following diagnoses were made: a tubulovil-
lous adenoma with dysplasia in the proximal
rectum of a 60 year old male; an invasive ductal
adenocarcinoma of the breast and an adenocar-
cinoma of the colon in a 49 year old female; a
small tubular adenoma and endometrial hyper-
plasia in a 50 year old female; and an adenoma
in a female aged 48. Of the remaining 13
carriers, four were under the age of 45 and four
were above 70 years without any symptoms of
the genetic predisposition. However, a 92 year
old female underwent a hysterectomy because
of leiomyomata of the uterus at the age of 55.
The family included five dead obligate
mutation carriers, three females and two males.
Three of them had been diagnosed with a
HNPCC related tumour (table 1). One male
reached the age of 83 without having developed
any HNPCC related tumour.
We were not able to determine the MSH6
status of five cancer patients in this family: one
colorectal cancer (onset >70) in a female
patient (III.13) whose 13 descendants tested
negative for the mutation; one male with an
astrocytoma (III.19) at the age of 75, three of
whose four children did not carry the muta-
tion; two breast cancer patients (IV.14, IV.20,
onset >50); and one patient with cancer of
unknown origin around the age of 40 (III.6).
In total, 34 mutation carriers (29 alive and
five dead) were identified in this pedigree, 17 of
whom developed a (pre)malignant tumour
(table 1). Of the carriers with a malignancy,
four had two primary HNPCC related tu-
mours. Using the Kaplan-Meyer method, 7%
of the carriers developed colorectal cancer by
the age of 50 years and 32% by the age of 80
years (mean age of onset 55 years, ranging from
32 to 83 years). Of the female carriers, 52%
developed endometrial cancer by the age of 80
and all of them were diagnosed above the age of
50 years. Three carriers had a papillary transi-
tional cell carcinoma of the urinary tract (10%
of the carriers).
Microsatellite instability (MSI) and
immunohistochemical (IHC) analyses
We performed MSI analysis and/or immuno-
histochemistry with antibodies against MLH1,
MSH2, and MSH612 on tumour samples
derived from 12 subjects; in four cases, two
independent tumour samples were tested
(table 3).
Using the markers recommended by Boland
et al,16 MSI analysis showed variable patterns
(table 3). However, all tumour samples derived
from theMSH6 carriers displayed instability of
at least one mononucleotide marker when an
extended set of markers, including BAT40, was
used.
Immunohistochemical (IHC) analysis of the
MSH6 protein in tumour sections showed no
expression in any of the samples tested, with




II.2 Colorectal cancer 60 Obligate carrier
III.2 Transitional cell carcinoma right pyelum 77 Obligate carrier
& transitional cell carcinoma left ureter 79
III.4 Transitional cell carcinoma 78 +
III.6 Unknown 40 Not tested
III.11 Endometrial carcinoma ? Obligate carrier
Colon carcinoma >70
III.13 Colon carcinoma >70 Not tested
III.18 Colon carcinoma 83 +
III.19 Astrocytoma 75 Not tested
IV.4 Transitional cell carcinoma ureter 59 +
IV.6 Multiple adenomatous polyps of the colon 53 −
IV.8 Adenoma 50 +
IV.9 Adenoma 48 +
IV.11 Tubulovillous adenoma 60 +
IV.13 Endometrial & rectal carcinoma 55 +
IV.14 Breast cancer 51 Not tested
IV.15 Breast & colon carcinoma 49 +
IV.20 Breast cancer >50 Not tested
IV.26 Endometrial carcinoma 57 +
IV.27 Endometrial carcinoma 60 +
IV.30 Endometroid adenocarcinoma ovary 50 +
IV.32 Endometrial carcinoma 53 +
IV.33 Endometrial carcinoma 50 +
V.8 Colorectal cancer 32 +
+ indicates the presence of the MSH6 mutation.
 indicates the absence of the MSH6 mutation.
Table 2 Results of mutation analysis
Male Female Total
Pretest risk 100%* 50% 25% 100%* 50% 25%
Tested 5 15 7 8 31 14 80
MSH6+ 4 4 0 8 13 0 29
MSH6− 1 11 7 0 18 14 51
Not tested 0 19 17 0 10 6 52
Total 5 34 24 8 41 20 132
*Relatives with an HNPCC related tumour and obligate carriers.
Table 3 Microsatellite and immunohistochemical analysis in tumours from 12 aVected relatives
Subject
III.2 III.4 III.13 III.18 IV.4 IV.6 IV.13 IV.15 IV.26 IV.27 IV.30 IV.32
Tumour type U U U C C U U P R E C B E E O E
Microsatellite status H H L NT H H L S H L S H H L H S
Mononucleotide markers
BAT25* + + + NT + + − − + − − + + − + −
BAT26* NT + − NT + + + − + + − + + + + −
BAT40 + + + NT + + +/− − + + + + NT + + +
Dinucleotide markers
D2S123* + NT − NT − − NT − − − − − − − − −
D5S346* − + − NT + − − − + − − − − − − −
D17S250* + NT − NT + − − − + − − − − − − −
Immunohistochemistry
MLH1 NT NT + ++ + + NT + + ++ + + + + ++ +++
MSH2 NT NT + ++ ++ + NT + − + + + ++ + + ++
MSH6 NT NT − + − − NT + − − − − − − NT −
* = markers recommended by NCI for MSI analysis.16 + = Unstable. − = Stable. NT = not tested/not conclusive. H = MSI high according to NCI recommenda-
tions.16 L = MSI low according to NCI recommendations.16 S = MSI stable according to NCI recommendations.16 C = colon tumour. U = urinary tract tumour.
E = endometrial tumour. O = ovarian tumour. R = rectal tumour. P = polyp. B = breast tumour.
Immunohistochemistry: +++ = strong staining, ++ = moderate staining, + = weak staining, − = no staining.
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the exception of III.13 and IV.6. Patient III.13
could not be tested for either the presence of
the germline mutation or for MSI, and is likely
to represent a phenocopy, in view of the late
age of onset (colon carcinoma at >70 years)
and the failure to detect the MSH6 mutation
in her 13 descendants. We were able to
perform MSI analysis in a single adenoma
from patient IV.6 that did not display
instability for any of the tested markers.
MLH1 and MSH2 IHC analysis was positive
in all samples with the exception of the
rectal carcinoma from IV.13, negative for
MSH2.
Discussion
Genetic heterogeneity and variable phenotypic
expression represent major complications in
the diagnosis and clinical management of
HNPCC, one of the most common inherited
predispositions to multiorgan tumorigenesis.
Although the hallmark of this condition is rep-
resented by colorectal lesions, a broad range of
cancer types, including tumours of the en-
dometrium, stomach, small intestine, hepato-
biliary system, and ureter, are established clini-
cal expressions of HNPCC. The vast majority
of HNPCC cases are known to result from
germline mutations in the DNA mismatch
repair genes MSH2 and MLH1.17 In these kin-
dreds, high penetrance and early onset of
colorectal and endometrial cancer are the
major clinical features. The set of diagnostic
criteria, Amsterdam criteria I and II, estab-
lished by the International Collaborative
Group on HNPCC18 19 well serve the purpose
of selecting families with a high likelihood of
carrying MSH2 and MLH1 mutations.17 More
recently, atypical HNPCC families, that is, not
complying with the Amsterdam criteria (ACI
and II) though clearly suggestive of a HNPCC-
like inherited condition, have been reported to
be caused by germline mutations in a third
MMR gene, namely MSH6.7–9 Preliminary
phenotypic analysis of these families showed a
reduced occurrence of colorectal cancer and a
prevalence of endometrial tumours.
Here, we have presented a detailed analysis
of an extended Dutch HNPCC pedigree
resulting from an inactivating germline muta-
tion of the MSH6 gene.
The expression of the MSH6 mutation in
this family suggests a reduced penetrance and a
delayed age of onset for colorectal cancer.
Using the Kaplan-Meyer method, 7% of the
carriers developed colorectal cancer by the age
of 50 years and 32% by the age of 80 years.
This is significantly reduced (p<0.001) com-
pared to “classical” HNPCC caused by MSH2
andMLH1 (55% by age 50 and >80% by age
80).15 Admittedly, these calculations are based
on a limited number of cases and may
represent an overestimate because not all
healthy eligible relatives were tested for the
MSH6 mutation. Moreover, the selection bias
introduced when studying a family with such a
striking clinical history may also lead to an
overestimation of the penetrance. The mean
age of onset of the colorectal carcinomas in this
family is 55 years. This is delayed when
compared with HNPCC families caused by
MSH2 (44 years) and MLH1 (41 years) muta-
tions.15 This delayed age of onset may also bias
the estimated penetrance. Notably, the young-
est diagnosed case was at 32 years, implying
that periodic screening recommendations
should not diVer from those established for
classical HNPCC until more data are available.
In this family, endometrial cancer is the most
common tumour type (six out of 13 malignant
tumours) among female carriers. All the
endometrial cancers were diagnosed above the
age of 50 and their mean age of onset was 55
years, that is, five to 10 years later when
compared with “classical” HNPCC caused by
mutations in MLH1 and MSH2.7 20
Another striking clinical phenotype in this
family is the papillary transitional cell carci-
noma of the ureter and renal pelvis observed in
three relatives (10% of the carriers). Notably,
the lifetime cumulative risk of this tumour type
in MLH1 or MSH2 mutation carriers is only
2.6%.21
As previously reported by us and others,7–9
the MSI phenotype caused by loss of MSH6
function is reduced when compared with
MLH1 and MSH2, and diVers in its predomi-
nance at mononucleotide runs. This is in
agreement with previous studies on yeast and
mouse model systems.22 23 From this point of
view, the set of markers previously recom-
mended by NCI for MSI analysis16 may not be
suitable for MSH6 mutation carriers and
should be complemented with a set of
mononucleotide markers. In six of the cases
reported here (III.4, IV.4U, IV.13E, IV.15C,
IV.27, and IV.32) (table 3), instability was
observed at only one or two mononucleotide
repeats (one of which was not included in the
NCI panel) leading to an MSI-low or stable
classification. In five of these cases, IHC was
performed and indicated the loss of MSH6 in
the tumour. Therefore, we recommend IHC
analysis in MSI-L and MSS tumours from
cases with a family history suggestive of
HNPCC.12
We also show the feasibility of the IHC
approach not only on colorectal tumours but
also in carcinoma of the endometrium, urinary
tract, and breast. The latter finding is relevant
for the inclusion of breast cancer in the
HNPCC tumour spectrum: breast tumour
samples from IV.15 showed bothMSI-high and
a negative IHC staining pattern in accordance
with the presence of the MSH6 germline
mutation in this person. Two additional
perimenopausal breast cancer cases were found
in the present study (IV.14 and IV.20).
However, as no material was available from
these patients, we could not establish their
MSH6 mutation carrier status.
IHC analysis was also helpful in the
assessment of the likely phenocopy status rela-
tive to III.13. As a limited amount of a colorec-
tal carcinoma was available from this dead
patient, we limited our analysis to IHC and
found normal MSH6 protein expression.
Moreover, all her descendants tested negative
for the mutation. Another dead patient from
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this family, III.19, was diagnosed with astrocy-
toma at the age of 75. Again, no archival mate-
rial was available from this patient. However,
the delayed age of onset and the fact that three
of his children tested negative for the mutation,
do not allow us to draw any conclusion on the
relationship between the presence of the brain
tumour and the MSH6 defect.
Patient IV.6 presented with a clinical pheno-
type more suggestive of attenuated polyposis24
rather than HNPCC. Accordingly, MSI analy-
sis of the colonic polyps was negative (MSS)
and normal MSH6 expression was found by
IHC. Failure to detect the MSH6 mutation in
this patient confirmed that the attenuated
polyposis is likely to result from an unlinked
genetic predisposition.
In conclusion, the clinical features associated
with MSH6 germline mutations strongly sup-
port the inclusion of endometrial cancer and
transitional cell cancer of the ureter and renal
pelvis in the diagnostic criteria for HNPCC in
the new Amsterdam Criteria (ACII) as formu-
lated by the ICG-HNPCC.19 In addition, we
propose to perform MSI in combination with
IHC in all Amsterdam negative families with a
clustering of endometrial or urinary tract can-
cers. The combined MSI and IHC analysis will
direct subsequent mutation analysis forMSH6.
We thank Dr J J P M Pieters, gynaecologist, for referring the
family to the Department of Clinical Genetics, Rotterdam.
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About 5% of colorectal cancers are associated with theautosomal dominantly inherited cancer susceptibilitysyndrome hereditary non-polyposis colorectal cancer
(HNPCC).1 2 HNPCC is characterised by a high risk of develop-
ing colorectal cancer and endometrial cancer at a young age
(cumulative lifetime risk 80-90% and 30-40%, respectively),
and by an increased risk of developing various other tumour
types, such as ovarian, uroepithelial, small intestine, biliary
tract, stomach, brain, and skin cancers.2–5 Germline mutations
in one of three mismatch repair genes (MSH2, MLH1, and
MSH6) were found to be responsible for a majority of HNPCC
families.6–9
Knowledge of the causativemutation in a particular HNPCC
family enables the identification of at risk family members by
genetic testing. Clearly, the absence or presence of a mutation
is of considerable medical and psychological significance.
Subjects not carrying the mutation are relieved from a
continuous anxiety and can be dismissed from medical
surveillance, saving them trouble and reducing health care
costs.10 Importantly, subjects with the mutation can benefit
from a medical surveillance programme. For HNPCC, colon-
oscopy has been shown to be a potent tool for the detection
and treatment of premalignant adenomas or early colorectal
carcinomas in at risk subjects, reducing the risk of developing
colorectal cancer and decreasing the overall mortality by about
65%.11 12 The possibility of early detection of colorectal cancer
by stool analysis using the genetic markers TP53, BAT26, and
K-RAS raises expectations for the development of less invasive
surveillance procedures.13 Furthermore, intervention trials
with non-steroidal anti-inflammatory drugs (NSAID) in sub-
jects at risk for developing colorectal cancer are in
progress.14 15
So far, studies on the use of genetic testing in HNPCC
families have used families or subjects who had been
registered for research purposes.10 16 17 It is conceivable,
however, that these research families represent a selected
group of HNPCC families where decision making processes
are different from those in families in a clinical setting. Here,
we report the use of genetic testing in 18 clinically
ascertained HNPCC families with a known mutation in
MSH2, MLH1, or MSH6.
MATERIAL AND METHODS
Patients
Eligible HNPCC families have been referred to the Department
of Clinical Genetics of the Erasmus University Medical Centre
Rotterdam for oncogenetic counselling by general practition-
ers and medical specialists since 1992. DNA analysis of the
MSH2, MLH1, and MSH6 genes was performed at the
Department of Human and Clinical Genetics, Leiden Univer-
sity Medical Centre, as described previously.18–20 Families were
included in the study when a mutation in either of these three
mismatch repair genes was identified before 2000. Subjects of
these families were included when they were aged 18 years
and over at the time of molecular diagnosis in the family and
when they had a pre-test genetic risk for carrying the
mutation of 100%, 50%, or 25% (see results).
Procedure
In general, the initial search for the causative mutation had
been performed on blood DNA of the youngest colorectal
cancer patient in the family (the index subject). Identified
mutations were confirmed in all relatives affected with an
HNPCC related tumour from which DNA samples were avail-
able. The initial counsellee and index subjects were asked to
inform all the adult first and second degree relatives of
patients with an HNPCC related tumour about the genetic
predisposition to cancer in their family. Written information
to distribute among their family members was made
available to them. This information included facts on the
inheritance of the cancer susceptibility in their family, the
Key points
• In a clinical setting, considerable interest was observed
for genetic testing in HNPCC families with a known
germline mutation.
• Testing was used more frequently by subjects with a
higher pre-test genetic risk for the mutation, by women,
and by subjects with children.
• Genetic testing has earned a place in the standard
medical care for subjects at risk for HNPCC.
Table 1 Mutations in the MLH1, MSH2, and MSH6
genes in the HNPCC families studied
Gene Nature of the mutation (nucleotide change)
Families
(n=18)
MSH2 Genomic deletion exon 3 1
Splice acceptor site intron 9 (IVS9_2A>G) 1
Frame shift mutation exon 2 (229_230delAG) 1
Nonsense mutation exon 13 (2038C>T) 1
Genomic deletion exon 1 1
Nonsense mutation exon 8 (1285C>T) 2
Frameshift mutation exon 2 (1705_1706delGA) 1
Frameshift mutation exon 14 (2347delC) 1
MLH1 Splice donor site intron 8 (IVS8+1delG) 1
In frame deletion exon 16 (1852_1854delAAG) 5
Splice donor site exon 16 (1896G>A) 1
Splice acceptor site intron 9 (IVS9-1G>C) 1
MSH6 Frameshift mutation exon 4 (1784delT) 1
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possibility of genetic testing, the risks of developing cancer,
and the options for intervention. Relatives opting for genetic
testing received one or more individual pre-test counselling
sessions according to the recommendations of the American
Society of Clinical Oncology,21 including the discussion
of medical, genetic, and psychosocial aspects of genetic
testing. Psychological support was offered to all subjects
throughout the testing procedure. Disclosure of the test
results followed within 6-12 weeks after blood sampling.
Mutation carriers were referred to local specialists for follow
up and surveillance. In The Netherlands, this surveillance
comprises colonoscopy and gynaecological examination
every one to two years. In this country, prophylactic
colectomy is currently not offered to unaffected mutation
carriers.
Data collection and statistical analysis
All data were collected from medical records. Descriptive sta-
tistics were used to establish test rates of genetic testing. The
influence of pre-test genetic risk, gender, parenthood, and age
on the use of genetic testing was first assessed by univariate
analysis. Subjects were categorised into subjects younger
than 50 years and subjects 50 years and older. The simultane-
ous influence of gender, parenthood, and age was also
assessed by multivariate logistic regression analysis in the
50% risk subjects. Pre-test genetic risk had been excluded
from the multivariate analysis, as about half of the data
on parenthood and age were missing for the 25% risk
subjects.
To assess the time dependent rate of genetic testing,
Kaplan-Meier survival probabilities were calculated for 50%
risk subjects with a first degree relative with an HNPCC
related tumour. By doing so, we avoided including the time
25% risk subjects had to wait for the genetic test result of
their parent.
RESULTS
A cohort of 18 consecutive HNPCC families was selected that
had a knownmutation inMSH2 (n=9),MLH1 (n=8), orMSH6
(n=1) (table 1). All families were of European origin. Five
apparently unrelated families had an identical MLH1 muta-
tion and two apparently unrelated families had an identical
MSH2 mutation (table 1). At the time of clinical ascertain-
ment, 15 of the 18 families fulfilled the Amsterdam II
criteria.22 Of the other three families, two families presented
with a single patient with colorectal cancer under the age of 40
years and one family had three patients with endometrial
cancer and one patient with ovarian cancer, all diagnosed over
the age of 50 years.23 Specific details of the number of
colorectal and endometrial cancers per family and ages of
onset are listed in table 2.
The 18 selected families consisted of 523 living
subjects with a 100% (n=60), 50% (n=308), or 25% (n=155)
pre-test genetic risk of carrying the family specific mutation
(table 3). For practical reasons, the subjects diagnosed with
an HNPCC related tumour (n=56) and obligate carriers
(n=4) were designated as having a 100% pre-test genetic
risk. The subjects with a 50% risk had a first degree
relative with an HNPCC related tumour (n=267) or a first
degree relative who was a mutation carrier (n=41).
The subjects with a 25% risk had a living unaffected parent
with a 50% risk (n=64) or a parent with a 50% risk who
had died without evidence of an HNPCC related tumour
(n=91).
Genetic testing was used by 260 of 523 (50%) eligible
subjects (table 3). A mutation was detected in 133 (51%)
subjects, of whom 83 were unaffected. Of the subjects
with a pre-test genetic risk of 100%, 50%, and 25% for
carrying the mutation, 87%, 57%, and 21% respectively
used genetic testing (p<0.0001 for 100% v 50%; p<0.0001 for
50% v 25%) (tables 3 and 4). Of the 25% risk subjects who had
an unaffected 50% risk parent who did not opt for testing,
only three of 64 (5%) subjects used genetic testing. In
contrast, of the 25% risk subjects with a dead unaffected 50%
risk parent, 30 of 91 (33%) subjects used genetic testing
(table 4). The test rate among the 308 50% risk subjects was
62% in women versus 51% in men, suggesting a small but
significant preference for women to use genetic testing
(p=0.041, table 4). The test rate in 50% risk subjects with
children was 70% versus 45% for those without children,
indicating parenthood as a stronger positive predictor
towards testing (p<0.001, table 4). The age of the subjects did
not influence test rates (table 4). Multivariate analysis of the
data was consistent with the univariate analysis, again
indicating gender and parenthood as significant parameters
for genetic test usage (table 4).The mean time of follow up
after identification of the mutation in the family was 42
months (range 12-74 months). Forty-one percent of 50% risk
subjects decided for genetic testing within one year. At a












MSH2 9 4.8 43.8 y (23–75) 1 46.4 y (30–54)
MLH1 8 5.4 43.7 y (27–72) 0.5 46.3 y (41–82)
MSH6 1 7 60.4 y (32–84) 5 55 y (50–60)
CRC, colorectal cancer. EC, endometrial cancer.
Table 3 Genetic testing and outcome in 100%, 50%, and 25% risk carriers in the
18 HNPCC families
Pre-test risk 100% 50%
25%
TotalParent alive Parent dead Total
Number 60 308 64 91 155 523
Tested 52 (87%) 175 (57%) 3 (5%) 30 (33%) 33 (21%) 260 (50%)
Mutation carrier 50 (96%) 80 (46%) 0 3 (10%) 3 (9%) 133 (51%)
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follow up at two years and three years after molecular
diagnosis, 58% and 65% respectively of the 50% risk subjects
were tested (fig 1).
DISCUSSION
To our knowledge, the present study is the first to evaluate the
use of genetic testing for HNPCC in a clinical setting.
Importantly, we determined the use of genetic testing in com-
plete pedigrees, including all affected family members and
their unaffected first and second degree relatives. This was
done in 18 HNPCC families with an identified pathogenic
mutation in MSH2,MLH1, or MSH6. These families were quite
extensive, with an average of 29 study subjects per family. The
use of genetic testing by 50% risk carriers in our families was
57%. This test rate was lower than the 75% test rate in a Finn-
ish cohort of 446 subjects at similar risk for an HNPCC germ-
line mutation.16 The Finnish subjects, however, had consented
to registration and participation in research, which is likely to
be positively correlated with interest in genetic testing. Also,
the Finnish population is known for its positive attitude
towards genetic testing.24 In a Northern American study only
90 out of 208 subjects (43%) from four extended HNPCC
research families were tested.17 As the pre-test genetic risks of
the study subjects were not specified,we cannot compare their
data with ours.
We found that the magnitude of pre-test genetic risk for
carrying the mutation was strongly correlated with test rates
(87%, 57%, and 21% for 100%, 50%, and 25% risk subjects,
table 3). This phenomenon has also been observed in other
inherited diseases.25–27 Interestingly, 25% risk subjects with an
unaffected 50% risk parent who was alive rarely opted for
genetic testing (5%), whereas subjects with the same pre-test
genetic risk but with a dead unaffected 50% risk parent
used genetic testing in one-third of the cases (tables 3 and 4).
This may be because the identification of the mutation in a
child designates the parent as an obligate carrier and children
from a living unaffected 50% risk subject may therefore be
more likely to refrain from genetic testing in order not to
overrule their parents’ preference for “not knowing”. Also,
children may share strategies to cope with genetic risks with
their parents. The slightly higher genetic test rates in women
than men (62% v 51%) was also seen in another late onset
inherited disease.26 In HNPCC, however, the additional risk
for endometrial cancer in female mutation carriers probably
also influences the use of genetic testing. The significantly
higher test rates among subjects with children compared to
subjects without children (70% v 45%) has also been observed
in families with inherited breast and ovarian cancer
(HBOC).25 These findings emphasise that knowledge of the
cancer risks for offspring is a major reason for subjects to
opt for genetic testing. The high test rate in the affected
100% risk subjects also seems to reflect this phenomenon,
since their participation is pivotal especially for the
identification and conformation of the pathogenic mutation
in the family, but generally has few medical implications for
themselves.
A significant proportion of subjects was tested more than
one year after the identification of the family specific
mutation (65% of the 50% risk carriers at a follow up of three
years) (fig 1). Interestingly, at our institute, the time period
for deciding for genetic testing was strikingly longer for sub-
jects at risk for HNPCC than for subjects at risk for HBOC
(50% at 18 months versus 9 months).25 The differences in
time needed for decision making may perhaps be related to
the one to two years interval for colonoscopy in HNPCC
families versus the six months interval for breast surveillance
in HBOC families.
Genetic testing rates depend on the natural history of the
disease concerned, the success of treatment, the efficacy and
acceptability of surveillance and prevention, and the costs
involved.28 The use of genetic testing in 50% risk subjects
varies from about 20% in Huntington’s disease (no interven-
tions available, but relief of uncertainty and relevance for, for
example, reproductive choices)26 29 to 55% in hereditary
breast and ovarian cancer (BRCA1 and BRCA2 genes, surveil-
lance and prophylactic mastectomy, prophylactic oophorec-
tomy, and chemoprevention available for female carriers),26 30
to 90% in familial hypercholesterolaemia (lipid lowering
treatment available).31 The 57% HNPCC genetic testing rate in
50% risk carriers reported here is similar to that of women
with the same genetic risk for carrying a BRCA1 or BRCA2
mutation. This suggests that the total load of factors that
influence the choice to opt for genetic testing in HNPCC
equals that in HBOC. The efficacy of regular colonoscopy in
HNPCC mutation carriers is more favourable compared to
regular mammography in young women with a BRCA1 or
BRCA2 mutation.11 32 This limited efficacy of mammography
causes some women with a BRCA1 or BRCA2 mutation to opt
for prophylactic mastectomy.25 30 Though colonoscopy is not as
invasive as the prophylactic mastectomy in HBOC, the burden
and violation of physical integrity of this surveillance may be
an underestimated factor. Also, the additional risks for other
HNPCC related cancers, like brain tumours, for which no
Table 4 Genetic test use in relation to gender,
parenthood, age, and pre-test genetic risk
Total Tested (%) Univariate Multivariate
Gender*
Females 156 97 (62) p=0.041 p=0.045
Males 152 78 (51)
Children*
Yes 182 127 (70) p<0.001 p=0.013
No 107 48 (45)
Age*
<50 y 191 104 (55) p=0.24 p=0.39
>50 y 117 72 (62)
Pre-test risk
50% 308 175 (57) p<0.0001 -
25% 155 33 (21)
25% risk carriers
Parent alive 64 3 (5) p<0.0001 -
Parent dead 91 30 (33)
*In subjects with a pre-test genetic risk of 50%.
Figure 1 Time dependent rate of genetic testing in subjects with a
50% pre-test genetic risk. The proportion of 50% risk carriers not
having the genetic test is shown at 0, 6, 12, 24, and 36 months
after the identification of the familial mutation. Only 50% risk




options for surveillance and prevention are available, can
cause subjects to refrain from testing. Other reasons not to
opt for testing might be fear of financial and social discrimi-
nation and inability to cope with a positive test result. Nota-
bly, in The Netherlands, cancer predisposition is no reason for
exclusion by the health insurance companies, nor for denial
of access to employment. It was shown that most tested sub-
jects are able to cope with genetic testing for cancer predispo-
sition in the short term, particularly also for HNPCC.16 33–36
More data on the long term psychosocial impact of genetic
testing for HNPCC as well as data on the reasons and
psychosocial impact of refraining from genetic testing are
needed.
From the data reported here, however, it can be concluded
that there is considerable interest in genetic testing in
subjects from HNPCC families with a known mutation. Also,
in view of the reduction in morbidity and mortality upon
surveillance of identified mutation carriers, genetic testing
has earned a place in the standard medical care for people at
risk for HNPCC.
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Hereditary Non Polyposis Colorectal Cancer (HNPCC) is a hereditary predisposition to 
colorectal and endometrial cancer, caused by mutations of the mismatch repair (MMR) 
genes MSH2, MLH1 and MSH6. Regular colonoscopy reduces the incidence of colorectal 
cancer in mutation carriers dramatically. The aim of this study was to evaluate the use of 
colonoscopy by proven HNPCC mutation carriers. We also evaluated the satisfaction with 
the counseling and screening procedures at the long term. A questionnaire survey was 
performed among 94 proven MMR gene mutation carriers. Data were analyzed using 
univariate and multivariate analysis. The average time of follow-up was 3,5 years (range 
0.5-8.5 years). The response rate was 74%. The proportion of unaffected mutation carriers 
under colonoscopic screening increased from 31% to 88% upon genetic testing, and for 
gynecological screening from 17% to 69%.  However, more than half of the responders 
experienced colonoscopy as unpleasant or painful. About 97% felt well informed during 
counseling, and 88% felt sufficiently supported. Ten percent of the responders reported a 
high cancer worry, that was significantly (p=0.007) associated with a high perceived cancer 
risk. Six responders (9%) regretted being tested. Remarkably, of 4 of these 6 a close 
relative died recently of cancer. Problems with obtaining a disability or life insurance or 
mortgage were experienced by 4 out 10 healthy carriers opting for these services.  In 
conclusion, genetic testing for HNPCC considerably improves compliance for screening, 
which will result in a reduction of HNPCC related cancer morbidity and mortality in 
mutation carriers. Most HNPCC gene mutation carriers cope well with their cancer 
susceptibility on the long term.  
 
Introduction 
Hereditary Non-Polyposis Colorectal Cancer (HNPCC, OMIM #114500) is an autosomal 
dominantly inherited predisposition to colorectal and endometrial cancer. It is caused by 
germline mutations of mismatch repair (MMR) genes, particularly MSH2, MLH1 and 
MSH6 [1-4]. MMR gene mutation carriers have cumulative lifetime risks of colorectal and 
endometrial cancer of 70-90% and 30-40%, respectively [5-8]. Also cancers of the stomach, 
ovaries, small bowel, urinary tract, skin and brain occur in mutation carriers, but the 
cumulative lifetime risks of each of these tumors do not exceed 15% [5-8].  
The identification of MMR gene mutations in HNPCC enabled genetic testing 
within families with HNPCC. In the context of a known mutation in the family, 
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identification of individuals with or without the mutation is possible by DNA testing.  Non-
mutation carriers will be relieved from anxiety and can be dismissed from regular screening 
programs, while individuals with the mutation may benefit from these procedures. 
Colonoscopy was shown a potent tool for the detection and treatment of premalignant 
adenomas or early colorectal carcinomas in individuals at risk of HNPCC. Järvinen et al. 
[9] reported a decrease of overall mortality of about 65% by regular colonoscopy within 
this group. However, colonoscopy is an invasive screening technique with a clear burden 
and some risk [10]. The efficacy of screening for extra-colonic tumors in HNPCC carriers, 
like gynecological screening, is controversial [11, 12]. To date little is known about cancer 
screening practices among proven MMR gene mutation carriers. At a follow-up of 12 
months Hadley et al. [13] reported a slight increase (41% to 53%) of colonoscopic 
screening among 17 MMR gene mutation carriers.   
Here we evaluate the use of regular colonoscopy by proven MMR gene mutation 
carriers on the long term. In view of the significant psychosocial impact of genetic testing 
and related surveillance strategies, we simultaneously evaluated the long-term satisfaction 
with the counseling procedure and the screening program. 
 
Patients and methods 
Between November, 1994 and December, 2002, 115 MMR gene mutation carriers were 
identified at the Department of Clinical Genetics of Erasmus MC. Questionnaires were sent 
to carriers with known addresses and who were still alive on May 2003. 
The counseling procedure was as follows. In the search for the causative MMR 
gene mutation within a family, we initially invited the relatives affected with an HNPCC 
related tumor for genetic testing. After identification of a pathogenic mutation, the initial 
counselees were asked to inform all adult first and second-degree relatives of patients with 
an HNPCC related tumor about the possibility of genetic testing. Written information to 
distribute among their family members was available to them. This information included 
facts on the inheritance of the cancer susceptibility in their family, the possibility of genetic 
testing, the risks of developing cancer, and the options for intervention. Relatives opting for 
genetic testing received one or more individual pre-test counseling sessions according to 
the recommendations of the American Society of Clinical Oncology [14]. Psychological 
support was offered to all subjects throughout the testing procedure. Disclosure of the test 




local specialists for follow-up and surveillance. The advised colonic screening consisted of 
colonoscopy every 1-2 year from the age of 20-25 years on. The procedure was generally 
prepared by PEG-solution with or without fluid diet and performed under sedation. Female 
carriers were offered gynecological screening by vaginal ultrasound and CA125-
maesurement in blood from the age of 30-35 years on. Additional screening advices for the 
stomach, duodenum or urinary tract were occasionally given, based on family history.  
Our questionnaire addressed sociodemografic characteristics, experience with 
HNPCC related cancer, compliance with screening, satisfaction with the screening methods 
and counseling procedure, knowledge and perception of cancer risks, and discrimination by 
insurance companies. Sociodemographic characteristics included age, gender, marital 
status, highest level of education, employment and number and age of children. The use of 
pre- and post-test screening was asked (1=no; 2=yes), including the frequency and method 
of screening. Satisfaction with the screening methods and counseling procedure was rated 
on a 5-point scale and classified in 2 groups. Group 1, the satisfied group, scored 1, 2, or 3, 
and group 2, the unsatisfied group, scored 4 or 5. Since an HNPCC related colorectal 
cancer risk of about 80% had generally been counseled, reported colorectal cancer risks for 
MMR mutation carriers were scored as underestimated or overestimated if lower than 70% 
and higher than 90% respectively. Perceived colorectal cancer risk was rated on a 5-point 
scale and classified in 3 groups. Group 1, the low risk group, scored 1 or 2, the intermediate 
group scored 3, and the high risk group 4 or 5. For the evaluation of cancer worry three 
questions based on the “cancer worry scale” of Lerman et al. [15] were used, addressing (1) 
how often the mutation carrier worried about developing colorectal cancer and whether the 
carrier’s (2) mood or (3) daily activities were impaired by these worries. Response scales 
varied from 1=”almost never” to 4=”always”. Thus, the range of the total score of these 
three questions was 3-12. The level of worry was interpreted as low (when all three 
questions were answered by “almost never”, total score =3), as intermediate (total score: 4-
6) or as high (total score: 7-12). Interference of the genetic status with work and insurance 
were asked for (1=no; 2=yes), differentiating the type of insurance (health insurance, 
mortgage, life and disability insurance).  
All data analyses were done with the program SPSS for Windows (version 9.0). 
Differences in sociodemographic characteristics between individuals affected and not-
affected with an HNPCC related tumor, differences in compliance with screening before 
and after genetic testing and differences between reported HNPCC related risk, perceived 
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risk and cancer worry between groups were tested by Pearson’s Chi square test, a Fisher’s 
exact test, or a Mc Nemar Chi square test. Multiple logistic regression analysis was used to 
determine factors associated with reporting a wrong HNPCC related colorectal cancer risk. 
All P values were two sided. P values less than 0.05 were considered significant.  
 
Results 
We identified 24 families with a MMR gene germline mutation (11 of MSH2, 10 of MLH1 
and 3 of MSH6), encompassing 115 mutation carriers. Questionnaires were sent to 94 
individuals (the remaining had died or had moved to unknown addresses). Of the 94 
questionnaires, 70 were received back, resulting in a response rate of 74%. Of the 70 
responders 24 (34%) were male and 46 (66%) were female, and 28 individuals (40%) were 
already diagnosed with an HNPCC related tumor at the time of testing (17 with colorectal 
cancer, 8 with endometrial cancer and 3 with both colorectal and endometrial cancer)(Table 
1). There was no significant difference in gender and parenthood between the affected and 
not affected responders (Table 1). However, the responders affected with an HNPCC 
related tumor were significantly older than the not affected responders (p<0.001). The 24 
non-responders did not differ significantly from the responders with respect to gender, 
clinical status, age and parenthood (data not shown). The average time of follow-up from 
the individual genetic diagnosis was 3,5 years (range 0.5-8.5 years). 
Thirty-one percent of the unaffected risk carriers had regular colonoscopy before 
genetic testing (Table 2); 62% every 2 years, and 38% less frequent. The vast majority 
(79%) of individuals who had no screening prior to genetic testing was not aware of being 
at increased risk for colorectal cancer. After being identified as a mutation carrier, 88% of 
the healthy risk carriers indicated to have colonoscopic screening every 1-2 year. Five 
individuals refrained from colonoscopic screening so far; one because of the burdensome 
procedure, one because of lack of time due to a busy lifestyle, and three individuals planned 
to go for screening in the near future. Gynecological screening was performed in three of 
18 unaffected female risk carriers (17%) that were over 35 years before the genetic test 
(Table 2). At the time of the questionnaire 20 of 29 female mutation carriers (69%) over 35 
years of age had had gynecological screening. Noteworthy, endometrial cancer had 
occurred in the families of 7 of the 9 women not opting for gynecological screening. We 




Fifty-seven percent of the healthy carriers experienced colonoscopy as unpleasant 
(Table 3), 32% as fearful, 51% as painful, 16% as shameful, and 14% as hazardous. The 
majority (71%) would prefer a less burdensome screening technique. About 90% of the 
carriers believed that screening reduced colorectal cancer risk. Ten of the 37 (27%) healthy 
risk carriers that underwent colonoscopic screening reported the detection of colorectal 
polyps. No colorectal cancers were detected during the study period. 
Eighty-eight percent of the mutation carriers judged the way they were informed 
about the possibility of genetic testing for HNPCC as appropriate (Table 4). Also, the 
information about HNPCC given during counseling was judged sufficiently by 97%. 
However, almost one third of the mutation carriers with a previous HNPCC related cancer 
and half of the healthy individuals would have liked information about life-style 
adjustments and/or food supplements to prevent cancer. Also, updates about new 
developments on the field of HNPCC were appreciated on the long term.  
Interestingly, 63% of the respondents affected by an HNPCC related cancer and 
37.5% of the unaffected underestimated the HNPCC related cumulative lifetime colorectal 
cancer risk (Table 5). Reporting an incorrect HNPCC related risk was in the univariate 
analysis associated with age and being affected with an HNPCC related tumor, but in the 
multivariate analysis only with age (Table 6). About half of the respondents experienced 
their own colorectal cancer risk as high (Table 5).  
Sixty-nine percent of the mutation carriers reported some degree of cancer worry, 
of whom 10% a high level (Table 7). This worry was significantly (p=0.007) associated 
with a high perceived colorectal cancer risk. Clinical status, gender, age, parenthood and 
reporting high or correct HNPCC related colorectal cancer risks, were not significantly 
associated with cancer worry. However, our study group may be too small to detect more 
subtle associations. Eight mutation carriers had expected more support from the genetic 
department (Table 4), mainly with respect to the arrangement of screening and the 
psychological handling of cancer risks.  
Regret of genetic testing was reported by six respondents (9%). They stated that 
they would not choose for genetic testing for the familial MMR gene mutation with their 
current knowledge and experience (Table 4).  Within this subgroup, four had recently lost a 
relative because of cancer, three had high levels of cancer worry, three expected to die of 
cancer despite screening, and one had insurance problems.  
 6
Insurance problems regarding disability, life insurance or mortgage, were reported 
by 4 out of 10 unaffected respondents, who opted for these services (Table 4). None 
indicated problems with getting a job or health insurance.  
 
Discussion 
We show that genetic testing largely improved colorectal and gynecological screening 
compliance in the studied group of proven HNPCC risk carriers (from 31% to 88% and 
from 17% to 69% respectively). This can be expected to lead to a considerable reduction in 
HNPCC related morbidity and deaths in this group.  
Although, the vast majority (90%) of healthy risk carriers has faith in the efficacy 
and safety of the colonoscopic screening, it is certainly experienced as an invasive and 
burdensome technique. A main effort should be made to improve preventive options in this 
group of risk carriers that faces a life-long colorectal screening.  
Almost two-thirds of the responders affected with an HNPCC related tumor and a 
third of the not affected report a lower HNPCC related cumulative lifetime colorectal 
cancer risk than counseled. Also, only about half of the responders perceived their own 
colorectal cancer risk as high. Underestimation of colorectal cancer risks by HNPCC 
carriers was previously described by Aktan et al. [16]. It may be due to coping strategies to 
deal with the personal colorectal cancer risk and to failing memory [16, 17]. Less accurate 
recollection of risks is also correlated with age. Since the affected responders are 
significantly older than the not affected, this may be an explanation for the difference in 
reported HNPCC related colorectal cancer risks between the responders affected and not 
affected with an HNPCC related tumor.     
On the long term most MMR gene mutation carriers tested at our department were 
able to cope with having this cancer predisposition. The vast majority of proven carriers 
judged the information and support they received during the counseling procedure as 
sufficient. Noteworthy, 59% would have appreciated updates on scientific developments 
regarding HNPCC. High cancer worry regarding their colorectal cancer risk was indicated 
by 10% of the responders (3 affected and 4 not affected with an HNPCC related tumor). 
This is comparable to the figures presented by Aktan et al. in 83 MMR mutation carriers at 
one year of follow-up (8%) [16]. Cancer worry in our study was correlated significantly 
with a high perceived colorectal cancer risk. During counseling and follow-up an effort 




psychological support should be more actively offered. Even more so, since, in our study, 
underestimation of the HNPCC related colorectal cancer risk did not influence screening 
behavior negatively.   
Regret of being tested for the familial susceptibility for HNPCC was expressed by 
6 respondents (9%). Remarkably, in the families of 4 of the six responders a relative 
recently died of cancer. Events in the family are known to influence perceived cancer risk 
[17]. Also, faith in the efficacy of screening may be violated. Tailor-made psychological 
support may help relatives with coping problems due to newly diagnosed cancer cases or 
deaths in the family. Since relatives can develop HNPCC related or non-related cancer at 
any moment in time, it is optimal to have an ongoing follow-up of the MMR mutation 
positive families. This could be obtained by yearly telephone contact or information 
gatherings. Also, offering screening to all carriers in a multidisciplinary outpatient facility 
can improve long-term follow-up and satisfaction.    
In the Netherlands employers or insurers are prohibited to exclude individuals with 
a genetic predisposition for cancer from jobs or health insurance. For life or disability 
insurance no questions about genetic predisposition may be asked by insurers for insurance 
below a certain limit; ∈160.00 for health insurance and ∈32.000 in the first year of a 
disability insurance and ∈22.000 the following years. As a result of these regulations, the 
studied group experienced no problems with jobs or health insurance. However, almost half 
of the healthy risk carriers opting for life insurance, disability insurance or mortgage, had 
some kind of trouble. This represents a potential threat to the accessibility of genetic testing 
for cancer susceptibilities. 
In conclusion, this study indicates that genetic testing for HNPCC considerably 
improves compliance with screening. Also, most MMR gene mutation carriers can cope 
with their cancer susceptibility on the long term. We identified a need for updates regarding 
new developments and for more support of a vulnerable minority that has coping problems 
at the time of genetic testing or later on. We therefore propose an ongoing access to 
psychological and counseling facilities for MMR gene mutation carriers, preferably in the 
setting of a multidisciplinary family cancer clinic.     
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Table 1:  
Gender, Age and Parenthood in MMR mutation carriers affected and not affected 
with an HNPCC-related tumor 
   Affected (%) 
n=28 





Gender:    Male 








Age:        25-50 
                >50 







Children:  No 
                 Yes 
  1/28   (4) 
27/28 (96)   
  7/42 (17) 
35/42 (83)   
  8/70 (11) 




Table 2:  
Screening behaviour among MMR mutation carriers without an HNPCC-related tumor 
before and after genetic testing.  
 Number of carriers (%) P value 
Regular colonoscopy:           Before genetic testing 




Gynecological screening:     Before genetic testing 
                                              After genetic testing 





Table 3:  
Satisfaction with colonoscopic screening among the studied MMR gene mutation carriers 
without an HNPCC-related tumor.  
 Number of carriers (%) 
Colonoscopy*:     unpleasant 
                             fearful 
                             painful 




  6/37 (16) 
Faith effectiveness of colonoscopy 38/42 (90) 
Worry of complication of colonoscopy   6/42 (14) 
Wish other screening method 30/42 (71) 
*Scored in the 37 healthy carriers who underwent colonoscopy 
 
 
Table 4:  
Long term satisfaction with the counseling procedure and genetic testing in the studied 
MMR gene mutation carriers.   
 Affected (%) Not affected (%) Total (%) 
Appropriately invited   25/27   (93) 35/41 (85) 60/68 (88) 
Sufficiently informed   26/26 (100) 40/42 (95) 66/68 (97) 
Sufficiently supported   23/26   (88) 35/40 (88) 58/66 (88) 
Regret of testing     2/28     (7)   4/42 (10)    6/70  (9) 
Insurance problems     3/4     (75)   4/10 (40)   7/14*(50) 
Not all items were scored by all 70 carriers 





Table 5:  
Reported and perceived HNPCC related cumulative lifetime colorectal cancer risks by the 
MMR gene mutation carriers. 









          ≤50 years 
          >50 years 
 
0/35 
 4/32  (12) 
 
24/35 (69) 







                No 
                Yes 
   
1/40  (2.5)       
 3/27  (11)    
 
24/40 (60)   
  7/27 (26) 
    
15/40 (37.5) 
17/27 (63)    
 
0.016 









Age:   
         ≤50 years 













                No 








14/42 (33)   
  9/28 (32) 
 
0.7 




Table 6:  
Comparison of correct vs. incorrect reported HNPCC-related cumulative lifetime colorectal 
cancer risk in respondents affected with and without an HNPCC-related tumor and 
according to age. 
Reported HNPCC related colorectal cancer risk 
Univariate Multivariate  Correct 
n=31 
Incorrect 
n=36 OR 95% CI P value OR 95% CI P value 
Age:  
  ≤50 years 

























           No 
































Table 7:  
Long term cancer worry in the studied MMR gene mutation carriers. 








               No 












Gender:   
               Male 
               Female 
  











Age:        
               ≤50yrs 







          
       3/36 (8) 




               No 
               Yes  
 
  2/8   (25) 
20/62 (32) 
    
      5/8  (62.5) 
36/62 (58) 
      
      1/8   (12.5) 
  6/62 (10) 
 
0.91 
Reported HNPCC risk*:  
               Underestimated 
               Correct 
               Overestimated 
 
 11/32 (34.5) 
9/31 (29) 
2/4   (50) 
 
18/32  (56) 
    20/31 (64.5) 




     1/4   (25) 
 
0.58 
Perceived risk:     
               Low  
               Intermediate 
               High 
 
11/23 (48) 
  4/13 (31) 
     7/34 (20.5) 
 
12/23 (52) 





     6/34 (17.5) 
 
0.007 
















The diagnosis of HNPCC represents a major challenge for geneticists and clinicians 
because of its geno- and phenotypic heterogeneity191. In my PhD thesis, I have attempted 
to define the spectrum of mutations at the main MMR genes causing HNPCC, and the 
establishment of genotype-phenotype correlations to allow clinical selection of families, 
guide their mutation analysis, and delineate surveillance protocols based on the specific 
genetic lesion. 
In chapter 2, we addressed the molecular genetic analysis of HNPCC. We showed that the 
vast majority of ‘classical’ HNPCC families is due to MLH1 or MSH2 mutations. MSH6 and 
possibly PMS2 mutations cause a more atypical phenotype and are responsible for only a 
small proportion of classical families. Based on our observations, it is unlikely that other 
major HNPCC genes will be found in the future. Failure of mutation detection in the major 
MMR genes in Amsterdam criteria positive families is likely to be due to: 1. marginal 
fulfilment of the clinical criteria in colorectal cancer only, true mutation-negative 
families; 2. wrong selection of patients to be tested from otherwise mutation-positive 
families (e.g. phenocopies); 3. failure of mutation detection techniques in mutation-
positive families. 
Colorectal cancer is a relatively common tumour type. Families may therefore fulfil the 
Amsterdam criteria by chance or because of additional susceptibility factors. Also, within 
families with a MLH1, MSH2, or MSH6 mutation, “sporadic” colorectal cancer cases may 
occur. In my opinion, extensive and detailed pedigree analysis is still the cornerstone for 
the selection of individuals for genetic testing for HNPCC. The establishment of a detailed 
family history is a time consuming and painstaking exercise, but it additionally allows the 
selection for testing for other susceptibility factors for colorectal cancer. In classical 
HNPCC families mutation analysis is indicated and does not require preselection by 
microsatellite instability tests (MSI) or immunohistochemical (IHC) analysis, although IHC 
analysis can direct mutation analysis. MSI and IHC analyses of tumours are in particular 
helpful for selection for mutation analysis within families not or marginally fulfilling the 
Amsterdam criteria. For selection for MSI and IHC analysis the revised Bethesda guidelines 
are very useful. However, I advocate liberal inclusion for MSI and IHC analysis. Some 
practical guidelines for the management of HNPCC and HNPCC-like families based on our 
own experience and on the literature are formulated in Figure 10. IHC and/or MSI analysis 
as a pre-screen tool for MMR gene analysis can also be routinely offered to certain 
patient-groups like colorectal patients diagnosed under the age of 50 years or patients 
with multiple tumours. However, some form of pre-test counselling of patients is 
requisite, since absent staining of MSH2 and/or MSH6 are strongly indicative for the 




Our discovery of large genomic rearrangements in MLH1 and MSH2 dramatically increased 
mutation detection rate at these major HNPCC genes. These findings underscore the need 
to implement molecular approaches capable to detect large genomic rearrangements. To 
date, many DNA-diagnostic laboratories have added PCR-based mutation techniques for 
large genomic deletions, e.g. MLPA77, to their routine mutation detection techniques35, 232, 
279. Notably, MLPA likely would have missed the 10Mb paracentric inversion of 
chromosome 2p we detected by Southern blot analysis in a classical HNPCC kindred, as 
reported in chapter 2.3. The identification of this inactivating MSH2 mutation within this 
family was of medical benefit, as it enabled the selection of a suitable kidney donor for 
one of the relatives189. I advocate that DNA-diagnostic laboratories refine their search for 
atypical mutations (genomic deletion, inversions, and insertions) within families with a 
high chance of carrying a MLH1, MSH2 and/or MSH6 mutation which tested negative by 
conventional mutational analysis.  
In our search for genomic rearrangements, we also identified a common North-American 
deletion in MSH2, accounting for as much as ~10% of our cohort (chapter 2.1 and 2.2). 
The combination of clinical and molecular genetic data indicated that all families carrying 
this MSH2 exon 1-6 deletion descend from one ancestor who lived in Germany in the 18th 
century. The identification of this founder mutation enabled a conclusive genetic test in 
large numbers of HNPCC risk carriers in North America.  
The second main diagnostic challenge of HNPCC is represented by its clinical variability. 
As reported in chapter 3.1 and 3.2, the cancer phenotype of MSH6 mutation carriers 
differs from that of MLH1 and MSH2. MSH6 mutations are associated with a delayed age of 
onset of colorectal and endometrial cancer (55-57 years vs. 43-44 years, and 54 years vs. 
48-49 years, respectively). Moreover, the cumulative lifetime risk of endometrial cancer 
in female mutation carriers is increased compared to MLH1 and MSH2 mutation carriers 
(71% vs. 27-40% at 70 years of age), while the risk of colorectal cancer is reduced (30% vs. 
53-68% at 70 years). These observations will aid the clinical recognition of MSH6 mutation 
positive families, and contribute to the development of MSH6-tailored cancer 
recommendations for screening and preventative options.  
 
Above all, HNPCC challenges families who have to live with the disease and its threats. 
The availability of a genetic test for HNPCC adds to this complexity, but also offers hope 
for interference. 
The detection of a pathogenic MLH1, MSH2 or MSH6 mutation within a family enables 
relatives conclusive genetic testing, allowing them to obtain certainty about their cancer 
risks. The use of predictive genetic testing is influenced by several factors, among which 
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the availability of effective and acceptable risk-reducing interventions. Former studies 
reported a high uptake for predictive genetic testing for HNPCC (75-81%)12, 272. However, 
we believe that these studies are likely to be biased in favour of a high uptake as only 
individuals who had agreed to register for research purposes were included. It is 
conceivable that these individuals are also willing to undertake genetic testing, and are 
thus not representative for HNPCC patients at large. We studied the use of genetic testing 
in families with a known MLH1, MSH2 or MSH6 mutation in a clinical setting (chapter 3.3). 
Fifty-seven percent of 308 individuals with an a priori 50% risk of carrying the germline 
mutation opted for genetic testing, which is approximately 20% lower than in the Finnish 
study. Hence, in our study a considerable portion of risk carriers refrained from genetic 
testing. This was confirmed by Hadley et al.85 and Ponz de Leon et al.235, who found a use 
of genetic testing of respectively 51% and 44% among 50% risk carriers. Reasons for not 
testing may include lack of information, fear for cancer for themselves or their children, 
fear for screening procedures or fear for social discrimination. In the Netherlands, 
knowledge of a genetic predisposition for cancer is passed among relatives. In our study, 
the vast majority of gene carriers appreciated the way they were informed about the 
possibility of genetic testing, and the information they received during counselling (88% 
and 97%, respectively; chapter 3.4). Of note, little is known about the views and feelings 
of relatives who refrain from counselling and testing. Both a very high and a very low 
cancer concern may prevent individuals from seeking genetic advice. In risk carriers for 
Hereditary Breast Ovarian Cancer (caused by BRCA1 or BRCA2 gene mutations), Lerman et 
al.154 found that individuals who refrained from obtaining their personal genetic test result 
had higher depression levels than those who chose to learn their personal test result 
(irrespective of outcome). However, Lodder et al.173 found no difference in anxiety and 
depression levels between healthy women who opted for testing for the family-specific 
BRCA1 or BRCA2 mutation and women who refrained from testing. The latter were higher 
educated, more often childless and more reluctant towards prophylactic surgery. Having 
children was also positively correlated with testing for HNPCC in our study, indicating that 
other factors than cancer fear are also important in the decision to opt for genetic 
testing.   
Colonoscopy is experienced as a burdensome screening technique among HNPCC mutation 
carriers diagnosed at our department (chapter 3.4). The development of less invasive 
screening and preventative options is clearly needed. The availability of less repulsive 
preparation fluid would already represent a significant improvement. In the future, 
testing for genetic markers in stool or other non-invasive approaches such as virtual 




above mentioned techniques share the drawback that once a polyp or a given genetic 
marker is detected, conventional colonoscopy has to be performed after all to allow 
polypectomy. In the future, significant advances in in vivo optical imaging based on 
specific molecular markers will allow the selective identification of dysplastic lesions to 
guide polypectomy194. The elucidation of the molecular mechanisms underlying tumour 
formation and progression will also result in the development of tailor-made 
pharmacological intervention. However, availability of such ‘smart drugs’ may not be 
expected in the near future. Also, the characterisation of peptides specific for MSI-
positive colorectal cancer cells, that can be recognised by T cells, fuels hope for the 
development of a prophylactic vaccine for HNPCC carriers on the long term250.   
Finally, fear for financial and social discrimination is an important reason for not opting 
for genetic testing85. In the Netherlands, health insurance companies fund genetic 
counselling, genetic testing and the various screening strategies. The Dutch law prohibits 
discrimination of employees and exclusion from health insurance on grounds of genetic 
susceptibility for cancer. Since 1995 the Association of Insurance Companies (The Hague) 
has agreed on a moratorium which ensures that a clients’ genetic susceptibility is not 
taken into account in case of insurances for disablement up to €32.000 in the first year 
and €22.000 in the following years, and life-insurances up to €160.000. As a result of this 
policy, no problems with health insurance or employment were reported among Dutch 
MMR gene mutation carriers, though 4 out of 10 healthy carriers who opted for life 
insurance or mortgage experienced some kind of restraint (chapter 3.4). 
Additional research on the reasons for and psychosocial impact of refraining from genetic 
testing is needed. The more since, 88% of proven Dutch HNPCC carriers diagnosed at our 
department opted for regular colonoscopic screening after genetic testing, compared with 
33% before testing (chapter 3.4). The significant impact of genetic testing on surveillance 
will lead to a considerable decrease of HNPCC-related cancer morbidity and mortality. 
Also, we showed that most tested individuals are able to cope with their cancer 
predisposition at a mean follow-up of three and a half years (chapter 3.4). Ten percent of 
the studied mutation carriers had high cancer concerns and 9% felt regret of testing. This 
was associated with a high-perceived colorectal cancer risk, possibly induced by recent 
cancer related events in the family. Years after genetic testing, some mutation carriers 
may thus need additional counselling and psychological support. Based on our findings and 
experience, I advocate that from the moment a family is identified as at risk for HNPCC, 
ongoing psychological support and counselling facilities should be available to the 
individual family members. This can easily be implemented in a multidisciplinary family 
cancer clinic facility. 
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In conclusion, future challenges for clinical geneticists and other professionals active in 
HNPCC diagnosis and clinical management include: further unravelling of the molecular 
mechanisms underlying this susceptibility, translation of this ‘molecular knowledge’ into 
preventative tools, the development of less burdensome screenings options, the delivery 
of optimal multidisciplinary care, and the contribution (by education and counselling) to a 
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HNPCC is a hereditary cancer syndrome with an increased risk of tumours of the 
colorectum and endometrium. The cumulative lifetime risk of colorectal cancer is 60-90% 
and of endometrial cancer 30-40%. Also cancers of the stomach, small intestine, biliary 
system, urinary tract, ovary, brain and skin may occur among HNPCC patients though their 
relative risks generally do not exceed 10%. From a clinical point of view, HNPCC families 
are characterised by the Amsterdam criteria: two first degree relatives in two generations 
with colorectal, endometrial, urinary tract, or small bowel cancer, with at least one being 
diagnosed under the age of 50 years; FAP has to be excluded and the diagnoses must be 
pathologically verified. HNPCC is caused by mutations in mismatch repair (MMR) genes, 
involved in the repair of replication errors in DNA. Mutations in at least 4 different 
mismatch repair (MMR) genes are described, namely MSH2 and MLH1 in the majority of 
cases and, more rarely, MSH6 and PMS2. Former studies failed to detect germline 
mutations in MSH2 and MLH1 in a still considerable proportion (36-55%) of the Amsterdam 
criteria positive families.   
To answere the question whether unresolved HNPCC families were due to a lack of 
sensitivity of MSH2 and MLH1 mutation detection techniques, or to mutations of MSH6 or 
other genes. We analysed a cohort of 59 families, selected by Prof H.T. Lynch as 
suspected for HNPCC, for MSH2, MLH1 and MSH6 mutations. In this cohort we detected a 
mutation in 88% of the families. This high mutation detection rate is partly due to the 
optimal clinical selection. Another reason was that the families were analysed for genomic 
rearrangements at the major MMR genes. In 24% of the families a genomic rearrangement 
was found. One of these appeared a common MSH2 deletion accounting for ~10% of our 
cohort. Genealogical, molecular and haplotype studies showed that this common deletion 
represents a North-American founder mutation that originates from Germany and could be 
traced back to the 18th century. We also identified of a 10Mb paracentric inversion of 
chromosome 2p inactivatig the MSH2 gene. 
A small portion of the classic HNPCC families negative for MSH2 or MLH1 mutations is 
caused by MSH6 mutations. We showed a delayed age of onset of colorectal and 
endometrial cancer in MSH6 mutation carriers (55-57 years vs. 43-44 years and 54 years 
vs. 48-49 years respectively). Moreover, the cumulative lifetime risk of endometrial 
cancer in female carriers is increased when compared to MLH1 and MSH2 mutation 
carriers (71% vs. 27-40% at 70 years of age), while the risk of colorectal cancer is reduced 




MSH6 mutation analysis and in view of the screening and preventative advices for female 
MSH6 carriers, that may be modulated.  
In conclusion, we showed that the vast majority of ‘classical’ HNPCC families is due to 
MLH1 or MSH2 mutations. MSH6 and possibly PMS2 mutations cause a more atypical 
phenotype and are responsible for only a small proportion of classical families. Based on 
our observations, it is unlikely that other major HNPCC genes will be found in the future. 
 
The detection of a familial MMR gene mutation, enables individuals at risk to obtain 
certainty about whether they inherited the HNPCC susceptibility or not. HNPCC is 
inherited in an autosomal dominant fashion. Therefore, children of MMR gene mutation 
carriers have 50% risk to carry the familial mutation. If tested negative, relatives can be 
dismissed from screening. MMR gene mutation carriers can benefit from cancer screening. 
Regular colonoscopic screening drasticly decreases colorectal cancer risk in HNPCC risk 
carriers.  
We performed a pedigree study based on 18 families with a known MLH1, MSH2 or MSH6 
mutation diagnosed in a clinical setting. Fifty-seven percent of the 50% risk carriers opted 
for genetic testing at a mean follow-up of 42 months. As for other late onset genetic 
predispositions, testing was used more frequently by women (women vs. men = 62% vs. 
51%; p=0.045), and by subjects with children (with children vs. without children = 70% vs. 
45%; p=0.013). Hence, in a clinical setting a considerable portion of the risk carriers 
refrains from the genetic test. Reasons for not testing may include lack of information, 
fear for cancer for themselves or their children, fear for screening procedures or fear for 
social discrimination. More data on the reasons and psychosocial impact of refraining from 
genetic testing are needed. The more since 88% of proven Dutch HNPCC carriers opted for 
regular colonoscopic screening compared to 31% before testing at our department. This 
leads to a considerable decrease of their colorectal cancer risk. Despite the positive 
impact of screening protocols, the majority of mutation carriers diagnosed at our 
department experienced colonoscopic screening as a burden. An important task for the 
professionals involved in the care for HNPCC carriers is to develop and evaluate less 
invasive screening and preventive options.  
It has been previously shown that most tested individuals are satisfied about the 
counselling procedure and are able to cope with genetic testing for a cancer 
predisposition, including HNPCC, on the short-term (one year follow-up). At a follow-up of 
three and a half years, we also found that the majority of the carriers tested at our 
department was satisfied about the information and support during counselling. Also, the 
majority can cope with their cancer risks. Ten percent of the carriers experienced high 
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cancer worry and 9% regrets having taken the test. High cancer worry was significantly 
associated with a high perception of colorectal cancer risk, possibly induced by cancer 
related events in the family. Our data indicate that from the day suspicion of HNPCC 
arises in a family, relatives should have ongoing acces to counselling and psychological 
support. Finally, 4 out of 10 healthy carriers tested at our department who opted for life 
insurance, disability insurance or mortgage, experienced some kind of restraint. The latter 
represents a potential threat to the accessibility of genetic testing for cancer 
susceptibilities. 
The challenge for clinical geneticists and others working in the field of hereditary cancer, 
is to supply optimal multidisciplinary care on the short and long term, to develop non-
invasive screening and prevention options, and to contribute to a social climate necessary 
for individuals to make free and personal though educated choices relative to testing for 






HNPCC is een erfelijk kankersyndroom met een verhoogd risico op met name dikkedarm-, 
en baarmoederkanker. Het cumulatieve risico op dikkedarmkanker is 60-90% en op 
baarmoederkanker 30-40%, op de leeftijd van 70 jaar. Daarnaast komen soms andere 
vormen van kanker voor, namelijk maagkanker, dunnedarmkanker, urinewegtumoren, 
eierstokkanker, hersentumoren en huidkanker. Het risico op deze tumoren ligt meestal 
niet boven 10%. Om klinisch een familie met HNPCC te definiëren wordt veelal gebruik 
gemaakt van de Amsterdam criteria: drie familieleden, waarvan één eerste graads van de 
twee anderen, met dikkedarm-, baarmoeder-, urineweg-, of dunnedarm-kanker, bij 
minimaal één gediagnosticeerd onder de 50 jaar, waarbij FAP (familiaire adenomateuze 
polyposis) is uitgesloten en de diagnoses pathologisch bevestigd zijn.  
HNPCC wordt veroorzaakt door afwijkingen (mutaties) in zogenaamde mismatch repair 
genen. De eiwitten die naar deze genen gemaakt worden, zijn betrokken bij de reparatie 
van fouten in het DNA die met name bij de DNA-verdubbeling (replicatie) ontstaan. 
Kiembaanmutaties in ten minste vier verschillende genen zijn beschreven als oorzaak van 
HNPCC, namelijk in MLH1 en MSH2 en in mindere mate in MSH6 en PMS2. In eerder 
verrichte studies werd in 45-64% van de Amsterdam criteria positieve families een MLH1- 
of MSH2-mutatie gevonden. Dit betekent dat in een aanzienlijk aantal families geen 
moleculaire diagnose werd gesteld. Om na te gaan of dit veroorzaakt werd doordat in 
deze families sprake was van een mutatie in MSH6 of een ander HNPCC-gen of door het 
tekort schieten van de mutatie-analyse, onderzochten wij een groep van 59 families, door 
Professor H.T. Lynch geselecteerd op HNPCC, op MLH1-, MSH2- en MSH6-mutaties. In dit 
cohort vonden wij een mutatie in MLH1 of MSH2 in 88% van de families. Daarnaast 
bevatten 3 families een MSH6-mutatie. De hoge mutatie-detectie is toe te schrijven aan 
de goede klinische selectie van de families. Bovendien verrichtten wij naast de 
conventionele mutatie-analyse ook onderzoek naar genomische herrangschikkingen. 
Hierbij werd in 24% van de families een genomische herrangschikking van MLH1 of MSH2 
gevonden. Een van de genomische deleties in MSH2 bleek een Amerikaanse founder-
mutatie. Door middel van uitgebreid genealogisch en moleculair onderzoek kon deze 
mutatie teruggevoerd worden op een Duitse immigrantenfamilie, welke in het begin van 
de 18e eeuw naar Amerika emigreerde. Ook werd een paracentrische inversie van 
chromosoom 2 ontdekt, die inactivatie van MSH2 veroorzaakt.  
In een klein gedeelte van de klassieke HNPCC-families wordt een mutatie in MSH6 
gevonden. Door middel van analyse van 20 MSH6-families, waaronder een zeer grote 
Nederlandse familie, toonden wij aan dat de leeftijd bij het onstaan van de darm-, en 
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baarmoederkanker in MSH6-mutatiedragers significant hoger is dan in MLH1- en MSH2-
mutatiedragers (respectievelijk 55-57 jaar vs. 43-44 jaar en 54 jaar vs. 48-49 jaar). 
Daarnaast is het cumulatieve risico op dikkedarmkanker op de leeftijd van 70 jaar voor 
vrouwelijke MSH6-draagsters lager en het risico op baarmoederkanker hoger dan voor 
MLH1- en MSH2-mutatiedragers/draagsters (30% vs. 53-68% and 71% vs. 27-40%). Dit is van 
belang voor de selectie van families voor mutatie-analyse en voor het geven van adviezen 
voor controle en preventie. 
Concluderend toonden wij aan dat verreweg het merendeel van de klassieke HNPCC-
families het gevolg is van mutaties in MLH1 of MSH2. MSH6- en mogelijk PMS2-mutaties 
geven een atypischer fenotype en veroorzaken maar een klein deel van de klassieke 
families. Bovendien lijkt het onwaarschijnlijk dat er naast de nu bekende HNPCC-genen 
nog een klassiek HNPCC-gen van betekenis bestaat. 
  
Wanneer in een familie met HNPCC een ziekteveroorzakende mutatie in MLH1, MSH2 of 
MSH6 gevonden wordt, is het mogelijk familieleden te testen op de aanwezigheid van 
deze aanleg. HNPCC erft autosomaal dominant over. Dit betekent dat kinderen van 
iemand met een MLH1-, MSH2- of MSH6-mutatie 50% kans hebben de aanleg voor kanker 
te hebben geërfd. Wanneer een familielid de familiaire aanleg niet bij zich draagt, heeft 
hij of zij niet het familiaire risico op kanker en kan de aanleg ook niet doorgeven of 
doorgegeven hebben aan eventuele kinderen. Familieleden die de aanleg wel geërfd 
hebben, komen in aanmerking voor intensieve controle: colonoscopie iedere 1 à 2 jaar 
vanaf de leeftijd van 20-25 jaar, jaarlijks gynaecologische controle vanaf de leeftijd van 
30-35 jaar, en controle van maag, dunnedarm en urinewegen afhankelijk van de 
familiegeschiedenis. Ook kunnen zij de aanleg aan hun eventuele kinderen doorgeven of 
gegeven hebben. Regelmatige darmcontrole brengt het risico op dikkedarmkanker bij 
HNPCC-mutatiedragers drastisch omlaag.  
In 18 Nederlandse families met een bewezen MLH1-, MSH2- of MSH6- mutatie koos 57% van 
de personen met een à priori kans van 50% op de familaire aanleg voor de genetische test. 
Het wel of niet kiezen voor testen bleek gecorreleerd aan het risico op het hebben van de 
mutatie en het hebben van kinderen (wel kinderen vs. geen kinderen = 70% vs. 45%; 
p=0.013). Ook kozen vrouwen, net als bij het genetisch testen voor andere, later in het 
leven tot uiting komende aandoeningen, vaker voor testen (vrouwen vs. mannen = 62% vs. 
51%; p=0.045). Hoewel dus het merendeel van de risicodragers geïnteresseerd is in 
genetisch testen, ziet ook een aanzienlijk deel hiervan af. Dit kan komen doordat zij niet 
goed zijn voorgelicht, door angst dat zij zelf of hun kinderen kanker zullen krijgen, of 




te krijgen in de redenen waarom risicodragers afzien van testen, met name omdat van de 
op onze afdeling geteste dragers 88% gebruik maakt van colonoscopie, terwijl voor de 
genetische test 31% van hen regelmatig colonoscopie liet verrichten. Deze toename van 
dikkedarmcontrole brengt hun risico op het krijgen van dikkedarmkanker sterk omlaag. 
Ondanks dat dragers goed gebruik maken van de mogelijkheid om colonoscopie te laten 
verrichten, ervaart een groot deel van de dragers het onderzoek als onplezierig en zou het 
merendeel een andere manier van controle op prijs stellen (respectievelijk 57% en 71%). 
Een belangrijke taak voor de deskundigen is dan ook weggelegd voor wat betreft het 
ontwikkelen van minder belastende methoden van onderzoek en preventie.  
Eerdere studies op het gebied van HNPCC gaven aan dat op de kortere termijn (follow-up 
van 1 jaar) het merendeel van de HNPCC-risicodragers tevreden is over de 
counselingsprocedure en goed om kan gaan met het hebben van de aanleg voor HNPCC. Op 
basis van vragenlijsten, ingevuld door 70 MLH1-, MSH2- en MSH6-mutatiedragers uit 24 
Nederlandse families, blijkt dat ook op de langere termijn het merendeel van de dragers 
tevreden is over de tijdens de counseling ontvangen informatie en begeleiding. Bij een 
gemiddelde follow-up van 3,5 jaar maakt 10% van de dragers zich nog ernstig zorgen om 
hun kankerrisico, waarbij zes dragers (9%) zelfs spijt hebben van de genetische test. Grote 
kankerangst is significant gekoppeld aan het ervaren van een hoog eigen risico op 
dikkedarmkanker, wat mogelijk geïnduceerd wordt door het overlijden aan kanker van 
familieleden. Onze studie geeft aan dat vanaf het moment dat de verdenking van HNPCC 
in een familie rijst, de familieleden toegang moeten hebben tot counseling en 
psychologische ondersteuning, zowel op de korte als op de lange termijn. Tenslotte 
rapporteerden 4 van 10 gezonde mutatiedragers, die een levensverzekering, 
arbeidsongeschiktheidsverzekering of hypotheek wilden afsluiten, hierbij problemen te 
hebben ondervonden. Sociale discriminatie, of de angst daarvoor, kan een serieuze 
bedreiging vormen voor de vrije keuze van risicodragers voor het genetisch testen op een 
aanleg voor kanker. 
De uitdaging voor deskundigen op het gebied van kankergenetica is om goede 
multidisciplinaire zorg te bieden, nieuwe minder invasieve controle- en 
preventiemogelijkheden te ontwikkelen en bij te dragen aan een sociaal klimaat dat nodig 
is om voor betrokken personen een vrije keus ten aanzien van testen op een genetisch 
risico op HNPCC te waarborgen.    
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